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Snake venom, a rich source of pharmacologically active proteins and 
peptides, provides excellent opportunities for the development of 
research tools and therapeutic agents. To identify novel 
proteins/peptides from Bungarus fasciatus venom, we screened the 
fractionated venom using a variety of biological assays. Neurotoxicity 
and cytotoxicity were detected in some fractions, whose contents 
showed similarities to well characterized α/β-bungarotoxins. 
Interestingly, we also detected haemostatic effects in a few fractions. 
Although haemostatic effects exist ubiquitously in snake venom 
envenomation, haemostatic toxins from Bungarus genus are less 
studied. Thus, we characterized the identified proteins with haemostatic 
effects in detail. The results indicated that they belong to two types of 
inhibitors: extrinsic tenase complex inhibitors and FXIa inhibitors.  
The extrinsic tenase complex inhibitors, BF-AC1 and BF-AC2, have 
potent inhibitory activities (IC50 of 10 nM) on the extrinsic tenase 
complex. Structurally, they each has two subunits covalently held 
together by disulfide bond(s). The N-terminal sequences of the 
individual subunits of BF-AC1 and BF-AC2 showed that the larger 
subunit is homologous to phospholipase A2, while the smaller subunit is 
homologous to Kunitz type serine proteinase inhibitor. Functionally, in 
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addition to their anticoagulant activity, these proteins showed 
presynaptic neurotoxic effects in both in vivo and ex vivo experiments. 
Thus, BF-AC1 and BF-AC2 are structurally and functionally similar to 
β-bungarotoxins, a class of neurotoxins. The enzymatic activity of 
phospholipase A2 subunit plays a significant role in the anticoagulant 
activities. This is the first report on the anticoagulant activity of 
β-bungarotoxins and these results expand on the existing catalogue of 
haemostatically active snake venom proteins.  
Since standard anticoagulant drugs such as vitamin K antagonists and 
heparin (non-specific inhibitors), inhibitors target thrombin, FXa, and 
extrinsic and common coagulation pathway (specific inhibitors), are 
commonly associated with serious bleeding problems, intrinsic 
coagulation factors (FXIa, FXIIa, prekallikrein) are being investigated as 
possible alternative targets for developing anticoagulant drugs with 
minimal bleeding effects. We have isolated and sequenced a specific 
FXIa inhibitor, henceforth named Fasxiator (B. fasciatus FXIa inhibitor). 
It is a Kunitz-type protease inhibitor that prolonged activated partial 
thromboplastin time (aPTT) without significant effects on prothrombin 
time (PT). Fasxiator was recombinantly expressed (rFasxiator), purified 
and characterized to be a slow-type inhibitor of FXIa (IC50 ~2 µM with 
30 min pre-incubation) that exerts its anticoagulant activities (doubled 
IX 
 
aPTT at ~3 µM) by selectively inhibiting human FXIa in in vitro assays. 
A series of mutants were subsequently generated to improve the 
potency and selectivity of rFasxiator. rFasxiatorN17R,L19E showed the 
best balance between potency (IC50 ~1 nM) and selectivity (over 100 
times) and was characterized in detail. rFasxiatorN17R,L19E is a 
competitive slow-type inhibitor of FXIa (Ki = 0.86 nM), possesses 
anticoagulant activity that is ~10 times stronger in human plasma than 
in murine plasma, and prolonged the occlusion time of mice carotid 
artery in thrombosis models induced by FeCl3. Thus, we have isolated 
the first exogenous FXIa specific inhibitor and engineered it to improve 
the potency by ~1000 times and demonstrated its anti-thrombotic 
activity in in vivo thrombosis model. 
 
 









List of Tables 
Chapter Two 
Table 2.1: In vivo toxicity of purified proteins. 
Table 2.2: Molecular weights of cytotoxic fractions. 
Table 2.3: Molecular weights of proteins in RP-HPLC pooled fractions of 
anticoagulant assays. 
Table 2.4: N-terminal sequences of purified proteins. 
Chapter Three 
Table 3.1: Number of cysteines in BF-AC1 and BF-AC2. 
Chapter Four 
Table 4.1: Primers for point mutagenesis. 
Table 4.2: Molecular weights of proteins in RP-HPLC pooled fractions. 
Table 4.3: Molecular weights of rFasxiator mutants first set. 
Table 4.4: Molecular weights of rFasxiator mutants second set. 







List of Figures 
Chapter One 
Figure 1.1: Three-dimensional structures of three-finger toxins (3FTx) showing 
loops and disulfide bridges. 
Figure 1.2: Anti-hypertensive agents from snake venoms. 
Figure 1.3: Factors from snake venom affecting blood coagulation and platelet 
aggregation. 
Figure 1.4: The coagulation cascade. 
Chapter Two 
Figure 2.1: Fractionation of Bungarus fasciatus venom for in vivo toxicity 
assay. 
Figure 2.2: Fractionation of Bungarus fasciatus venom for cytotoxicity assay. 
Figure 2.3: Cytotoxicity effects of pooled fractions. 
Figure 2.4: Dose dependent effect of cytotoxic proteins. 
Figure 2.5: Fractionation of Bungarus fasciatus venom for hemolytic assay. 
Figure 2.6: Hemolytic assays of pooled fractions. 
Figure 2.7: Fractionation of Bungarus fasciatus venom for anticoagulant 
activity assay. 
Figure 2.8: Anticoagulant activity of pooled fractions. 
Chapter Three 
Figure 3.1: Purification of BF-AC1 and BF-AC2 from the venom of B. fasciatus. 
Figure 3.2: ESI-MS profile of BF-AC1 (A) and BF-AC2 (B). 
Figure 3.3: Structural characterization of BF-AC1 and BF-AC2. 
XII 
 
Figure 3.4: N-terminal sequence alignment of Chain A and Chain B of BF-AC1 
and BF-AC2 with protein sequences in the database. 
Figure 3.5: Anticoagulant activity of BF-AC1 and BF-AC2 mixture. 
Figure 3.6: BF-AC1 and BF-AC2 selectively inhibit the extrinsic tenase 
complex. 
Figure 3.7: PLA2 activity plays an important part in inhibition of extrinsic tenase 
complex. 
Figure 3.8: Effect of BF-AC1 on CMCB preparations. 
Figure 3.9: Activity comparison between BF-AC1/2 and β-bungarotoxins. 
Figure 3.10: Selectivity profile of Latoxan β -bungarotoxin. 
Chapter Four 
Figure 4.1: Synthetic gene sequences of Fasxiator. 
Figure 4.2: Identification of novel anticoagulants from Bungarus fasciatus 
venom. 
Figure 4.3: Effects of BF01 and BF02 on various procoagulant proteases in 
the blood coagulation cascade. 
Figure 4.4: Sequence determination of BF01/02. 
Figure 4.5: Recombinant expression and purification of rFasxiator. 
Figure 4.6: Anticoagulant activity and protease specificity of rFasxiator. 
Figure 4.7: Effect of rFasxiator on the intrinsic and the extrinsic tenase 
complexes. 
Figure 4.8: rFasxiator interacts with and inhibits FXIa.   
Figure 4.9: Effects of rFasxiator on aPTT of human (A) and murine (B) plasma. 
Figure 4.10: Structure-function relationships of rFasxiator. 
Figure 4.11: ESI-MS of first set point mutations. 
XIII 
 
Figure 4.12: ESI-MS of second set point mutations. 
Figure 4.13: Selectivity of double variants (mutations second set). 
Figure 4.14: Functional characterization of rFasxiatorN17R,L19E. 
Figure 4.15: Anti-thrombotic effect of rFasxiatorN17R,L19E in FeCl3-induced 
carotid artery thrombosis model in mice. 




















Units and measurements 
cm     Centi meter 
CPS           Counts per second 
Da           Daltons 
°C            Degree Celsius 
U            Enzyme unit 
g             Gram 
h             Hour 
kDa     Kilo Daltons 
kg      Kilo gram 
l      Liter 
µg      Micro gram 
µl      Micro liter 
µM     Micro molar 
µmol     Micro mole 
µ      Micron 
mg     Milli gram 
ml      Milli liter 
mm     Milli meter 
mM     Milli molar 
XV 
 
min     Minute 
M      Molar 
ng      Nano gram 
nm     Nano meter 
nM                Nano molar 
nmol     Nano mole 
rcf      Relative centrifugal force 
rpm     Revolutions per minute 
s      Second 
V       Volt 
Others 
Ach     Acetylcholine 
ACS     Acute coronary syndrome 
ADP     Adenosine di phosphate 
APC     Activated protein C 
aPTT     Activated partial thromboplastin time 
ATIII     Antithrombin-III 
BSA     Bovine serum albumin 
Cch     Carbamyl choline (carbachol) 
CD     Circular dichroism 
DVT     Deep-vein thrombosis 
XVI 
 
ESI-MS    Electrospray ionization mass spectrometry 
FeCl3         Ferric chloride  
FIX, FIXa    Factor IX, activated factor IX 
FV, FVa    Factor V, activated factor V 
FVII, FVIIa    Factor VII, activated factor VII 
FVIII, FVIIIa   Factor VIII, activated factor VIII 
FX, FXa    Factor X, activated factor X 
FXI, FXIa    Factor XI, activated factor XI 
FXII, FXIIa    Factor XII, activated factor XII 
FXIIIa     Activated factor XIII 
Gla     Gamma-carboxyglutamic acid 
HCII     Heparin cofactor II 
HEPES    4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid 
HIT     Heparin-induced thrombocytopenia 
HMWK     High-molecular weight kallikrein 
i.p      Intraperitoneal 
i.v      Intravenous 
KCl     Potassium chloride 
LMWH     Low-molecular-weight heparin 
MI      Myocardial infarction 
nAChRs    Nicotinic acetylcholine receptors 
XVII 
 
PDB     Protein Data Bank 
PK     Prekallikrein 
pNA     p-nitroaniline 
PT      Prothrombin time 
RP-HPLC    Reverse-phase high performance liquid chromatography 
RVV-X     Russell’s viper venom factor X activator 
Serpin     Serine proteinase inhibitor 
Spectrozyme® FIXa  H-D-Leu-phenylalanyl-Gly-Arg-pNA•2-AcOH 
TF      Tissue factor 
TFA     Trifluoroacetic acid 
TFPI     Tissue factor pathway inhibitor 
tPA     Tissue plasminogen activator 
TT      Thrombin time 
UFH     Unfractionated heparin 
u-PA     Urokinase –type plasminogen activator 


























Chapter 1 Introduction 
1.1 Snake venom toxins 
Snakes (class Reptilia and suborder Serpentes) can be classified into 
non-venomous or venomous snakes. Venomous snakes can be classified into 
five different families: Colubridae, Elapidae, Hydrophiidae, Viperidae and 
Crotalidae [1]. The venomous snakes have specialized venom glands along 
with fangs which enable them to bite their prey. Snake venom is produced by 
the venom grand and is a mixture of proteins and polypeptides that exert 
different physiological functions. Research on snake venom components have 
led to the discovery of a list of potent drug leads and useful research tools [2]. 
Based on the functions of snake venom toxins, they can be divided into the 
following catalogues: (1), Toxins affecting the nervous system; (2), toxins 
affecting the cardiovascular systems; (3), toxins affecting the muscular system; 
and (4) toxins affecting the haemostatic system [2]. Some toxins can affect 
more than one system. 
1.1.1 Toxins affecting the nervous system 
Toxins affecting the nervous system, or neurotoxins, are adopted by the 
snakes to immobilize their prey. Snake neurotoxins were first reported about 
50 years ago, when Chang and Lee isolated α, β, γ- bungarotoxins from 
Bungarus multicinctus venom using electrophoresis [3]. The typical symptoms 
of poisoning by snake venom neurotoxins include paralysis, breathing failure 
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and eventually death. By the mechanisms of function, neurotoxins can be 
divided into α-neurotoxins and β-neurotoxins. α-neurotoxins affect the 
post-synaptic membrane while β-neurotoxins affecting the release of 
acetylcholine from the pre-synaptic membrane [4]. 
1.1.1.1 α-neurotoxins 
α-neurotoxins were also referred to as curare mimetic neurotoxins and they 
are mainly obtained from elapid, hydrophid and colubrid snake venoms [5]. 
Here we focus on α-neurotoxins from elapid venom as our snake of interest 
belongs to this catalogue.  
Most of the α-neurotoxins isolated from the elapid snake venom belong to 
three finger toxins [6]. Three finger toxins are small molecules with three loops 
(the three finger) extending from a globular hydrophobic core. The structure of 
the globular core is secured by four disulfide bonds, while within the three 
loops five antiparallel β-strands are formed [7].  
These three finger toxin type α-neurotoxins can be classified into short (type I) 
and long (type II) α-neurotoxins based on their amino acid sequences. Both 
short and long α-neurotoxins shared a similar N-terminal sequence and a 
typical three finger structure. However, long α-neurotoxins have a fifth 
disulfide bond located at the second loop and a longer C terminal tail when 
compared with short α-neurotoxins [6]. 
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α-neurotoxins act as antagonists at the nicotinic acetylcholine receptor 
(nAChRs), thus, α-neurotoxins prohibit the transduction of nerve signals by 
preventing the binding of acetylcholine to nAChR. In contrast to the fact that 
they share similar structures, α-neurotoxins showed diverse species and 
tissue specificity. For example, short and long chain α-neurotoxins exhibit 
different inhibitory potency against muscular and neuronal nAChRs [5]: even 
though both types of the α-neurotoxins bind to muscular nAChRs (α1 type) 
with high affinity, only long chain α-neurotoxins are able to bind to neuronal 
nAChRs (α7 type) strongly [8].  Recent studies attribute this difference to the 
presence of the fifth disulfide bond in the long chain neurotoxins [9]. Most 
α-neurotoxins caused irreversible effects in in vitro experiments, with the 
exception of weak α-neurotoxins [5].  
Positively charged residues (arginine and lysine) at the surface of loop II are 
believed to be essential for the high affinity binding to nAChR in both short and 
long α-neurotoxins [10]. Other important functional residues include a number 
of residues (Ser8, Gln7 and Gln10) in the loop I region of short chain 





Figure 1.1: Three-dimensional structures of three-finger toxins (3FTx) showing loops and 
disulfide bridges. A) Short-chain (Erabutoxin (1QKD)); B) Long-chain (κ-bungarotoxin (1KBA)), 
The extension of second loop in long-chain 3FTx due to fifth disulphide bridge is shown in red 
color. Figures and legend cited from “Kini, R.M. and R. Doley, Structure, function and evolution 
of three-finger toxins: mini proteins with multiple targets. Toxicon, 2010. 56(6): p. 855-67.” 
1.1.1.2 β-neurotoxins 
β-neurotoxins affect the release of acetylcholine from pre-synaptic membrane 
via several different mechanisms [11]. The most well characterized 
β-neurotoxins are β-bungarotoxin, crotoxin and dendrotoxins.  
1.1.1.2.1 β-bungarotoxin 
β-bungarotoxin was first isolated and characterized from the venom of 
Bungarus multicinctus. It is a basic heterodimer protein with a molecular 
weight of ~21,800 Da. The larger subunit is structurally homologous to PLA2. 
The smaller subunit is homologous to Kunitz type proteinase inhibitor.  The 
two subunits are linked by a single intra-chain disulfide bridge. The PLA2 
subunit was found to be the active subunit responsible for both of the PLA2 
enzymatic activity and neurotoxicity, while the Kunitz subunit was postulated 
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to serve as a guiding probe for the protein and block certain voltage gated K+ 
channels.  Animal studies showed that peritoneal injection of β-bungarotoxin 
into mice resulted in respiratory failure and death, as a result of presynaptic 
neuromuscular blockade by inhibiting the release of acetylcholine [12]. 
1.1.1.2.2 Crotoxin 
Crotoxin is isolated from the venom of Crotalus durissus. Its effects are 
primarily presynaptic, resulting in a triphasic modification of neurotransmitter 
release from nerve terminals (depression, facilitation, and final block) [13]. It is 
also observed that crotoxin can block the response to acetylcholine 
post-synaptically through stabilizing acetylcholine receptor in an inactive form 
[14]. Crotoxin is made up of two non-identical phospholipase A2 subunits. One 
of the subunits is basic and weakly toxic (component B) while the other one is 
acidic and nontoxic (component A). Component A has three polypeptides that 
linked through seven disulfide bonds while component B is a single 
polypeptide [15].  
1.1.1.2.3 Dendrotoxin  
Dendrotoxins are small proteins (57-60 amino acids) isolated from mamba 
(Dendroaspis) snakes [16]. They are homologous to Kunitz type protease 
inhibitors but have little inhibitory effects on proteases. Instead, they block 
certain members of voltage-dependent potassium channels of the Kv1 family. 
To date, several subtypes of dendrotoxins have been identified, such as 
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α-dendrotoxin, toxin I, toxin K and δ-dendrotoxin [17]. Different dendrotoxins 
bind to subtypes of Kv1 channels with various affinity and selectivity. 
α-dendrotoxin and toxin I block Kv1.1, Kv1.2 and Kv1.3 in low nanomolar 
range while toxin K block Kv1.1 in picomolar range [16].  
Two modes have been proposed for the interaction between dendrotoxins and 
potassium channel. One is that dendrotoxins physically plug into the pore 
while the other one is that dendrotoxins bind near the pore entryway [18, 19]. 
Structural and functional relationship studies have revealed the functional 
important residues of dendrotoxins. Lys5 and Leu9 are considered to be the 
mostly crucial residue for α-dendrotoxin and toxin I. Other important residues 
include Arg3, Leu6 and Ile8 [20, 21]. In contrast, Lys3 and Lys6 are proved to 
be essential for the activity of δ-dendrotoxin and toxin K. Tyr4, Pro8, Arg10 
and Lys 26 also play an important part in the interaction of δ-dendrotoxin with 
Kv1 channels [22, 23]. A key Lys residue (such as Lys5 in α-dendrotoxin) in 
association with a hydrophobic residue (Leu9 in α-dendrotoxin) is believed to 
be a common feature for dendrotoxins in blocking potassium channels.  
1.1.2 Toxins affecting the cardiovascular system 
The first successful example of developing a drug from snake venom lead is 
captopril, an anti-hypotensive agent. Captopril was designed from 
bradykinin-potentiating peptides (BBPs), a toxin that targets the 
cardiovascular system [24]. To date, a number of toxins affecting the 
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cardiovascular system have been reported, such as BBPs, Natriuretic 
peptides (NPs), L-type Ca2+ channel blockers and cardiotoxins [25]. 
1.1.2.1 Bradykinin-potentiating peptides (BPPs) 
BPPs are proline-rich oligopeptides (5-10 amino acids). They were first 
isolated from the venom of Bothrops jararaca. Functionally, they are capable 
of inhibition of angiotensin-converting enzyme (ACE). ACE tightly regulates 
the level of Bradykinin through degradation of Bradykinin [26]. Bradykinin is an 
endogenous molecule that has potent hypotensive effects. ACE also helps to 
produce a potent hypertensive agent, angiotensin II. Thus, inhibition of ACE 
stabilizes bradykinin and reduces the level of angiotensin II, which together 
lead to drop in blood pressure [27]. It is worth to note that the design of the 
wildly used drug, captopril, an active site competitive inhibitor of ACE, was 
inspired by the structure of BBPs [28]. 
1.1.2.2 Natriuretic peptides (NPs)  
NPs are important regulators of cardiovascular and renal systems. They are 
released upon myocardial overload and through participating in a series of 
effects such as vasodilation, hypotension, they reduce the mechanical load on 
the heart. Mammalian NPs are classified into ANP, BNP and CNP. All NPs 




Snake venom NPs was first isolated from the venom of Dendroaspis 
angusticeps and was named DNP [29]. NPs were then subsequently found in 
the venom of a number of snakes, such as Micrurus corallines, Trimeresurus 
gramineus and Bungarus flaviceps [25]. In contrast to mammalian NPs, snake 
NPs display diverse variations in structure and function. Thus, snake NPs are 
considered as good drug leads for cardiovascular agents [30]. In particular, 
the chimeric peptides CD-NP, a combination of the C-terminal tail of DNP with 
human CNP (the full molecule), has given promising results in the first phase 
of clinical trials [31] [32]. 
1.1.2.3 L-type Ca2+-channel blockers 
L-type Ca2+ channels mediate the entry of Ca2+ into cells and thus participate 
in the regulating of muscle contraction and hormone/neurotransmitter 
releasing, which further result in vasodilation and blood pressure drop. Snake 
venom L-type Ca2+ channel blockers are mainly identified from the venom of 
Dendroaspis genus [33]. These blockers belong to the three finger toxin family 
and inhibit the L-type Ca2+ channels in cardiovascular system with selectivity 





Figure 1.2: Anti-hypertensive agents from snake venoms. (A) Protein sequence alignment 
of ANP, BNP, CNP from human and DNP from D. angusticeps, as well as the designed peptide 
CN-DP. Identical residues are shaded in gray. All NP have a conserved 17-residue disulfide 
loop but with variable number of residues on N- and C-termini. The last 15 residues on the DNP 
C-terminus were grafted on to CNP to form the peptide CN-DP. (B) Protein sequence alignment 
of L-type Ca2+-channel blockers from snake venoms. Identical residues are shaded in gray. 
Based on sequence identity and the positions of flanking prolines, functional sites of these 
proteins are predicted to reside between Pro42 and Pro47 (PTAMWP, as underlined). L-calchin, 
an 8-residue peptide (APTAMWPA) synthesized based on this segment retained the ability to 
block L-type Ca2+-channel. Figures and legend cited from “Koh, C.Y. and R.M. Kini, From snake 
venom toxins to therapeutics--cardiovascular examples. Toxicon, 2012. 59(4): p. 497-506.” 
1.1.2.4 Cardiotoxin 
Cardiotoxins (also referred to as cytotoxins) are only found in the venom of 
cobra and rinkhals [36, 37]. They are closely related to α-neurotoxins. 
However, instead of high affinity binding to receptors, cardiotoxin are direct 
lytic factors and pore forming agents that cause depolarization and contracture 
of cardiac, skeletal and smooth muscles [38, 39].   The specific binding of 
cardiotoxins to glycosaminoglycans (the sulphated carbohydrate moieties that 
abundant existed in cardiovascular cells) may contribute to the cardiotoxicity 
of cardiotoxins [40].  Cardiotoxins are capable of influencing the muscular 
system as well through depolarization of muscle cells [38]. 
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1.1.3 Toxins affecting the muscular system 
Several catalogues of snake venom toxins have been reported to affect the 
muscular system, such as myotoxins, cardiotoxins and PLA2s. In contrast to 
PLA2 and cardiotoxins, which can affect other systems as well as muscular 
system, myotoxins act primly within the muscular system. 
Myotoxins are a class of small, basic peptides that are mainly found in the 
venom of rattlesnakes. Crotamine, being the first identified myotoxin, is well 
characterized. It is a strongly basic protein that contains 42 amino acids [41]. 
Crotamine causes spastic paralysis in the hind limbs of experimental animals 
through acting on the Na+ channel of plasmatic membrane of skeletal muscle 
cells to induce depolarization of these cells and influx of Na+ [42]. Several 
other myotoxins such as myotoxin a, myotoxin I and II were also identified and 
characterized. They share similar structural properties but differ in 
mechanisms for muscular effects [43, 44].  
1.1.4 Toxins affecting the haemostatic system 
Exogenous factors originated from snake venoms that affect thrombosis and 
haemostasis have provided insights into the design of useful research tools 
and life-saving drugs [45]. These factors target various key points in the blood 
coagulation pathway and platelet aggregation system for functioning. They 
can be divided into two categories: enzymatic and non-enzymatic proteins [46]. 
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A detailed description of the blood coagulation components and pathways will 
be discussed later. 
 
Figure 1.3: Factors from snake venom affecting blood coagulation and platelet 
aggregation. (A) Factors affect blood coagulation. Proteinases interfere by proteolysis of 
specific factors (thick arrowheads), while other factors interfere by binding (red blocks). Green 
boxes, procoagulant proteinases; red boxes, anticoagulant proteinases and proteinases that 
affect fibrinolysis; blue boxes, PLA2s; and yellow boxes, non-enzymatic proteins. (B) Factors 
affect platelet aggregation. Proteinases that induce or inhibit platelet aggregation are shown in 
yellow or blue boxes, respectively. Non-enzymatic proteins that induce and inhibit platelet 
aggregation are shown in green and pink boxes, respectively. Figures and legend cited from 
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“Kini, R.M., Toxins in thrombosis and haemostasis: potential beyond imagination. J Thromb 
Haemost, 2011. 9 Suppl 1: p. 195-208.” 
1.1.4.1 Enzymatic proteins affecting haemostasis and thrombosis 
This category includes metalloproteinases, serine proteases, phospholipase 
A2, ADPases and L-amino acid oxidases. Metalloproteinase, serine proteases 
and phospholipase A2 are discussed here. 
1.1.4.1.1 Metalloproteinase 
Snake metalloproteinases affect blood coagulation and platelet aggregation 
through several different mechanisms. Most of them (such as 
α-fibrinogenases) cleave fibrinogen into a truncated version whose ability to 
form stable fibrin was compromised, and thus behave as an anticoagulant [47]. 
Some of the snake metalloproteinases (RVV-X and ecarin for example) have 
potent and selective activation activity on procoagulant factors, such as Factor 
X (FX) and prothrombin, and thus act as effective pro-coagulant [48]. In the 
contrast, some of the snake metalloproteinases are capable of inhibiting or 
activating platelet aggregation via distinct modes [49].  
1.1.4.1.2 Serine proteinase 
Snake venom serine proteinases selective cleavage the key components 
involving in the haemostatic system to affect blood clogs formation. For 
example, thrombin-like enzymes directly cleave fibrinopeptide A/B to induce 
clotting, while, some other serine proteinases activate protein C to slow down 
the blood coagulation processes [50]. 
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1.1.4.1.3 Phospholipase A2 enzyme 
Based on the potency, snake venom Phospholipase A2 (PLA2) can be 
classified as strong, weak and non-anticoagulant. PLA2s serve their 
anticoagulant activity through both enzymatic and non-enzymatic mechanisms, 
thus there is no linear relationship between the potency of PLA2 enzymatic 
activity and their anticoagulant properties [51]. The anticoagulant properties of 
PLA2s will be discussed with more detail in chapter 3.  
1.1.4.2 Non-enzymatic proteins affecting haemostasis and thrombosis 
This category includes a number of structurally and functionally different 
proteins, such as disintegrins, snaclecs (C-type lectins and their related 
proteins) and three finger toxins. 
1.1.4.2.1 Disintegrins 
Integrins, made up of two subunits (α and β), are transmembrane receptors 
that serve as bridges for cell-cell and cell-extracellular interactions. Integrins 
when bound to ligand trigger response of cells to changes in their surrounding 
environments. They have two main functions: attachment of cells to 
extracellular matrix and signal transduction from the extracellular matrix to 
cells [52]. For example, GPIIbIIIa (integrin αIIbβ3), the integrin found on the 
surface of platelets, dramatically increase its ability in binding to 
fibrin/fibrinogen upon the association of platelet to collagens in wound sites 
and thus facilitate clot formation [53].  
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Snake disintegrins are antagonist of integrins and are mainly found in 
Viperinae and Crotalinae subfamilies [54]. The first disintegrin, trigramin, was 
isolated from the venom of Trimeresurus gramineus as a non-enzymatic small 
peptide that inhibited the aggregation of platelets. This inhibition was later 
attributed to the high affinity binding of trigramin to the fibrinogen binding 
integrin GPIIbIIIa which hindered the association of platelet with 
fibrin/fibrinogen [55]. And thus, trigramin is a potent inhibitor of platelet 
aggregation. In the last few decades, various disintegrins have been identified 
and characterized. They inhibit a broad spectrum of integrin. 
Structural studies on disintegrins suggested that they inhibit GPIIbIIIa through 
plugging the active (R/K)GD sequence (the integrin recognizing motif), which 
is in turn harbored by an 11-residue loop, into a crevice in GPIIbIIIa [56]. The 
N- and C-terminal regions of disintegrins are believed to participate in 
determining their potencies and selectivity against different integrins [57]. Two 
drugs, Tirogiban and Eptifibatide were developed based on the structure of 
disintegrins and were used in the treatment of acute coronary ischaemic 
syndrome [58]. 





Lectins are a structurally diverse group of proteins or protein domains capable 
of binding carbohydrates with considerable specificity that perform recognition 
on the cellular and molecular level. Snaclecs (snake C-type lectins) comprises 
C-type lectins and their related proteins [59]. C-type lectins contain a 
carbohydrate-binding domain and are designated for its requirement of 
calcium for binding. C-type lectins are usually homodimers, while C-type lectin 
related proteins are heterodimers or oligomers of heterodimers with α- and 
β-chains connecting through an interchain disulfide bond [60]. C-type 
lectin-like proteins get their names from their high sequence homology 
(15%-40%) with the carbohydrate recognition domains of C-type lectins. In 
contrast to C-type lectins, most C-type lectin like proteins have lost their ability 
to bind carbohydrate as well as calcium [61].  
Snaclecs affect the haemostatic systems by serving as anticoagulants, 
platelet aggregation inducers or inhibitors [45].  
FIX/X-binding protein (IX/X-bp) from Protobothrops flavoviridis venom was the 
first snaclecs that has been sequenced. It binds to Gla domains of coagulation 
factors with nanomolar and subnanomolar affinities, leading to sequestering of 
FX and FIX [62]. Other anticoagulant snaclecs includes bothrojaracin and 
bothroalternin that interact specifically with thrombin/prothrombin.  
Snaclecs can bind to platelets to induce platelet secretion and aggregation 
[63]. For example, convulxin induces platelet aggregation through GPVI, 
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which was isolated and purified using convulxin as the affinity ligand and 
Aggretin induces platelet aggregation through interacting with α2β1, GPIb and 
ClEC2 [64, 65]. The above snaclecs induce platelet aggregation without 
plasma proteins, but several other snaclecs require plasma factors for this 
function, such as Botrocetin and bitiscetin [66]. Botrocetin induces platelet 
aggregation through binding to von Willebrand Factor (VWF) and inducing its 
interaction with GPIb. Botrocetin is currently widely used in the detection of 
von Willebrand disease and GPIb-related disorders [67].  
A large group of snaclecs can bind to GPIb and inhibit GPIb-VWF binding and 
platelet aggregation. These snaclecs bind to different sites on GPIb and are 
used for identifying functional sites. Another group of snaclecs, such as 
rhodocetin and EMS16, can bind to integrins to inhibit platelet aggregation [68, 
69].  
1.1.4.2.3 Three finger toxins 
The structures of three finger toxins were discussed in section 1.1.1.1. One of 
the three finger toxin, dendroaspin (ormambin), has an RGD sequence in loop 
III that strongly interferes with the interaction between fibrinogen and its 
receptor αIIbβ3 complex to inhibit platelet aggregation [70]. Another three finger 
toxin, hemextin AB complex, specifically inhibits FVIIa and FVIIa-TF in the 
absence of FXa to exert its anticoagulant function [71].  
1.1.5 Non-toxic venom proteins 
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One class of the well-studied non-toxic venom proteins are Kunitz-type 
inhibitors. They are characterized by a conserved fold of approximately 60 
amino acids, stabilized by three disulfide bridges. Snake Kunitz-type inhibitors 
have been divided into two groups based on their function [72]. Trypsin 
inhibitor and chymotrypsin inhibitor are referred to as non-neurotoxic snake 
Kunitz-type inhibitors, whereas the homologs with neurotoxic effects belong to 
the neurotoxic snake Kunitz-type group [73], such as dendrotoxin described in 
section 1.1.1.2.3. Most of the snake Kunitz-type inhibitors inhibit serine 
proteinases of the trypsin/chymotrypsin family through their highly conserved 
P1 site. The specificity towards serine proteases is defined by the P1 amino 
acid and small sequence differences in the region that interacts with the 
proteases. The physiological role of non-toxic Kunitz-type inhibitors in snakes 
is unknown. It has been proposed that they are involved in the processes of 
coagulation, fibrinolysis and inflammation through undefined interactions with 
proteases. For example, textilinins (Txs), BPTI homologs from Pseudonaja 
textilis textilis, inhibit trypsin and plasmin. Therefore, they might be involved in 
plasmin-mediated digestion of fibrin clots. In fact, they reduce blood loss in a 
murine bleeding model [74].  
1.1.6 Summary 
Snake venoms are a rich source of pharmacologically active proteins and 
peptides, which provide excellent opportunities for the development of 
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research tools and therapeutic agents. Even after decades of study, snake 
venom remains as a hot area for discovering of new drug leads: 1) There are 
still a large portion of snake venom proteins that have never been studied due 
to the availability of venom or other technique limitations; 2) new applications 
of well documented proteins are reported, such as other than just inhibitors of 
platelet aggregation, recent studies have revealed disintegrins as possible 
leads for anti-cancer treatment [75]. Thus, there is a great potential in the 
study of snake venom proteins. 
1.2 Blood coagulation 
An intricate hemostatic system is designed to maintain blood in a fluid state 
under physiologic conditions. This system is also evolved to react to vascular 
injury to stop blood loss by sealing the defect in the vessel wall. Several 
components or systems are involved in haemostasis and thrombosis, 
including endothelium, platelet, coagulation system and the fibrin 
formation/fibrinolysis system. In this report, we will focus our discussion on the 
coagulation system as our proteins of interest are shown to be anticoagulants.   
1.2.1 Overview of blood coagulation 





Figure 1.4: The coagulation cascade. The blood coagulation cascade can be divided into 
three pathways: Intrinsic, extrinsic and common blood coagulation pathway. The intrinsic 
pathway is initiated by surface contact, while the extrinsic pathway is activated by tissue 
damage. In the intrinsic pathway, FVIIIa, FIXa and phospholipids form the intrinsic tenase 
complex, while in the extrinsic pathway, FVIIa, tissue factor and phospholipids form the extrinsic 
tenase complex. Both the complexes are able to activate FX to FXa. The two pathways merge 
into the common pathway at FXa. FXa together with FVa and phospholipids form the 
prothrombinase complex which in turn activates thrombin. Thrombin is responsible for the 
activation of fibrinogen to fibrin.  
Alternatively in the extrinsic pathway, TF:VIIa complex can first activate FIX. The newly 
generated FIXa then binds FVIIIa, on a phospholipid (PL) surface to form the extrinsic tenase 
complex, which catalyzes the conversion of FX to FXa. 
In addition, recent study indicats that thrombin can activate FXI, the intrinsic pathway 
coagulation factor, through a feedback loop. Thus, FXI may play a role in the growth and 
stability of thrombus.  
The principle initiating pathway of blooding coagulation under physiological 
conditions is the extrinsic pathway (tissue factor pathway), which involves 
components from both the blood and vascular system [76]. The central event 
in the extrinsic pathway is considered to involve tissue factor (TF), which is not 
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exposed to blood under normal physiological conditions. With vascular or 
endothelial cell injury, TF acts in concert with activated Factor VII (FVIIa) and 
phospholipids (the extrinsic tenase complex) to activate Factor IX and Factor 
X. Reaction in extrinsic pathway (FVIIa/TF complex) is tightly regulated by 
tissue factor pathway inhibitor (TFPI), a protein produced by the endothelial 
cell and consisting of three Kunitz domains. The first domain binds to and 
inhibits TF–VIIa, and the second, activated Factor X (FXa). The direct 
activation of FX is thereby rapidly down-regulated. FXa is required for TFPI to 
inhibit TF–VIIa. 
In contrast to the extrinsic pathway, the intrinsic pathway (contact pathway) 
can be defined as coagulation initiated by components entirely contained 
within the vascular system [76]. The intrinsic pathway is so called because it 
appears to be an intrinsic property of plasma: when blood or plasma is placed 
in a glass tube, it will clot spontaneously. This pathway results in the activation 
of FIX by FXIa providing a coagulation pathway independent of FVII. FIXa in 
turn activates FX, in concert with FVIIIa and phospholipid (the intrinsic tenase 
complex). The zymogen FXII is the first protein in the tightly regulated 
reactions who binds to negatively charged surface such as kaolin, dextran 
sulfate and sulfatides, resulting in auto-activation and action on its substrates 
– prekallikrein and FXI- to form kallikrein and FXIa. The major inhibitor of the 
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contact system is C1 inhibitor, which accounts for 95% of the plasma inhibitory 
capacity for FXIIa and more than 50% toward kallikrein [77].  
The extrinsic and intrinsic pathways both activate FX and merge into the 
common pathway. Once FXa is formed, it converts prothrombin to thrombin. 
The interaction of the four components of the prothrombinase complex (FXa, 
FV, phospholipids and calcium) provides a markedly increased rate of 
prothrombin activation than that achievable with only the enzyme (FXa) and 
substrate (thrombin). The catalytic-site serine of thrombin reacts with an 
arginine in the active center of antithrombin III (ATIII) to form a covalent 
inactive complex [78]. The inhibition produced by ATIII is potentiated by 
heparin. Once thrombin is bound to fibrin, it is resistant to ATIII and even more 
so to ATIII–heparin complex [79, 80]. Heparin cofactor II is a serpin (serine 
protease inhibitor) that selectively inactivates thrombin in the presence of 
heparin or dermatan sulfate [81]. When thrombin binds to thrombomodulin, it 
changes its substrate specificity and loses its ability to cleave fibrinogen and 
activation of FV and FVIII. Instead, it cleaves and activates protein C [82], 
which, in the presence of protein S, can inactivate FVa and FVIIIa. Protein C 
inhibitor also is a serpin that can inactivate protein C and thereby function as a 
potential procoagulant molecule. FXa also has a specific inhibitor, Z protease 
inhibitor, the action of which is markedly enhanced by protein Z, a vitamin 
K–dependent protein, in a phospholipid and Ca2+-dependent manner [83]. 
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Several of the components of the blood coagulation pathway are discussed in 
details here as they are targets or closely related to the functions of our 
proteins of interest.  
1.2.2 Factor VIIa and tissue factor 
The first enzyme in the clotting cascade consists of two subunits: a serine 
protease, FVIIa and a protein cofactor, TF [84]. The complex of TF and FVIIa 
(TF:VIIa) is tethered to the cell surface via TF. FVII circulate in the plasma as 
inert zymogen, while trace amounts of FVIIa are present in the circulation at all 
times [85]. TF binds Factor VII or VIIa with high affinity, resulting in a 1:1 
complex of the two proteins on the cell surface. So, there are two ways to form 
the TF:VIIa complex: through direct capture of circulating FVIIa by TF or 
through capture of FVII by TF followed by conversion of the bound FVII to VIIa. 
Once formed, the TF:VIIa complex triggers the blood clotting cascade in two 
ways. TF:VIIa can first activate FIX. The newly generated FIXa then binds with 
a protein cofactor, FVIIIa, on a phospholipid (PL) surface to form the IXa:VIIIa 
complex, which catalyzes the conversion of FX to FXa. Alternatively, TF:VIIa 
can directly activate FX. In in vitro conditions, FX is the preferred substrate of 
TF:VIIa. The low initial levels of TF:VIIa are thought to trigger enough of the 
clotting cascade to result in the back-activation of the rest of the bound FVII by 
downstream proteases. In addition, the TF:VIIa complex can catalyze the 
autoactivation of FVII bound to TF [86]. 
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1.2.3 Factor IX 
FIX is activated by cleavage of the Arg145–Ala146 and Arg180–Val181 
peptide bonds and release of a 35-residue activation peptide. Physiologically, 
FIX can be activated by either the FVIIa:TF or FXIa [87]. FXIa activation of FIX 
is part of the sustained phase of clotting because FVIIa/TF complex is rapidly 
inhibited by TFPI after generating small amounts of FXa and thrombin. The 
extrinsic pathway activation of FIX was at least the major path in vivo. The 
current formulation is that initially, a small amount of FVIIa is generated and 
with limiting amounts of TF, FIX activation is preferred to direct extrinsic FX 
activation [88]. The initiation phase of extrinsic FIX activation is followed by a 
burst of intrinsically activated FX that overwhelms the TFPI. This later stage, 
propagation, leads to a sufficiently high concentration of localized thrombin to 
clot fibrinogen. This theory accounts for the bleeding tendencies associated 
with FVIII or FIX deficiency and why most contact activation protein 
deficiencies do not have bleeding tendencies. 
1.2.4 Phospholipids 
Phospholipids interact with substrates, enzymes, and cofactors to play a 
critical role in the assembly and functional activity of the coagulation protease 
complexes. FIX and FX will bind to phospholipid vesicles only if they contain 
negatively charged phospholipids, most particularly phosphatidylserine. In 
vivo, the negatively charged phospholipids are likely provided by activated 
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platelets and damaged endothelial cells [89]. FVIII and FV bind 
phosphatidylserine by both hydrophobic and electrostatic interactions [90]. 
FVIII binding to phospholipid involves stereo-selective recognition of the 
o-phospho-L-serine moiety of phosphatidylserine [91]. Because the 
composition of phosphatidylserine exposed on the platelet membrane surface 
can increase from 2% to 13% after stimulation, the increase in 
phosphatidylserine content could account for the ability for FVIII to specifically 
bind the surface of thrombin-activated platelets [89]. 
1.2.5 Factor XI 
FXI is the zymogen of a trypsin-like serine protease that is activated by FXIIa 
and by both thrombin and FXIa [92], and it can then recognize FIX as its 
normal macromolecular substrate in plasma [93]. 
Human FXI is a disulfide-linked homodimer presenting in human plasma at a 
concentration of 4 to 6 µg/mL (approximately 30 nM) [94]. Plasma FXI 
circulates as a zymogen in human plasma as a complex with HK, which is 
required for binding of FXI to negatively charged surfaces [95]. The zymogen 
form of the protein is unique among coagulation factors because it is a 
disulfide-linked homodimer consisting of two identical polypeptide chains. 
Each FXI polypeptide contains 607 amino acids. Both the two polypeptides 
can be activated by FXIIa at an internal R369–I370 bond to yield a heavy 
chain (369 amino acids) and a light chain (238 amino acids) that contain a 
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typical trypsin-like substrate-binding pocket consisting of H413, D464, and 
S557 [96, 97]. FXI can also be activated by thrombin or by autoactivation. The 
presence of dextran sulfate as a negatively charged surface enhances the rate 
of activation of FXI by thrombin by approximately 2,000-fold. On the other 
hand, HK and fibrinogen have major inhibitory effects on the autoactivation 
and the thrombin-mediated activation of FXI in the presence of dextran sulfate 
[92, 98]. Activated platelets were shown to promote FXI activation by thrombin 
in the presence of either HK or ZnCl2 or in the presence of prothrombin and 
CaCl2 [99]. On the activated platelet surface, thrombin has been shown to be 
the preferred activator, compared with FXIIa or FXIa [100, 101].  
Human FXI is also shown to bind to platelet. Platelet FXI coagulant activity 
and antigen are present in well-washed platelet suspensions and constitute 
approximately 0.5% of the FXI activity in normal plasma [102, 103]. It has 
been suggested that platelet FXI could represent a disulfide-linked tetramer of 
four identical subunits. The individual subunit is a truncated form of plasma 
FXI lacking exon V. It is also possible that platelet FXI represents a protein 
linking to a platelet membrane protein via disulfide bond [104, 105]. 
The serine protease active site of FXIa can cleave and activate two major 
macromolecular substrates, including FIX and FXI. The regulation of FXIa 
depends on its localization. Within the plasma, four serpins have been 
demonstrated to inactivate FXIa: antithrombin III, α1-protease inhibitor, C1 
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inhibitor, and α2 antiplasmin [106-109]. In addition, platelets are known to 
secrete inhibitors of FXIa including protease nexin 2 (PN2), a truncated form of 
the transmembrane Alzheimer β-amyloid protein precursor that contains a 
Kunitz-type serine protease inhibitor domain [110]. PN2 is a potent inhibitor of 
FXIa that has considerably enhanced inhibitory activity in the presence of 
heparin, which provides a template for the assembly of FXIa/PN2 complexes 
[111]. Although the release of PN2 from activated platelets inhibits plasma 
FXIa activity in the environment of the heamostatic thrombus, platelet-bound 
dimeric (but not monomeric) FXIa is protected from inactivation by PN2 [112]. 
In contrast, endothelial cells have no such protective effect. Therefore, it has 
been suggested that the co-localization of dimeric FXIa and FIX to the 
activated platelet surface may serve to localize the FIX activation and 
subsequent coagulation reactions to the activated platelet surface that 
contains specific, high-affinity binding sites for the enzyme FIXa [113].  
It is worth to note that several observations suggest that FXI, in addition to its 
procoagulant activity, has an antifibrinolytic activity. For example, patients with 
severe plasma FXI deficiency are especially at risk for bleeding from tissues 
with high local fibrinolytic activity, including the urinary tract, the nose, the oral 
cavity, and the tonsils [114]. Moreover, FXI can be activated by thrombin and 
appears to play a role in the protection of fibrin clots against fibrinolysis [115]. 
This FXI–dependent down-regulation of the activation of fibrinolysis has been 
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postulated to occur as a consequence of a FXI–dependent burst in thrombin 
generation, resulting in the activation of thrombin-activatable fibrinolysis 
inhibitor (TAFI) or procarboxypeptidase B [116, 117].  
Recently evidence has drawn attentions on the possible contributions of high 
levels of FXI as a risk factor for venous thrombosis and cardiovascular disease 
in women. In addition, mice with targeted FXI gene deletion showed protection 
from FeCl3 induced carotid thrombosis [118]. Another study reported the 
dependence of surface- and tissue-factor–initiated thrombus propagation on 
FXI in primates [119]. Therefore, Factor XI levels may comprise a significant 
risk factor for thrombosis. 
1.3 Anti-thrombotic agents  
Thrombosis may occur if the capacity of anticoagulant mechanism is 
overwhelmed by the intensity of procoagulant stimulus. Pathologic thrombosis 
affects one person in 1000 individuals, can cause complications during 
pregnancy and surgery, and contributes to a number of cardiovascular 
diseases. Anti-thrombotic agents form the basis in the prevention and 
treatment of pathologic thrombosis. Anti-thrombotic agents can be classified 
as anti-platelets, anticoagulants and thrombolytic agents based on their 
targets and mechanisms. Here, we focus our discussion on the anticoagulants, 
which inhibit one or more steps in the blood coagulation cascade. The current 
available anticoagulants can be divided into traditional anticoagulants 
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(warfarin and heparin) and new anticoagulants that target specific 
factors/components (FXa and thrombin inhibitors) of the blood coagulation 
pathway.  
1.3.1 Warfarin 
Warfarin is a vitamin K antagonist. It interferes with the vitamin K cycle by 
inhibiting the reduction of vitamin K to vitamin K hydroquinone. As an 
anticoagulant, warfarin blocks the recycling of vitamin K, inhibits the vitamin 
K–dependent γ-carboxylation of Factors II, VII, IX, and X, an important step in 
the proper functioning of these anticoagulation factors that allows them to bind 
calcium at phospholipid surfaces upon coagulation occurs, and thus causes 
the liver to synthesize nonfunctional coagulation factors. Warfarin also 
interferes the vitamin K–dependent γ-carboxylation of proteins C and S, two 
antithrombotic proteins required to inhibit activated clotting Factors VIII and V. 
Further, warfarin also interferes with the reduction of vitamin K epoxide (KO) to 
vitamin K hydroquinone (K1H2) by blocking the vitamin K epoxide reductase 
complex (VKORC), the most important enzyme in recycling of vitamin K [120].  
Warfarin is mainly absorbed through the gastrointestinal tract mucosa and 
largely binds to albumin, while the unbound warfarin is the biologically active 
part. Therefore, any agent that binds to albumin and displaces warfarin may 
increase warfarin’s biological activity [121]. Standard fixed dose is not 
available for warfarin, as dosing is complicated by numerous drug-drug and 
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drug-food interactions. Further, warfarin function is affected by medical 
comorbidites, age, weight, and liver function. Thus, achieving safe and 
effective warfarin dosing is a challenge. In clinical usage, doses of warfarin 
must be titrated to the prothrombin time coagulation test, standardized and 
reported as the International Normalized Ratio (INR) [122]. 
1.3.2 Heparin 
Heparin is a sulfated polysaccharide with the highest negative charge of any 
naturally occurring polymer and a close relative to the heparan sulfate that 
exists on the endothelial surface. 
Both unfractioned heparin (UHF) and low molecular weight heparin (LMWH) 
are sulfated glycosaminoglycans extracted from animal sources, most 
commonly, porcine intestinal mucosa. The molecular range of UFH is 3000 to 
30,000 Da. UFH serves as a catalyst to ATIII by binding to lysine residues on 
the serine protease inhibitor and inducing a conformational change in its 
reactive center loop. This increases the inhibiting capacity of ATIII by several 
orders of magnitude, and it binds covalently to the serine residue in the active 
center of coagulation Factors XIIa, XIa, IXa, Xa, and thrombin [123]. 
Subsequently, heparin dissociates from ATIII and is then available to bind to 
additional ATIII molecules. However, the anticoagulant effect of UFH is 
variably reduced by binding to plasma proteins, such as VWF and platelet 
factor 4, as well as to different cells [124]. 
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LMWHs contain glycosaminoglycan chains of 2000 to 9000 Da, and are 
prepared by fragmentation or depolymerization of UFH. The dominant effect of 
LMWH is to inhibit FXa as their chains are not long enough to bridge thrombin 
to ATIII. As, LMWHs exhibit less binding to cells and plasma proteins than 
UFH, they have more predictable pharmacokinetics and almost 100% 
bioavailability after subcutaneous injection [125]. 
Both UFH and LMWH have limitations and potential side effects. UFH binding 
to osteoblasts and osteoclasts causes heparin-induced osteoporosis, and 
UFH interaction with platelet factor 4 and platelets can cause 
immune-mediated platelet activation and heparin-induced thrombocytopenia 
(HIT), a life threatening disease. HIT is characterized by thrombocytopenia 
caused by in vivo immunoglobulin G (IgG)-mediated platelet activation, with 
increased risk of thrombosis [126].  
1.3.3 Factor Xa inhibitors 
FXa inhibitors, including agents that block FXa indirectly or directly, have been 
developed. Indirect inhibitors act by catalyzing FXa inhibition by ATIII. In 
contrast, direct FXa inhibitors bind directly to the active site of FXa to block its 
interaction with substrates.  
Pentasaccharides were used as template for developing indirect FXa 
inhibitors as they contain structural features that allow tight binding to ATIII. 
Fondaparinux, which consists of five saccharide units and has been modified 
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from the native pentasaccharide by the addition of four specific sulfate groups, 
is the shortest mucopolysaccharide chain that binds to ATIII. Like UFH and 
LMWH, fondaparinux, is an indirect inhibitor of coagulation, but it lacks any 
effect on thrombin. It catalyzes the inhibition of pure FXa without any effect on 
platelets or TFPI [127, 128]. Later, Idraparinux is made by the addition of 
seven methyl groups to fondaparinux. It binds to ATIII with high affinity and 
has a half-life of 80 hours [129]. One disadvantage of pentasaccharides is 
their clearance route. Pentasaccharides are excreted via the kidneys without 
prior metabolism and therefore have the potential to accumulate in patients 
with impaired renal function, which could lead to an increased risk of bleeding 
[130]. 
Direct FXa inhibitors are small molecules that reversibly block the active site of 
FXa. Advances have been made on the development of oral inhibitors of FXa 
in recent years. One of the oral FXa inhibitor, apixaban, was proved to have 
superior pharmacological properties. It has high oral bioavailability and a 
half-life of about 12 hours. Food has no effect on its absorption, and the drug 
produces a predictable anticoagulant effect. Apixaban is cleared through both 
the fecal and renal route with renal elimination accounting for about 25% of 
drug clearance [131, 132]. Another oral FXa inhibitor, rivaroxaban, is an 
oxazolidone derivative. It inhibits FXa with a Ki of 0.4 nM, and has a half-life of 
about nine hours [133].  
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1.3.4 Thrombin inhibitors 
As the same of FXa, thrombin can be inhibited indirectly or directly. Indirect 
inhibitors that are specific for thrombin act by catalyzing heparin cofactor II. In 
contrast, direct inhibitors bind to thrombin and block its interaction with 
substrates. Based on the administering route, thrombin inhibitors can be 
classified as parenteral and oral inhibitors.  
Parenteral inhibitors include hirudin, lepirudin, argatroban and bivalirudin. 
Hirudin is the principal anticoagulant in the saliva of the medicinal leech 
(Hirudo medicinalis). Hirudin consists of a single polypeptide chain of 65 
amino acids, with a sulfate group that increases affinity for thrombin. Lepirudin 
is produced in yeast using recombinant technology. Its structure is similar to 
natural hirudin, though the absence of the sulfate group reduces its activity. 
Hirudins are bivalent direct thrombin inhibitors—they bind thrombin with high 
affinity, forming noncovalent, essentially irreversible, 1:1 stoichiometric 
complexes. Binding occurs at exosite 1 (substrate-binding site) and the 
apolar-binding site located near the catalytic site of thrombin [134]. Argatroban 
is a potent agent that stands apart among the parenteral direct thrombin 
inhibitors, as a univalent inhibitor that binds reversibly only to the active site of 
thrombin. It is a synthetic heterocyclic derivative of L-arginine, and inhibits 
both free and clot-bound thrombin [135]. Bivalirudin is a hirudin analogue. It is 
a 20 amino-acid synthetic polypeptide. Bivalirudin has several key similarities 
34 
 
to hirudin. Bivalirudin is also a bivalent direct thrombin inhibitor, with its 
N-terminus moiety binding to the active site of thrombin and its C-terminus 
moiety binding to exosite 1. Bivalirudin binds thrombin with high affinity to form 
a 1:1 stoichiometric complex. However, once bound, thrombin cleaves the 
Arg–Pro bond in the N-terminus of bivalirudin. This allows for recovery of 
thrombin activity, with fibrinogen competing with the bivalirudin remnant for 
thrombin [136, 137]. 
Oral thrombin inhibitors include ximelagatran and dabigatran etexilate. 
Ximelagatran is the orally available prodrug of the univalent direct thrombin 
inhibitor melagatran. Dabigatran etexilate is a double prodrug. It is absorbed 
from the gastrointestinal tract with a bioavailability of 5% to 6%. Absorption 
requires an acid microenvironment and is reduced by acid suppression 
therapy. Once absorbed, dabigatran etexilate is converted by esterases into 
its active metabolite, dabigatran [138, 139].  
1.4 Rational and scope of the study 
The banded krait (Bungarus fasciatus) is a species of elapid snake found on 
the Indian Subcontinent and in Southeast Asia. Though a plethora of different 
proteins, including three-finger toxins, Kunitz-type protease inhibitors, 
natriuretic peptides and C-type lectins, have been isolated from the venom of 
Bungarus snakes, the venom of Bungarus fasciatus has not been extensively 
studied. Thus, there is an opportunity to identify novel proteins/peptides from 
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this venom. In order to identify novel proteins/peptides, we screened the 
fractionated B. fasciatus venom using a variety of biological assays. 
Neurotoxicity and cytotoxicity were detected in some fractions, whose 
contents showed similarities to well characterized α/β-bungarotoxins. 
Interestingly, we also detected haemostatic effects in a few fractions. Although 
haemostatic effects exist ubiquitously in snake venom envenomation, 
haemostatic toxins from Bungarus genus are less studied.  
Haemostasis is an important physiological process that maintains the integrity 
of the blood circulatory system during vascular injury through the cessation of 
blood loss [140]. In the event when procoagulant stimuli overwhelms the 
anticoagulant and fibrinolytic systems, pathological thrombosis occurs, leading 
to vascular occlusion and consequences such as stroke, myocardial infarction, 
deep vein thrombosis and pulmonary embolism [141]. Therefore, effective 
anticoagulation forms the basis of thromboprophylaxis in susceptible patients 
by preventing unwanted clot formation while facilitating the clearance of 
existing clots by intrinsic fibrinolytic system. The clinical benefits of 
anticoagulation therapy have been widely reported in literature [142-144].   
Despite the importance of anticoagulation therapy and intensive research, few 
effective and safe anticoagulants have emerged in the market over the last 70 
years. Heparin, the first widely available anticoagulant agent, was introduced 
in the 1930s and presented the first breakthrough in anticoagulation therapy. 
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However, the usage of heparin was limited by the need for parenteral dosing, 
which made self-administration of the drug nearly impossible [145]. This was 
overcome when warfarin, a vitamin K antagonist, was synthesized in 1940 and 
became the first orally available anticoagulant [146]. Improved knowledge of 
the blood coagulation cascade has also led to the development of new 
anticoagulant agents such as low molecular weight heparin (LMWH), which 
has similar efficacy to heparin while having more convenient and cost-effective 
dosing [147-149]. In addition, several other selective anticoagulants such as 
fondaparinux, idraparinux and dabigatran have also been developed [132, 
150-152].  
The above-mentioned agents form the cornerstone in conventional 
anticoagulation therapy, but each bear significant limitations to their utility in 
anticoagulant therapy. For example, Heparin-Induced Thrombocytopenia (HIT) 
is a life threatening antibody-mediated reaction to heparin that can result in 
venous or arterial thrombosis. The newer LMWH, although reduces the risk of 
HIT incidence, it is not totally eliminated. Antidotes are not available for 
fondaparinux and idraparinux in the event of overdosage, which poses a 
problem especially with idraparinux owing to its long half-life. Warfarin, on the 
other hand, has a narrow therapeutic index, delayed onset of action, is 
susceptible to multiple food and drug interactions, and requires frequent 
monitoring to avoid consequences of over- or underdosing [153, 154]. Thus, it 
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is widely acknowledged as a cheaper but cumbersome anticoagulant agent to 
use. While newer oral anticoagulants such as dabigatran [155, 156] and 
rivaroxaban [157, 158] targeting specific steps in the anticoagulation pathway 
appear to offer the benefits of existing anticoagulants while minimizing on 
adverse bleeding events, none of these new agents are without risks of 
adverse reactions. For example, recent studies have reported their 
association with acute coronary events [159, 160]. As such, there is a 
tremendous demand for the development of novel anticoagulant agents.  
FXa, thrombin, FVIIa and tissue factor participating in the common and 
extrinsic pathways are prime targets for designing antithrombotic drugs, as the 
inhibition of these proteins can easily inhibit clot formation [161]. However, 
such drugs are usually associated with high risks of excessive bleeding [162, 
163]. Therefore, strategies that inhibit abnormal thrombus formation without 
impeding the clotting response to tissue injuries are highly attractive. One 
such strategy would be to target components along the intrinsic pathway 
which will slow down the coagulation cascade in the event of intravascular 
thrombosis, and yet not result in aberration to clot formation in response to 
injury. This theory is supported by the observation that patients suffering from 
deficiencies of proteins along the intrinsic pathway exhibit significantly milder 
bleeding symptoms as compared to patients deficient in factors of the extrinsic 
or common pathways[164].  
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Factor XI (FXI) is an important serine protease zymogen in the intrinsic 
pathway. It is suggested to play a significant role in animal thrombosis models 
[165, 166]. In contrast to FX and thrombin, disruption of FXI resulted in little 
bleeding tendency [167]. Further, patients with deficiency in plasma FXI 
experienced lower chance of deep vein thrombosis and ischemic stroke [168, 
169]. Thus, FXI has been recognized in recent years as a new drug target for 
antithrombotic drug design. 
In this report we identified and characterized two anticoagulants from 
Bungarus fasciatus snake venom in detail. The anticoagulants are extrinsic 
tenase complex inhibitors (BF-AC1 and BF-AC2) and FXIa inhibitors (fasxiator 
and its variants).  
The scope of this thesis covered the following points: 
1. Identification of novel anticoagulant proteins from Bungarus fasciatus 
venom through sequential fractionation coupled with functional assays. 
2. Structural and functional characterization of BF-AC1 and BF-AC2, 
selective extrinsic tenase complex inhibitors. 
3. Characterization of the anticoagulant properties of Fasxiator, selective 
inhibitor of FXIa. 
4. Point mutagenesis studies of rFasxiator to improve potency and selectivity. 
5. Characterization of rFasxiatorN17R,L19E in in vivo model. 
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Fractionation and functional screening of Bungarus 
fasciatus venom 
2.1 Introduction 
Snake venom is a highly modified and developed form of saliva, containing 
toxins that are injected into the prey via modified fangs. To study the functions 
of the individual protein inside the venom, proper fractionation methods are 
needed for separating the different compositions of the snake venom. 
Size-exclusion chromatography (SEC) can be used as an initial step for 
fractionating proteins. It can be followed by reverse-phase high performance 
liquid chromatography (RP-HPLC) where proteins will be separated on the 
basis of hydrophobicity. The mass and homogeneity of purified protein can be 
determined by electrospray ionization-mass spectrometry (ESI-MS). In order 
to identify novel proteins/peptides, we screened the fractionated B. fasciatus 
venom using a variety of biological assays, including in vivo toxicity, MTT 
assay，hemolytic assay and anticoagulant assays.  
2.2 Methods 
2.2.1 Size exclusion chromatography (SEC) 
Crude Bungarus fasciatus venom (50，100 or 150 mg) (a generous gift from 
Professor Cassian Bon, Pasteur Institute, Paris, France) was dissolved in 1 ml 
of distilled water and clarified by centrifugation at 13,200 rpm for 10 min. The 
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clarified venom solution was applied to a HiLoad 16/60 Superdex 30 
preparative grade size exclusion column (GE Healthcare Life Sciences, 
Piscataway, New Jersey, USA) equilibrated with 50 mM Tris-HCl buffer (pH 
8.0) and eluted with the same buffer using ÄKTA Prime Plus system (GE 
Healthcare Life Sciences, Piscataway, New Jersey, USA) at 0.5 ml/min flow 
rate. The elution of proteins from the column was monitored at 280 nm. 
2.2.2 Reverse phase high performance liquid chromatography 
(RP-HPLC) 
Pooled fractions from SEC were applied to a Jupiter C18 (250 x 4.6 mm or 250 
x 10 mm) reversed-phase column (Phenomenex, Torrance, California, USA) 
and resolved by a multi-step gradient elution profile (flow rate 1 ml/min or 5 
ml/min) with buffer A being 0.1% TFA in water and buffer B being 0.1% TFA in 
80% acetonitrile water solution using the Chromeleon Chromatography Data 
System on a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific, 
Waltham, Massachusetts USA). 
2.2.3 Electrospray ionization mass spectrometer (ESI-MS) 
Samples (20 µl) were injected through the auto-sampler into a LCQ Fleet Ion 
Trap Mass Spectrometer (Thermo Scientific, Waltham, Massachusetts, USA) 
with a flow rate of 100 µl/min, the signals after injection were captured using 




2.2.4 N-terminal sequencing 
N-terminal sequencing of the pyridylethylated proteins was performed by 
automated Edman degradation using a PPSQ31 protein sequencer 
(Shimadzu, Kyoto, Japan) equipped with an UV detector and a pump. The 
PTH amino acids were identified by matching their retention times with those 
of standards. The sequences obtained were compared to other protein 
sequences in the database using Basic Local Alignment Search Tool 
(BLAST). 
2.2.5 Protein concentration assay 
NanoDrop Spectrophotometer ND-1000 (Wilmington, Delaware, USA) was 
used to measure the protein concentration in the samples at 280 nm. With the 
sampling arm open, 2 µL of distilled water was first loaded onto the lower 
measurement pedestal using a pipette. The sampling arm was then closed 
and a spectral measurement made. The purpose was to blank the system. 2 
µL of the samples were then loaded, one at a time. The upper and lower 
measurement pedestals were cleaned with distilled water after each 
measurement to prevent sample carryover which may affect the accuracy of 
results. 
2.2.6 Cell culture 
Human derived neuroblastoma SH-SY5Y and colon carcinoma HCT116 cell 
lines were routinely cultured with Sigma-Aldrich Dulbecco’s Modified Eagle’s 
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Medium (DMEM) HEPES Modification and High Glucose in an incubator 
humidified with 95% air and 5% CO2. The medium contained 4500 mg/L 
glucose, L-glutamine and HEPES. Fetal bovine serum (10%), sodium 
bicarbonate (7.5% w/v) and penicillin (100 µg/ml) were also added. 
Hydrochloric acid or sodium hydroxide was used to adjust the pH of the 
medium to around 7.4 before filtering it through a 0.22 µm membrane filter.  
Cells were harvested from petri dishes after their detachment using trypsin 
diluted in Phosphate Buffered Saline (PBS) solution. The resuspended cells 
were then seeded in 96-well microplates, at an approximate initial density of 
2×104 cells/well, in the DMEM medium. These cells were utilized in the 
cytotoxicity assay. 
2.2.7 MTT cell proliferation assay 
Vybrant® MTT Cell Proliferation Assay Kit (V-13154) (Life technologies, 
Carlsbad, California, USA) was used for this assay. Appropriate volumes of 
the fractions were added to the seeded cells in the 96-well microplates as 
mentioned in above. The cells were then incubated for 72 h. The DMEM 
medium was then removed and replaced with 100 µL of fresh culture medium 
(Gibco® phenol red-free DMEM, Life technologies, Carlsbad, California, USA). 
MTT stock solution (10 µL of 12 mM) was then added to each well. MTT stock 
solution was prepared by adding 1 mL of sterile PBS to one 5 mg vial of MTT 
included in the kit. A negative control of 10 µL of MTT stock solution added to 
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100 µL of medium alone was also included. The cells were then incubated at 
37 °C for 4 h. SDS-HCl solution (100 µL), prepared by adding 10 mL of 0.01 
HCl to a tube containing 1 g of SDS, was then added to each well and mixed 
thoroughly using a pipette. The microplate was then incubated at 37 °C for 18 
h and its absorbance was read at 570 nm. 
2.2.8 In vivo toxicity 
The toxicity study was carried out under National University of Singapore 
animal protocol 001/11 approved by the Institutional Animal Care and Use 
Committee (IACUC). Toxicity of proteins in animals was examined by 
dissolving the protein in PBS before the solution was administered 
intraperitoneally into Swiss albino mice of approximately 20 g in weight. Mice 
behaviour was observed and recorded for an hour or until the time of death of 
the animal.  
2.2.9 Hemolytic assay  
Blood from health human donor was collected into a solution of 3.2% sodium 
citrate and centrifuged for 15 min at 3,000 rpm at room temperature. The 
plasma was discarded and the red blood cells (RCBs) were washed three 
times with saline. RBCs (50 µl) were added into 0.95 ml saline containing 
protein. For negative control, no protein was added. For positive control, 0.1% 
Triton was used. The tubes were incubated at 37 ºC for 1 h. RBCs were 
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removed by centrifugation at 3,000 rpm for 15 min at room temperature. The 
absorbance of the supernatant was measured at 540 nm.  
2.2.10 Effect on activated partial thromboplastin time (aPTT)  
Human plasma was obtained from healthy donor’s blood by centrifugation of 
the blood (containing one part 3.2% sodium citrate and 9 parts of blood) at 
1500 rcf for 15 min. Equal volumes (50 µl) of human plasma, APTT-XL, 20 mM 
CaCl2 and various concentrations of protein diluted with HEPES buffer (25 mM, 
pH 7.4) were pre-warmed to 37°C individually. Protein was added to plasma 
and incubated for 10 min, followed by the addition of APTT-XL and further 
incubation of 3 min. Clotting was initiated by the addition of 20 mM CaCl2 to 
the mixture and the clot formation was measured using an Infinite M200 
microplate reader [170] (Tecan, Männedorf, Switzerland) at 650 nm for fibrin 
polymers formation [171].  
2.2.11 Prothrombin time (PT)  
Plasma, thromboplastin-D and various concentrations of protein diluted with 
HEPES buffer (25 mM, pH 7.4) were pre-warmed to 37°C individually. Protein 
(100 µl) was added to plasma (100 µl) and incubated for 10 min. Clotting was 
initiated by the addition of thromboplastin-D (100 µl) to the mixture and the clot 
formation was measured using a BBL fibrometer (Becton Dickinson and Co., 




2.3 Results  
2.3.1 In vivo toxicity 
To isolate the different proteins we subjected Bungarus fasciatus venom (100 
mg) to a two-step fractionation using size exclusion chromatography (SEC) 
and reversed phase high performance liquid chromatography (RP-HPLC) 
(Figure 2.1 A-E). The RP-HPLC fractions were pooled according to the 
chromatography. The molecular weights (MW) and homogeneity of each 
RP-HPLC pools were then determined by electrospray ionization mass 
spectrometry (ESI-MS). Pools with only one major protein were lyophilized for 
further usage. While, several pools (Figure 2.1 F-I) were then subjected to a 
shallow gradient RP-HPLC to separate the two main proteins inside the pools 
and the resulted fractions were pooled and lyophilized based on ESI-MS 
results. The in vivo toxicity of the lyophilized proteins were determined by 
dissolving the proteins into PBS and administered intraperitoneally into Swiss 
albino mice. The symptoms of the mice after administering were recorded 
(Table 2.1). Results indicated that 6 proteins were able to induce neurotoxic 
symptoms and eventually death in tested animals, while the other 9 proteins 




Figure 2.1: Fractionation of Bungarus fasciatus venom for in vivo toxicity assay. (A) SEC 
of B. fasciatus venom. Crude venom (150 mg) was dissolved in 50 mM Tris-HCl buffer (pH 8.0) 
and separated on a HiLoad 16/60 Superdex 30 preparative grade column. Fractions (1 ml) were 
collected and pooled into pools A-D. Individual pools were subfractionated on a RP-HPLC 
column (B-E). The resulted RP-HPLC fractions were pooled into peaks A1, A2, A3, A4, A5, A6, 
B1, B2, B3, C1, C2, D1, D2 and D3. Peaks A2, B2&B3, C2 and D2&D3 were further subjected 
to another round of shallow gradient RP-HPLC (F-I).  
 
Table 2.1: In vivo toxicity of purified proteins. 







A1 40.88 6969 Cannot stand up after injection, died in 2’ 
A1 2.3 6969 6’ obviously weak, 7’ died 
A2-1 23.5 6699 9’30” lie down quietly; 11’ spasm and 
died 
A2-2 9.67 6912 Died in 5’, lie down and died; no much 
struggle. The mice was still active when 
at 2’ before lie down 
A3 9.1 7420 No response 
A4 20.5 7423 No response 
A5  51.6 7268 0-57’ stay active, play with bed material. 
57’ somehow not as active as before. 
Show body weight loss in 24 hours.  
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A5 50 7268 Repeat with three mice. Loss of body 
weight was not observed. 
A6 9.36 7459 No response 
B1 6.2 7424 No response 
B2&B3-1 20.9 6433 No response 
B2&B3-2 18.6 6977 No response 
C1 22.9 7133/7305 No response 
C2-1 42.2 6505 No response 
C2-1 148 6505 No response 
D1 10.54 6384 Clumsy after injection; 5’ lie down; 
seems try to hiccup, tremble movements; 
hind limb meaningless struggling and 
died. Organs were intact 
D2&D3-1 14.1 6325 Died in 5’; suddenly lie down, tremble 
movement for a while and died 
D2&D3-2 14.3 6374 0-5’ play with bed material, stay active, 
normal. 13’ suddenly not very active, 
hunch back appeared (just a moment, not 
very heavy); 16’ better, active again; 18’ 
lie down, but still reactive to stimulus 
and touch; 19’30” active again, play with 
bed material; 20’ lie down; 21’ stay in 
one corner; 22’ active, play with bed 
material; 22.5’ lie down again, hunch 
back appeared (not very heavy); 24’-32’ 
lie down; 38’ play around for a while; 
38’-58’ most of the time lied on the bed 
material’ 63’ a bit more active than the 
past; 68’ became active 
D2&D3-2 25 6374 5’ begin to show inactive; quiet, clumsy, 
stay in one corner, slightly twitch; the 
color of eyes changed from light to dark; 
hind limb meaningless struggling; seems 
try to hiccup, forelimb lift up from floor, 
body hiccup; eyes protruding; 10-15’ 







Bungarus fasciatus venom (100 mg) was fractionated (Figure 2.2) as 
described in section 2.3.1. The RP-HPLC fractions were pooled and 
lyophilized. The cytotoxicity of each RP-HPLC pools (20 µM) were tested 
using two cell lines: human derived neuroblastoma SH-SY5Y and colon 
carcinoma HCT116 cell lines (Figure 2.3). The results indicated that the 2 cell 
lines showed varying susceptibility to the protein pools. In general, SY5Y 
seemed more sensitive to the toxic proteins presenting in the venom 
compared to HCT116 as shown by the higher reduction in absorbance. 
Proteins presenting in pool G3 were most potent in decreasing viability of both 
cell lines. ESI-MS results indicated that the pools that yielded cytotoxicity were 
either 13kDa or 20kDa in molecular weight (Table 2.2). They are possibly 
PLA2 and β-bungarotoxin. Indeed, both the proteins showed PLA2 activity 
when tested using PLA2 kit (activity was reflected by an obviously color 
change of the reaction mixture). To confirm the cytotoxic activities, the dosage 
dependent effect of pool A2 and G3 were plotted (Figure 2.4). Pool A2 and G3 
were chosen for their relatively high abundance in the venom comparing to 
other active pools. The amount of other pools was not enough to generate a 
dose dependent curve. Indeed, pool A2 and G3 induced cell death in a dose 
dependent manner of SY5Y cells. Their effects on HCT116 cells were less 
significant which was consistent with the earlier observations that HCT116 
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cells were less sensitive to the toxic proteins presenting in the venom 
compared to SY5Y. 
 
Figure 2.2: Fractionation of Bungarus fasciatus venom for cytotoxicity assay. (A) SEC of 
B. fasciatus venom. Crude venom (100 mg) was dissolved in 50 mM Tris-HCl buffer (pH 8.0) 
and separated on a HiLoad 16/60 Superdex 30 preparative grade column. Fractions (1 ml) were 
collected and pooled into pools A-G. Individual pools were subfractionated on a RP-HPLC 
column (B-H). Fractions were pooled into A1, A2, A3, B1, B2, B3, B4, B5, C1, C2, C3, C4, C5, 





Figure 2.3: Cytotoxicity effects of pooled fractions. (A-D) The cytotoxicity effect of pooled 
fractions A1, A2, A3, B1, B2, B3, B4, B5, C1, C2, C3, C4, C5, C6, C7, D1, D2, D3, D4, E1, E2, 
E3, E4, F1, F2, F3, G1, G2, and G3 were tested using MTT assays. Assays were done in 
triplicates. Error bars represent standard deviations. 
Table 2.2: Molecular weights of cytotoxic fractions. 
Pool  
Name 
Molecular Weight (percentage in total) 
1 2 3 
A2 20687.9 (56.84%) 20626.6 (11.04%) 20706.6 (8.82%) 
D3 20752.9 (49.51%) 20783.3 (19.70%) 20689.9 (12.86%) 
D4 13306.8 (87.52%) 13323.9 (6.46%) 13339.9 (4.10%) 
F3 13361.2 (83.39%) 13455.5 (5.40%) 13379.0 (5.30%) 
G3 13360.6 (72.59%) 7528.5 (8.46%) 13455.8 (8.12%) 
 
 
Figure 2.4: Dose dependent effect of cytotoxic proteins. The cytotoxic pools A2 (A) and G3 
(B) were series diluted and tested with MTT assays. Assays were done in triplicates. Error bars 




2.3.3 Hemolytic assay 
Bungarus fasciatus venom (50 mg) was fractionated (Figure 2.5) as described 
in section 2.3.1. The RP-HPLC fractions were lyophilized. The fractions 
showing cytotoxic effects were excluded from this experiment. The effects of 
selected RP-HPLC fractions in lysing red blood cells were determined using 
hemolytic assays. As shown by the results (Figure 2.6), none of the tested 
fractions were able to lyse red blood cells.  
 
Figure 2.5: Fractionation of Bungarus fasciatus venom for hemolytic assay. (A) SEC of B. 
fasciatus venom. Crude venom (50 mg) was dissolved in 50 mM Tris-HCl buffer (pH 8.0) and 
separated on a HiLoad 16/60 Superdex 30 preparative grade column. Fractions (1 ml) were 
collected and pooled into pools A-E. Individual pools were subfractionated on a RP-HPLC 
column (B-F). Fractions A1, A2, A3, A4, A5, A6, A7, A8, B1, B2, B3, B4, B5, B6, B7, C1, C2, C3, 





Figure 2.6: Hemolytic assays of pooled fractions. (A-D) RP-HPLC fractions were tested for 
effects in lysing red blood cells. None of the proteins resulted in significant increases of the 
hemoglobin levels in the supernatant as compared to negative control (NC). Assays were done 
in triplicate. Error bars represent standard deviations. 
2.3.4 Anticoagulant activity 
Bungarus fasciatus venom (100 mg) was fractionated (Figure 2.7) as 
described in section 2.3.1. The RP-HPLC fractions were pooled and 
lyophilized. Monomeric and dimeric phospholipase A2 (PLA2) enzymes found 
in various snake venoms are known to exhibit highly potent anticoagulant 
activities [267]. Therefore, in bid of identifying novel anticoagulants, only 
fractions that contained proteins with molecular weights outside those of 
monomeric or dimeric PLA2 enzymes were screened for anticoagulant 
activities, namely aPTT and PT (Figure 2.8). 
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Three RP-HPLC pools (B1, C1 and D1) prolonged aPTT without significant 
effects on PT, while two RP-HPLC pools (A5 and E2) prolonged both aPTT 
and PT. The MWs of components of each RP-HPLC pools were determined 
by ESI-MS (Table 2.3). 
 
Figure 2.7: Fractionation of Bungarus fasciatus venom for anticoagulant activity assay. 
(A) SEC of B. fasciatus venom. Crude venom (100 mg) was dissolved in 50 mM Tris-HCl buffer 
(pH 8.0) and separated on a HiLoad 16/60 Superdex 30 preparative grade column. Fractions (1 
ml) were collected and pooled into pools A-E. Individual pools were subfractionated on a 
RP-HPLC column (B-F). Fractions were pooled into A1, A2, A3, A4, A5, B1, B2, C1, D1, D2, E1 
and E2. 
 
Figure 2.8: Anticoagulant activity of pooled fractions. Pooled fractions were evaluated using 
aPTT and PT in triplicates. Error bars represent standard deviations. Pools B1, C1 and D1 





Table 2.3: Molecular weights of proteins in RP-HPLC pooled fractions of anticoagulant assays. 
Pools  A1  A2  A3  A4  A5 B1 B2  C1  D1  D2  E1  E2  
Molecular 
Weight  












6505  6363 
/6325  
6373  
2.4 Discussion and conclusion 
The venom of the snakes belonging to Bungarus genus was reported to 
contain mainly neurotoxins. As expected, in vivo toxicity study has identified 
several neurotoxic proteins from the Bungarus fasciatus venom. However, we 
were not able to identify proteins with other activities from this study.  
We further tested the cytotoxic effects of the venom proteins. As neurotoxicity 
was detected, we have chosen a neural cell line and a non-neural cell line for 
this assay to test whether any of the proteins can induce cell death only on 
neural cells. The results indicated that a few pooled fractions were able to 
induce cell death and in general the cytotoxic effects were more significant in 
SY5Y cells than in HCT116 cells. Further analysis of the active fractions 
suggested that all of them possess PLA2 activity. As the mechanisms of PLA2 
induced cell death were well documented [173], we did not further proceed in 
this direction. 
We also tested the abilities of the venom proteins in lysing red blood cells. As 
PLA2 activity can potentially resulted in hemolytic effects [174], the fractions 
containing PLA2 activity were precluded from this assay. The results 
suggested that none of the tested fractions were able to lyse the red blood 
cells when incubated together with the red blood cells in PBS.  
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Finally, we tested the venom proteins for anticoagulant activity. Three pooled 
fractions were able to prolong aPTT while leaving PT unaffected. Two pools 
were able to prolong both aPTT and PT.  
To determine the identities of the interested proteins presenting in the venom, 
we have subjected them to N-terminal sequencing (Table 2.4). The proteins 
are named by their molecular weight. 7268 and 7425 are abundant proteins 
with undetermined activity; 6969 and 6383 are abundant proteins with 
neurotoxic effects; 6373 is a protein with both neurotoxic and anticoagulant 
effects; 6977 and 7307 are proteins with anticoagulant effects. The results 
indicated that 7268 and 7425 are non-conventional three finger toxins; 6969, 
6383 and 6373 are neurotoxic three finger toxins while 6977 and 7307 are 
Kunitz-type protease inhibitors.   
Although haemostatic effects ubiquitously exist in snake venom envenomation, 
haemostatic toxins from Bungarus genus are less studied. Thus, we focused 









Table 2.4: N-terminal sequences of purified proteins. 
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Identification and characterization of novel inhibitors on 
extrinsic tenase complex from Bungarus fasciatus 
(banded krait) venom 
3.1 Introduction  
In chapter 2 of the thesis, we subjected fractionated Bungarus fasciatus 
venom to several biological assays. Preliminary studies showed that some of 
the fractions exhibited anticoagulant effects when tested with standard clotting 
assays. Herein, we report the purification, structural elucidation and functional 
characterization of two venom proteins that have selective inhibitory effect on 
the extrinsic tenase complex of the blood coagulation pathway. Interestingly, 
our studies revealed that these two anticoagulant proteins are in fact isoforms 
of β-bungarotoxin, the key presynaptic neurotoxin found in Bungarus venoms. 
This is the first report of anticoagulant activity of β-bungarotoxins.  
3.2. Materials and methods 
3.2.1 Materials 
Lyophilized B. fasciatus venom was a generous gift from Professor Cassian 
Bon, Pasteur Institute, Paris, France. β-bungarotoxins were obtained from (i) 
Prof. Inn-Ho Tsai, Academia Sinica, Taiwan; (ii) Latoxan (Valence, France); (iii) 
Biotium (Hayward, California, USA). Thromboplastin and APTT-XL were 
purchased from Pacific Hemostasis, Thermo Scientific (Waltham, 
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Massachusetts, USA). HemosIL RecombiPlasTin 2G was from Instrumental 
Laboratory (Bedford, Massachusetts, USA), Thrombin from bovine plasma 
was purchased from Merck Millipore (Darmstadt, Germany). FVIIa, FIXa, FXa, 
FXIa, activated protein C, plasmin, thrombin and RVV-X were purchased from 
Hematologic Technologies (Essex Junction, Vermont, USA). FXIIa, kallikrein, 
trypsin and urokinase were purchased from Calbiochem, EMD Millipore 
(Billerica, Massachusetts, USA). Chromogenic substrates N-Benzoyl-L 
-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroaniline hydrochloride and its 
methyl ester (S-2222), H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline 
dihydrochloride (S-2238), H-D-Valyl-L-leucyl-L-lysine-p-nitroaniline 
dihydrochloride (S-2251), H-D-Isoleucyl-L-prolyl-L-arginine-p-nitroaniline 
dihydrochloride (S-2288), H-D-Prolyl-L-phenylalanyl-L-arginine-p-nitroaniline 
dihydrochloride (S-2302), L-Pyroglutamyl-L-prolyl-L-arginine-p-nitroaniline 
hydrochloride (S-2366), L-Pyroglutamyl-glycyl-L-arginine-p-nitroaniline 
hydrochloride (S-2444), and 3-Carbomethoxypropionyl-L-arginyl-L- 
prolyl-L-tyrosine-p-nitroaniline hydrochloride (S-2586) were purchased from 
DiaPharma (Westchester, Ohio, USA). D-leucyl-phenylglycyl-arginine-p 
-nitroanilide diacetate (Spectrozyme FIXa) was purchased from Sekisui 
Diagnostics (Stanford, Connecticut, USA). 
Dithiothreitol, 40 % acrylamide and Coomassie brilliant blue R-250 were 
purchased from Bio-Rad Laboratories (Hercules, California, USA). Ammonium 
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persulphate was purchased from AppliChem GmbH (Darmstadt, Germany). 
TEMED was purchased from MP Biomedicals (Solon, Ohio, USA). Tris-glycine 
SDS buffer was purchased from First Base (Singapore). Tris base and 
Guanidine HCl were purchased from Alfa Aesar (Ward Hill, Massachusetts, 
USA). Pre-stained protein ladder was purchased from Fermentas (Ottawa, 
Canada). Reagents for N-terminal protein sequencing were purchased from 
Sematec Pte Ltd (Tokyo, Japan). All other chemicals used, unless otherwise 
indicated, were of analytical grade and were obtained from Sigma-Aldrich (St. 
Louis, Missouri, USA).  
3.2.2 Purification of anticoagulant proteins 
3.2.2.1 Size exclusion chromatography (SEC) 
Crude Bungarus fasciatus venom (100 mg) was dissolved in 1 ml of distilled 
water and clarified by centrifugation at 13,200 rpm for 10 min. The clarified 
venom solution was applied to a HiLoad 16/60 Superdex 30 preparative grade 
size exclusion column (GE Healthcare Life Sciences, Piscataway, New Jersey, 
USA) equilibrated with 50 mM Tris-HCl buffer (pH 8.0) and eluted with the 
same buffer using ÄKTA Prime Plus system (GE Healthcare Life Sciences, 
Piscataway, New Jersey, USA) at 0.5 ml/min flow rate. The elution of proteins 
from the column was monitored by absorbance at 280 nm. Anticoagulant 
activity of each pooled fraction was assayed using Activated partial 
thromboplastin time (see below).  
62 
 
3.2.2.2 Reverse phase- high performance liquid chromatography 
(RP-HPLC)  
The pooled fractions from SEC with anticoagulant effects were individually 
resolved by RP-HPLC in a two-step process, using the Chromeleon 
Chromatography Data System on a Dionex Ultimate 3000 HPLC system 
(Thermo Fisher Scientific, Waltham, Massachusetts USA). The fraction with 
anticoagulant activity was applied to a Jupiter C18 (5 µm; 250 x 10 mm) 
reversed-phase column (Phenomenex, Torrance, California, USA) and 
resolved using a multi-step gradient concentration of acetonitrile containing 
0.1 % (v/v) trifluoroacetic acid (TFA) over 55 min at a flow rate of 5.0 ml/min. 
The fraction containing the proteins of interest was further resolved by 
reloading the sample onto the same column and eluting with a shallow, linear 
gradient of 28-30 % acetonitrile containing 0.1 % (v/v) TFA over 45 min at a 
flow rate of 5.0 ml/min. The homogeneity and mass of the protein fractions 
were determined by electrospray ionization mass spectrometry (ESI-MS) 
using the LCQ Fleet Ion Trap Mass Spectrometer (Thermo Scientific, Waltham, 
Massachusetts, USA). 
3.2.3 Structural characterization 




Protein samples were denatured by boiling with sample loading buffer (0.5 M 
Tris-HCl pH 6.8, 50% glycerol, 10% SDS, 0.25% bromophenol blue) in the 
presence or absence of β-mercaptoethanol for 5 min. SDS-PAGE was carried 
out with 15 % polyacrylamide gel and an electric field at a constant current of 
25 mA for 1 h. Protein bands were visualized by staining the gels with 
Coomassie brilliant blue R-250.  
3.2.3.2 Dithiothreitol reduction and subunit purification 
Reduction of protein was carried out by dissolving the protein in 1 ml of 0.2 M 
dithiothreitol (DTT) and shaking the mixture for 1 h at room temperature. The 
reduced protein sample was purified by RP-HPLC using an analytical Jupiter 
C18 (250 x 4.60 mm) column and a multi-step gradient concentration of 
acetonitrile containing 0.1 % (v/v) TFA at a flow rate of 1.0 ml/min. 
Pyridylethylation of cysteine residues was carried out using the method 
described by Ward et al. with minor modifications [175]. Protein was dissolved 
in 1 ml of denaturing buffer (0.1 M Tris-HCl, pH 8.5, 6 M guanidine 
hydrochloride) followed by the addition of 5 µl of β-mercaptoethanol and 2 µl of 
neat 4-vinyl-pyridine. Oxygen was displaced from the mixture by blowing 
nitrogen gas over the solution and the tube was sealed and incubated at 37 ˚C 
for 1 h. The pyridylethylated protein samples were purified by RP-HPLC in the 
same manner as the reduced protein samples.  
3.2.3.3 N-terminal sequencing 
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N-terminal sequencing of the pyridylethylated protein was performed by 
Edman degradation using the PPSQ-31A protein sequencer (Shimazu, Kyoto, 
Japan), and the PTH-amino acids were identified by matching their retention 
times with that of a PTH-amino acid standard mixture. The sequences 
obtained were compared to other known sequences using the protein 
database using Basic Local Alignment Search Tool (BLAST). 
3.2.3.4 Liquid chromatography – tandem mass spectrometry (LC-MS/MS) 
BF-AC1 was pyridylethylated and the two pyridylethylated chains were 
separated as described above. A and B chain were digested with trypsin 
(cat#V5280)/chymotrypsin (cat#V1061) (Promega, Madison, Wisconsin, USA) 
using the recommended protocol by the manufacturer, respectively. The 
reaction was stopped by adding TFA into the reaction system to reach a final 
concentration of 1% (v/v). Reaction mixtures were centrifuged for 10 min at 
13,000 rpm before applying to a Hypersil Gold column (50 mm x 2 mm) 
(Thermo Fisher Scientific, Waltham, Massachusetts USA) coupled with an 
LCQ Fleet Ion Trap Mass Spectrometer machine (Thermo Scientific, Waltham, 
Massachusetts, USA). The LC-MS data was collected and aligned with NCBI 
database using Mascot software.   
3.2.4 Functional characterization 
3.2.4.1 Anticoagulant activity 
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The anticoagulant activity of protein was determined by four coagulation 
assays using the Infinite M200 Microplate reader [176] (Tecan, Männedorf, 
Switzerland) and the BBL fibrometer (Becton Dickinson and Co., Maryland, 
USA) [172].  
Activated partial thromboplastin time (aPTT) – Plasma, APTT-XL, 25 mM 
CaCl2 and various concentrations of protein diluted with HEPES buffer (25 mM, 
pH 7.4) were pre-warmed to 37 °C individually. Protein (50 µl) was added to 
plasma (50 µl) and incubated for 10 min at 37 °C, followed by the addition of 
APTT-XL (50 µl) before further incubation for 2 min. Clotting was initiated by 
the addition of CaCl2 (50 µl) to the mixture and the time required for clot 
formation was measured at 650 nm for fibrin polymers formation [177] using 
Microplate reader. 
Prothrombin time (PT) – Plasma, thromboplastin-D and various concentrations 
of protein diluted with HEPES buffer (25 mM, pH 7.4) were pre-warmed to 
37 °C individually. Protein (100 µl) was added to plasma (100 µl) and 
incubated for 10 min. Clotting was initiated by the addition of thromboplastin-D 
(100 µl) to the mixture and the time required for clot formation was measured 
using BBL fibrometer. 
Stypven time – Plasma, RVV-X (10 ng/ml), 25 mM CaCl2 and various 
concentrations of protein diluted with HEPES buffer (25 mM, pH 7.4) were 
warmed to 37 °C individually. Protein (75 µl) was added to plasma (75 µl) and 
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incubated for 10 min, followed by the addition of RVV-X (75 µl) before further 
incubation for 2 min. Clotting was initiated by the addition of CaCl2 (75 µl) and 
the time required for clot formation was measured using BBL fibrometer. 
Thrombin time – Plasma, bovine thrombin (3 NIH units) and various 
concentrations of protein diluted with HEPES buffer (25 mM, pH 7.4) were 
warmed to 37 °C individually. Protein (100 µl) was added to plasma (100 µl) 
and incubated for 10 min. Clotting was initiated by the addition of bovine 
thrombin (100 µl) to the mixture and the time required for clot formation was 
measured using BBL fibrometer. 
3.2.4.2 Effect of anticoagulant protein on FX activation by extrinsic 
tenase complex 
The inhibitory effects of anticoagulant proteins on the activation of human FX 
by the extrinsic tenase complex were carried out using the method described 
by Koyama et al. with minor modification [178]. 
Dosage-dependent inhibition assay – Extrinsic tenase complex was 
reconstituted by adding 10 µl of 5% RecombiPlasTin (diluted with buffer 50 
mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 0.1 % BSA) and 15 µl of 
FVIIa (16.7 pM) to a microtiter plate and incubating at 37 °C for 15 min. 
Various concentrations of protein (12.5 µl) diluted with the same buffer were 
added to the mixture and further incubated for another 15 min, followed by the 
addition of 12.5 µl of human FX (400 nM) before incubation for further 3 min. 
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The activation of FX to FXa by tenase complex was stopped by adding 25 µl of 
quench buffer (50 mM HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 0.1 % 
BSA), after which 25 µl of 2 mM S-2222 was added as a substrate for 
hydrolysis by FXa. The cleavage of S-2222 was monitored by measuring the 
absorbance at 405 nm using the Microplate reader. 
Incubation time-dependent inhibition assay – Extrinsic tenase complex was 
reconstituted as described above. Anticoagulant protein (41.2 nM, 12.5 µl) in 
buffer was added and the mixture was incubated at different lengths of time, 
followed by the addition of 12.5 µl of human FX (400 nM) and further 
incubation for 3 min. The activation of FX was monitored as described as 
above.  
3.2.4.3 Effect of anticoagulant protein on FX activation by intrinsic 
tenase complex 
Activation of FVIII – FVIII (Bayer Pharmaceutics, Leverkusen, Germany) was 
reconstituted to a final concentration of 100 units/ml. FVIII (40 µl of 100 
units/ml) was mixed with 6 µl of activation buffer, 2 µl of 25 nM α-thrombin and 
incubated at 37 °C for 10 min. The reaction was stopped by adding 2 µl of 
11,500 units/ml Hirudin and incubating at 37 °C for 5 min.  
Preparation of PCPS vesicles – The vesicles were formed by dissolving 
phosphatidylcholine (cat#P3556) and phosphatidylserine (cat#7769), both 
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from Sigma, in 25 mM HEPES buffer (pH 7.4) and subsequent sonication on 
ice until the solution became clear.  
FX activation by intrinsic tenase complex – The  concentration-dependent 
inhibitory effect of anticoagulant proteins on the activation of human FX by the 
intrinsic tenase complex was carried out using the method as described by 
Koyama et al. [178] with minor modifications. Intrinsic tenase complex was 
reconstituted by adding 12.5 µl of PCPS (7:3) (8 µM), 6.25 µl of FVIIIa (80 
units/ml) and 6.25 µl of FIXa (80 pM) to a microtiter plate before incubating at 
37°C for 15 min. Various concentrations of protein (12.5 µl) diluted with buffer 
were added and the mixture was incubated for another 15 min, followed by the 
addition of 12.5 µl of human FX (400 nM) and further incubation for 3 min. The 
activation of FX to FXa by tenase complex was stopped by adding 25 µl of 
quench buffer (50 mM HEPES pH 7.4, 140 mM NaCl, , 50 mM EDTA, 0.1 % 
BSA), after which 25 µl of 2 mM S-2222 was added as a substrate for 
hydrolysis by FXa. The cleavage of S-2222 was monitored by measuring the 
absorbance at 405 nm using the Microplate reader.  
3.2.4.4 Knockdown of PLA2 activity with 4-bromophenacyl bromide 
The knockdown of PLA2 activity was carried out as described by Diaz-Oreiro 
and Gutierrez [179]. Briefly, proteins in 0.1 M Tris pH 8.0, 5 mM EDTA were 
mixed with 4-bromophenacyl bromide (10 mM in ethanol) to a molar ratio of 
1:10. The mixture was incubated in room temperature for 3 h and then was 
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desalted with Amicon ultra 3K column. The 4-bromophenacyl bromide-treated 
and vehicle treated proteins were evaluated for PLA2 activity using the sPLA2 
Assay Kit from Cayman Chemicals (Ann Arbor, Michigan, USA). The proteins 
were subsequently diluted with buffer (50 mM HEPEs, pH 7.4, 140 mM NaCl, 
5 mM CaCl2 and 0.1 % BSA) and assayed for inhibition on extrinsic tenase 
complex as described in section 3.3.4.2.  
3.2.4.5 Serine protease specificity 
The selectivity profiles of the anticoagulant proteins were examined against 
ten serine proteases: procoagulant serine proteases (FVIIa, FIXa, FXa, FXIa, 
FXIIa, kallikrein, and thrombin), anticoagulant serine protease (activated 
protein C) and fibrinolytic serine proteases (urokinase and plasmin).  
50 µl of the respective serine protease diluted with buffer (50 mM HEPES pH 
7.4, 140 mM NaCl, 5 mM CaCl2, 0.1 % BSA ) from stock was pre-incubated 
with 25 µl of different concentrations of proteins in a microtiter plate for 30 min 
at 37 °C, followed by the addition of 25 µl of the appropriate chromogenic 
substrate. In a total volume of 100 µl, the final serine protease/ chromogenic 
substrate concentrations were as follow: FVIIa (200 nM)/S-2288 (1 mM), FIXa 
(150 nM)/Spectrozyme FIXa (1 mM), FXa (2 nM)/S-2222 (0.5 mM), FXIa (0.5 
nM)/S-2366 (0.5 mM), FXIIa (10 nM)/S-2302 (0.5 mM), kallikrein (16 
nM)/S-2302 (0.5 mM), thrombin (2 nM)/S-2238 (0.1 mM), activated protein C 
(5 nM)/S-2366 (1 mM), urokinase (40 units/ml)/S-2444 (0.5 mM), plasmin (5 
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nM)/S-2251 (0.5 mM). The reaction velocities of substrate cleavage were 
monitored by measuring the absorbance at 405 nm using the Microplate 
reader. 
3.2.4.6 In vivo toxicity 
The toxicity study was carried out under National University of Singapore 
animal protocol 001/11 approved by the Institutional Animal Care and Use 
Committee (IACUC). Toxicity of proteins in animals was examined by 
dissolving the protein in phosphate buffered saline (PBS) to obtain a 
concentration of 0.25 mg/ml before 300 µl of the solution was administered 
intraperitoneally into Swiss albino mice of approximately 20 g in weight. Mice 
behaviour was observed and recorded for an hour or until the time of death of 
the animal.   
3.2.4.7 Chick biventer cervicis muscle (CBCM) preparation  
CBCM was isolated from a chick (6 days old) and mounted in an organ bath 
chamber under similar experimental conditions as described by Pawlak et al. 
[180]. Electrical field stimulation (EFS) was carried out through platinum ring 
electrodes using a S88 stimulator (Grass Instruments, Quincy, Massachusetts, 
USA). Effect of the protein (50 ng/ml) on nerve-evoked twitch responses of the 
CBCM preparation was transferred via a Model FT03 force displacement 
transducer (Grass Instruments, Quincy, Massachusetts, USA) and recorded 
using a PowerLab 6 system (ADInstruments, Bella Vista, New South Wales, 
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Australia). Contractile response to exogenously applied acetylcholine (ACh), 
carbachol (CCh) and potassium chloride (KCl) were obtained in the absence 
of an electrical field before and after treatment with the protein. 
3.2.4.8 Statistical analysis 
The data points in each figure represented average of duplicates or triplicates 
(as indicated in the corresponding figure legends). The error bars in each 
figure represented standard deviations for triplicates.  
3.3 Results 
3.3.1 Purification of anticoagulant proteins  
In chapter 2 of the thesis, we have identified Pool A5 (Figure 2.7 and Figure 
2.8) as anticoagulants that prolonged both aPTT and PT time. As all the 
proteins obtained from earlier fractionation of the venom were used up for the 
screening assays, here we carried out a new round of fractionation 
procedures. 
Briefly, crude Bungarus fasciatus venom was first separated into four major 
peaks by SEC (Figure 3.1A) on a HiLoad 16/60 Superdex 30 prep grade size 
exclusion column. Of the four major SEC fractions, Peak 2 (corresponding to 
Peak A in Figure 2.7A) was further resolved by RP-HPLC into five major pools 
(Figure 3.1B) and pool E was corresponding to pool A5 of Figure 2.7 that 
exhibited potent anticoagulant activity as tested previously (Figure 3.1C, data 
originated from Figure 2.8). On a slower gradient, pool E was separated into 
72 
 
two major proteins (Figure 3.1D). These purified proteins had molecular 
weights of 20,752 Da (denoted as BF-AC1) and 20,782 Da (denoted as 
BF-AC2), respectively (Figure 3.2A and 3.2B) as verified via ESI-MS. The 
similarity in size and polarity suggested that these two proteins could be 
isoforms of each other. 
 
Figure 3.1:  Purification of BF-AC1 and BF-AC2 from the venom of B. fasciatus. (A) 
Crude Bungarus fasciatus venom was fractionated using size exclusion chromatography (SEC). 
The venom has been resolved into four major peaks, named as Peak 1, 2, 3, 4. (B) Peak2 was 
subjected to a second purification step using multistep gradient RP-HPLC, in which buffer A is 
H2O with 0.1% TFA, buffer B is 80% ACN and 0.1% TFA in H2O. The pooled fractions were 
denoted as Pool A, B, C, D, E. (C) Fractions from RP-HPLC were tested for anticoagulant 
activities using aPTT and PT assays. Pool E prolonged both aPTT and PT significantly. (D) Pool 
E was further resolved into two main peaks denoted as BF-AC1 and BF-AC2 by shallow 
gradient RP-HPLC, in which buffer A is 28% ACN and 0.1% TFA in H2O, buffer B is 30% ACN 




Figure 3.2: ESI-MS profile of BF-AC1 (A) and BF-AC2 (B). The spectrum shows a series of 
multiple charged ions, corresponding to a single, homogenous protein with a molecular mass of 
20,752 Da (BF-AC1) and 20,782 Da (BF-AC2). Inset shows the reconstructed mass spectrum of 
BF-AC1 and BF-AC2. 
3.3.2 Structural characterization 
3.3.2.1 Determination of structural characteristics and disulfide 
connectivity  
In non-reducing conditions, both proteins appeared as single bands of 
approximately 20 kDa in SDS-PAGE (Figure 3.3A). However, reduction with 
β-mercaptoethanol revealed that the proteins were heterodimers comprising of 
two dissimilar peptide chains of 13 and 7 kDa. The results suggested that the 
subunits were linked by at least one inter-chain disulfide bond. BF-AC1 and 
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BF-AC2 were subjected to reduction and/or alkylation with 4-vinyl-pyridine and 
the subunits were separated by RP-HPLC and analyzed by ESI-MS. Two 
predominant peaks were identified in each of the RP-HPLC profiles of BF-AC1 
(Figure 3.3B, 3.3C) and BF-AC2 (data not shown due to its similarity with 
BF-AC1), which corresponded with the dimeric structure of protein inferred 
from SDS-PAGE analysis.  
ESI-MS confirmed that BF-AC1 and BF-AC2 are heterodimers, with the two 
subunits henceforth denoted as Chain A and Chain B. The reduced masses of 
Chain A for BF-AC1 and BF-AC2 are 13621.2 Da and 13649.6 Da respectively, 
while the mass of Chain B for both BF-AC1 and BF-AC2 are 7142.1 Da. By 
calculating the difference in masses between the reduced and pyridylethylated 
proteins using ESI-MS, Chain A and Chain B were deduced to possess 13 and 
7 cysteine residues respectively, forming at least one inter-chain disulfide 




Figure 3.3: Structural characterization of BF-AC1 and BF-AC2. (A) BF-AC1 and BF-AC2 
were subjected to SDS-PAGE analysis in presence or absence of β-mercaptoethanol. Both 
reduced (B) and alkylated (C) BF-AC1 showed two main peaks in RP-HPLC. 
 
Table 3.1: Number of cysteines in BF-AC1 and BF-AC2. The number of cysteines was 
estimated through the equation: Number of cysteines = (Pyridylethylated mass – reduced mass) 
/ 105.14 
Protein  Chain  Reduced 
mass (Da)  
Pyridylethylated 
mass (Da)  
Mass 
difference (Da)  
Number of 
cysteines  
BF-AC1 A  13621.2  14998.2  1377.0  13  
B  7142.1  7878.6  737.5  7  
BF-AC2 A  13649.6  15028.8  1379.2  13  
B  7142.1  7878.5  736.4  7  
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3.3.2.2 N-terminal sequencing 
N-terminal sequences were determined using Edman degradation of the 
pyridylethylated chains A and B of both BF-AC1 and BF-AC2 (Figure 3.4A). 
BLAST results (Figure 3.4A) with the partial sequences showed that BF-AC1 
and BF-AC2 are highly homologous to β-bungarotoxin, a well-characterized 
presynaptic neurotoxin, which is made up of two dissimilar subunits consisting 
of an A-chain that is structurally homologous to PLA2, and a B-chain that is 
structurally homologous to Kunitz-type protease inhibitor [12]. However, the 
partial sequence was insufficient to show the difference in the primary 
structure between BF-AC1 and BF-AC2.  
We analyzed the tryptic and chymotryptic fragments of A and B chain of 
BF-AC1 by LC-MS/MS studies to obtain further information on their amino acid 
sequences. Indeed, the sequences of the fragments are identical/highly 




Figure 3.4: N-terminal sequence alignment of Chain A and Chain B of BF-AC1 and 
BF-AC2 with protein sequences in the database. (A) Chain A shared high similarity with 
β-bungarotoxin Chain A. Chain B shared high similarity with β-bungarotoxin Chain B. (B, C) 
Alignments of sequences of tryptic and chymotryptic peptides of BF-AC1 A Chain (B) and B 
Chain (C) with β-bungarotoxin A Chain (Accession ID: P00619; Full name: Acidic phospholipase 
A2 beta-bungarotoxin A3 chain; Species: B. multicinctus) and B Chain (Accession ID: B2KTG2; 
Full name: Beta-bungarotoxin BF B1 chain; Species: B. fasciatus). The peptide sequences were 
determined by LC-MS/MS analysis. 
3.3.3 Functional characterization 
To the best of our knowledge, although β-bungarotoxins contain a PLA2 
component, this group of presynaptic neurotoxins has never been described 
as affecting the coagulation cascade. Therefore, our subsequent functional 
assays were focused on characterizing the anticoagulant activities of BF-AC1 
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and BF-AC2 and examining the role of the constituent PLA2’s enzymatic 
activity in influencing the haemostatic activities of the protein complexes. In 
addition, we examined the similarity in pharmacological toxicity between 
β-bungarotoxin and BF-AC1 or BF-AC2 proteins.  
3.3.3.1 Haemostatic effect 
To identify the site on the coagulation pathway where BF-AC1 and BF-AC2 
exert their anticoagulant effects, we utilized four coagulation assays: aPTT, 
prothrombin time, Stypven time, and thrombin time. aPTT measures the effect 
of an anticoagulant on the intrinsic and common pathway. Prothrombin time 
measures the effect of an anticoagulant on the extrinsic and common pathway. 
Prothrombin time, Stypven time and thrombin time assays were utilized in 
tandem to identify the effect of an anticoagulant on specific steps of the 
common pathway (Figure 3.5A) [181]. Due to limited availability of Bungarus 
fasciatus venom, these coagulation assays were carried out with partially 
purified chromatographic pooled fraction that contains a mixture of 
BF-AC1:BF-AC2 (~3:1). The protein mixture was found to exert significant 
anticoagulant effect on prothrombin time at 10 mg/ml, while not having 
significant influence on the other three coagulation tests (Figure 3.5B). The 
prolongation of prothrombin time was dose-dependent (Figure 3.5C). 
Therefore, it is likely that the proteins target the most upstream component of 




Figure 3.5: Anticoagulant activity of BF-AC1 and BF-AC2 mixture. (A) The dissection 
approach for determining mechanisms of an anticoagulant. (B) BF-AC1/2 mixture significantly 
prolonged prothrombin time at a dosage of 10 mg/ml while had only small effects on aPTT and 
stypven time at the same dosage. Each point represents duplicates. (C) BF-AC1/2 mixture 
prolonged prothrombin time in a dose-dependent manner. Each point represents triplicates. 
Error bar indicates standard deviations. 
In order to confirm this finding, we examined the dose-dependence effect of 
purified BF-AC1 and BF-AC2 on the reconstituted extrinsic tenase complex 
and intrinsic tenase complex (Figure 3.6A). Both proteins were found to inhibit 
the activation of FX to FXa by the extrinsic tenase complex in a 
dose-dependent relationship.  The IC50 for BF-AC1 and BF-AC2 on extrinsic 
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tenase complex was approximately 10 nM (Figure 3.6A). While BF-AC1 and 
BF-AC2 were also found to inhibit the activation of FX to FXa by the intrinsic 
tenase complex (Figure 3.6A), the IC50 of the proteins on intrinsic tenase 
complex was significantly higher, determined to be 100 nM. This one-order 
difference in inhibitory potency could explain the comparatively small increase 
in aPTT (Figure 3.5B). BF-AC1/2 inhibited extrinsic tenase complex in 
nanomolar range (IC50 ~ 10 nM), while >10 µM was needed in PT assays in 
whole plasma. This discrepancy could be due to higher quantities of 
phospholipids found in human plasma compared to in vitro assay conditions of 
extrinsic tenase complex. Further, it is also possible that a significant portion 
of BF-AC1/2 may interact with other components in the plasma and hence not 
be available to inhibit tenase complex.  
BF-AC1 was subsequently screened against ten serine proteases involved in 
the coagulation cascade to determine for the site of specific inhibition (Figure 
3.6B). Contrary to its effect on the extrinsic tenase complex and intrinsic 
tenase complex, BF-AC1 failed to exhibit strong inhibitory activity against any 
of the serine proteases along the coagulation cascade at a dose up to 10 µM 
purified protein. On the other hand, the results indicated that presence of 
BF-AC1 activated several serine proteases slightly, namely APC, FVIIa, FIXa, 
FXa, FXIa and Plasmin, in a dose dependent manner. Comparing to the 
inhibitory potency of BF-AC1 on the extrinsic tenase complex, the 
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concentrations needed for displaying activation effects were significantly 
higher. Neither BF-AC1 nor BF-AC2 showed any hydrolysis of the 
chromogenic substrates. The stimulatory effects are possibly due to 
non-specific stabilization effects.  
 
Figure 3.6: BF-AC1 and BF-AC2 selectively inhibit the extrinsic tenase complex. (A) Dose 
response curve of intrinsic and extrinsic tenase complex inhibition by BF-AC1 and BF-AC2. The 
final concentrations in activation of FX were 2,500 nM, 833.3 nM, 277.8 nM, 92.6 nM, 30.9 nM, 
10.3 nM, 3.4 nM, 1.1 nM, 0.38 nM. The IC50 for inhibition of extrinsic tenase complex was about 
10 nM while for inhibition of intrinsic tenase complex was about 100 nM. (B) Selectivity profile of 
BF-AC1. BF-AC1 was screened against 10 serine protease, intrinsic tenase complex and 
extrinsic tenase complex. BF-AC1 inhibited extrinsic tenase complex and intrinsic tenase 
complex while activated several serine proteases tested. Each point represents an average of 




3.3.3.2 Role of PLA2 activity in anticoagulant effect of BF-AC1/2 
Noting the PLA2 subunit within BF-AC1 and BF-AC2, we proceeded to 
investigate the role of PLA2’s enzymatic activity on their inhibition on the 
extrinsic tenase complex. We examined the time-dependent effect of the 
anticoagulant proteins. The percentage inhibition of FX activation by extrinsic 
tenase complex was measured after different duration of incubation with 10.3 
nM BF-AC1 or BF-AC2. The results showed that the inhibitory effect exerted 
by both proteins increased with incubation time (Figure 3.7A), suggesting an 
enzymatic mechanism in the inhibitory activity. To inactivate the PLA2 enzyme, 
we alkylated the anticoagulant proteins by 4-bromophenacyl bromide. BF-AC1 
and BF-AC2 were treated with 4-bromophenacyl bromide or vehicle (ethanol) 
control. It was observed that after desalting, vehicle control suffered from 
around 60% activity loss in PLA2 activity while the PLA2 activities of alkylated 
proteins were less than 1 % of the vehicle controls. Both the control and 
alkylated proteins were examined for inhibition on extrinsic tenase complex. 
The vehicle control proteins had an IC50 of around 40 nM (Figure 3.7B) and 
this increase could be due to the loss of PLA2 activity. In contrast, alkylated 
proteins had a more than 100 times higher IC50 (Figure 3.7B). These results 
suggested an integral role for the PLA2 enzymatic activity in the inhibitory 




Figure 3.7: PLA2 activity plays an important part in inhibition of extrinsic tenase complex. 
(A) Incubation time response curve of extrinsic tenase complex inhibition by BF-AC1 and 
BF-AC2. The final concentrations of BF-AC1 and BF-AC2 in activation of FX were 10.3 nM. The 
incubation times were 0 min, 2 min, 4 min, 8 min, 10min, 15 min, 30 min, 45 min and 60 min. (B) 
BF-AC1 and BF-AC2 were treated with 4-bromophenacyl bromide to abolish PLA2 activity. The 
final concentrations in the activation reactions are: Untreated BF-AC1: 1368.9 nM, 456.3 nM, 
152.1 nM, 50.7 nM, 16.9 nM, 5.6 nM, 1.8 nM, 0.6 nM, 0.2 nM; Untreated BF-AC2: 1029.4 nM, 
343.1 nM, 114.3 nM, 38.1 nM, 12.7 nM, 4.2 nM, 1.4 nM, 0.47 nM, 0.16 nM; Treated BF-AC1: 
30000 nM, 10000 nM, 3333.3 nM, 1111.1 nM, 370.4 nM; Treated BF-AC2: 22500 nM, 7500 nM, 
2500 nM, 833.3 nM, 277.8 nM. Each point represents an average of triplicates, error bar 
indicates standard deviations. 
3.3.3.3 Neurotoxic effect 
From the structural characterization of BF-AC1 and BF-AC2, we have 
ascertained that these two proteins are structurally homologous to 
β-bungarotoxin. Therefore, we investigated the neurotoxicity of BF-AC1 and 
BF-AC2. They were assessed for in vivo neurotoxic activity by injecting 3.75 
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mg/kg of the individual proteins intraperitoneally into Swiss albino mice. The 
animals exhibited signs of lethargy that progressed into awkward movements 
and breathing difficulties that culminated in death, suggesting that BF-AC1 
and BF-AC2 are possibly neurotoxic in nature. Further, the ex vivo neurotoxic 
effect of BF-AC1 was characterized using CBCM preparation. At a 
concentration of 50 ng/ml, BF-AC1 blocked neuromuscular junctions in CBCM 
preparation, with near complete inhibition achieved in approximately 40 min 
after the addition of the protein (Figure 3.8). Contractile responses to the three 
exogenous agonists ACh, CCh and KCl were not affected, indicating that 
BF-AC1 exhibits presynaptic neuromuscular blockade and lacks direct 
myotoxicity. 
 
Figure 3.8: Effect of BF-AC1 on CMCB preparations. Contractions were produced by 
exogenous ACh (300 µM), CCh (10 µm) and KCl (30 mM). The black bar indicated the 




3.3.3.4 Comparison of anticoagulant and PLA2 activities of BF-AC1/2 with 
β-bungarotoxins 
Because of the high sequence similarity of BF-AC1/2 to β-bungarotoxins, we 
compared the inhibitory effects of BF-AC1/2 on extrinsic tenase complex with 
that of three β-bungarotoxins obtained from different sources. The potency of 
these β-bungarotoxins was slightly lower compared to BF-AC1/2 (Figure 3.9A).  
Since PLA2 enzymatic activity plays a role in the inhibition of extrinsic tenase 
complex, we compared the PLA2 enzymatic activity of all three 
β-bungarotoxins with that of BF-AC1/2 (Figure 3.9B). Interestingly, the 
β-bungarotoxins exhibited 3-4 fold higher enzymatic activity than BF-AC1/2. 
Thus, there is no linear relationship between PLA2 enzymatic activity and 
inhibition of extrinsic tenase complex. These observations suggest that 
although PLA2 activity is essential in the inhibition of extrinsic tenase complex 




Figure 3.9: Activity comparison between BF-AC1/2 and β-bungarotoxins. (A) Inhibition of 
extrinsic tenase complex. The dose-dependent inhibitory effects of BF-AC1/2 and 
β-bungarotoxins on extrinsic tenase complex were measured and plotted; (B) PLA2 enzymatic 
activity. The PLA2 enzymatic activity of BF-AC1/2 and β-bungarotoxins were quantified. Activity 
of BF-AC1 was defined as 100%. The β-bungarotoxin sources are indicated. Each point 
represents an average of triplicates, error bar indicates standard deviations. 
3.4 Discussion  
In this work, we have studied the crude venom of Bungarus fasciatus, a 
member of the Elapidae family. Bungarus venoms are known to contain 
mainly neurotoxins [182, 183]. We have isolated, purified and identified of two 
novel anticoagulant proteins, BF-AC1 and BF-AC2. Structurally, they are 
isoforms of β-Bungarotoxin. Functionally, they exhibit anticoagulant effects, 
most notably they inhibit the extrinsic tenase complex of the blood coagulation 
pathway. Since β-bungarotoxins are well-characterized neurotoxins, BF-AC1 
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and BF-AC2 were examined for possible neurotoxic effect. BF-AC1 and 
BF-AC2 induced muscle twitching and shortness of breath in mice, which are 
classical presentations of respiratory failure due to snake neurotoxins. In 
addition, the effect of BF-AC1 on CBCM preparation also reaffirmed the 
protein’s presynaptic neuromuscular blocking capability.  
β-bungarotoxin is a presynaptic neurotoxin that was first isolated and 
characterized from the venom of the Taiwan banded krait, Bungarus 
multicinctus [3]. It is a basic heterodimer protein with a molecular weight of 
~21,800 Da. The larger subunit has a molecular weight of approximately 13 
kDa, contains six intra-chain disulfide bridges, and is structurally homologous 
to PLA2. The smaller subunit has a molecular weight of approximately 7.5 kDa, 
contains three intra-chain disulfide bridges, and is homologous to Kunitz type 
proteinase inhibitor [184-186].  The two subunits are in turn linked by a single 
intra-chain disulfide bridge. Various works on the functional characterization of 
β-bungarotoxin thus far have focused mainly on its PLA2 enzymatic activity 
and neurotoxicity. The PLA2 subunit was found to be the active subunit 
responsible for both of these properties, while the Kunitz subunit was 
postulated to serve as a guiding probe for the protein and block certain voltage 
gated K+ channels.  Animal studies showed that peritoneal injection of 
β-bungarotoxin into mice resulted in respiratory failure and death, as a result 
of presynaptic neuromuscular blockade by inhibiting the release of 
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acetylcholine [12]. This is the first report on the anticoagulant properties of 
β-bungarotoxins. 
As A chain of β-bungarotoxin has PLA2 enzymatic activity, it is conceivable 
that this enzyme could hydrolyze and destroy the phospholipid surface 
required for the activity of the extrinsic tenase complex. The selective 
inhibition of extrinsic tenase complex by BF-AC1/2 may partially due to the fact 
that the phospholipids requirements of extrinsic tenase complex are high as its 
component FVIIa is a membrane protein [187]. When we inactivate the PLA2 
enzymatic activity of BF-AC1/2, by specific alkylation of active site His residue, 
the inhibitory potency of BF-AC1/2 on extrinsic tenase complex dropped more 
than 100 times. Thus, PLA2 enzymatic activity plays a significant role in the 
inhibition of extrinsic tenase complex. However, there was no correlation 
between PLA2 enzymatic activity and inhibitory potency of β-bungarotoxins 
(Figure 3.9B); β-bungarotoxins with 3-4 times higher enzymatic activity show 
lower potency in inhibiting the extrinsic tenase complex. Thus, we propose 
that the phospholipase A2 enzymatic activity is necessary but not sufficient for 
the anticoagulant activity of β-bungarotoxins.  
This idea is supported by several other studies on anticoagulant activities of 
snake PLA2 where no correlations between catalytic activity/phospholipid 
hydrolysis and anticoagulant effects were observed [188-190]. In fact, snake 
PLA2 exert their anticoagulant activity via enzymatic as well as nonenzymatic 
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mechanisms. For example, three PLA2s –CM-I, CM-II and CM-IV- isolated 
from the Naja nigricollis venom perform anticoagulant activity through distinct 
ways. Strongly anticoagulant CM-IV inhibit extrinsic tenase complex by both 
enzymatic and nonenzymatic mechanisms and inhibit prothrombinase 
complex by nonenzymatic mechanism through directly binding to FXa. In 
contrast, weak anticoagulants CM-I and CM-II have no inhibitory effect on 
prothrombinase complex and inhibit extrinsic tenase complex only via 
enzymatic mechanism [191]. For further details on the mechanisms of 
anticoagulant PLA2 enzymes from snake venoms, refer to review [192]. 
It is important to note that studies on prothrombinase complex reconstituted on 
phospholipids membranes with low phosphatidylserine concentration (<10%) 
suggested that most PLA2 can inhibit this complex by enzymatic mechanisms. 
On the contrary, when phosphatidylserine concentration is increased, only 
PLA2 with strong anticoagulant activity can inhibit this complex via 
nonenzymatic mechanism [193]. Therefore, different phospholipids specificity 
may play a role in the observed discrepancy of potency between PLA2 
enzymatic activity and inhibitory effect on reconstituted tenase complex.  
From our studies the role of B Chain (non-PLA2 subunit) is not clear. Although 
B Chain is structurally similar to Kunitz type serine proteinase inhibitors, no 
inhibitory activity of β-bungarotoxin on proteinase were observed previously 
[194] and in our hand (Figure 3.10). Significant reduction in inhibitory potency 
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upon inactivation of PLA2 enzymatic activity indicates that Chain B of 
BF-AC1/2 alone is not capable of showing effects in inhibition of extrinsic 
tenase complex. It is possible that B Chain may help BF-AC1/2 to target the 
extrinsic tenase complex and may partially contribute to the time-dependent 
inhibition on the extrinsic tenase complex. This is supported by the 
observations that β-bungarotoxins have higher PLA2 activity but lower potency 
in inhibition of extrinsic tenase complex. 
  
Figure 3.10: Selectivity profile of Latoxan β-bungarotoxin. β-bungarotoxin was screened 
against 8 serine protease and extrinsic tenase complex. β-bungarotoxin inhibited extrinsic 
tenase complex while had no significant effects on the serine proteases. Each point represents 
an average of duplicates. 
In summary, this is the first report on the anticoagulant activity of 
β-bungarotoxins and these results expand on the existing catalogue of 
















Fasxiator, a novel FXIa inhibitor from snake 
venom, and its site-specific mutagenesis to 













Fasxiator, a novel FXIa inhibitor from snake venom, and 
its site-specific mutagenesis to improve potency and 
selectivity 
4.1 Introduction 
In chapter 2 of the thesis, we have identified three pools that prolonged aPTT 
while having no significant effects on PT (Figure 2.8). In this chapter, we will 
describe the characterization of these three pools in detail. The active 
components of these pools are determined to be selective FXIa inhibitors in 
our study. 
FXI has been recognized in recent years as a new drug target for 
anti-thrombotic drug design. Several approaches are adopted for targeting FXI 
such as antisense oligonucleotides [195, 196], mouse anti-human FXI 
antibodies [197], synthetic small molecules and peptidomimetic inhibitors [198, 
199]. However, these approaches have inherent limitations: (a) antisense 
oligonucleotides have a delayed effect as FXI has a half-life 52 hours in 
human plasma;[200] (b) mouse anti-human antibodies are usually associated 
with complex formation after repeated administrations, which may lead to 
allergic reactions; and (c) the synthetic small molecules and peptidomimetic 
inhibitors typically exhibit potent in vitro activity in enzyme activity assays, but 
suffer hundreds of fold drop in potency when tested for aPTT with human 
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plasma [198, 199]. Thus, there is still a need to develop alternate approaches 
for inhibiting FXI to achieve anti-thrombotic effect with fewer side effects. 
Protease nexin 2 (PN2) is a 120-kDa isoform of the Alzheimer β-amyloid 
protein precursor (AβPP) that has been shown to be a highly potent and 
physiologically relevant inhibitor of FXIa [110, 201]. It is a slow, tight binding 
inhibitor of FXIa (Ki 290-450 pM), with little or no detectable inhibitory activity 
against other coagulation enzymes [110, 201]. The recombinant truncated 
Kunitz domain (PN2KPI) retains the inhibitory activity against FXIa in in vitro 
assays and is being evaluated as an antithrombotic agent [202, 203]. 
In summary, here we describe the isolation, recombinant expression, 
structural and functional characterization of a novel Kunitz-type protease 
inhibitor from Bungarus fasciatus (Banded Krait) venom that selectively 
inhibited FXIa (henceforth termed Fasxiator: Bungarus fasciatus FXIa inhibitor) 
while exhibiting negligible inhibition on other proteases of the blood 
coagulation cascade. It is the first specific exogenous inhibitor of human FXIa, 
which shows only 45% identity (58% similarity) with PN2KPI and thus, 
provides an alternate molecule for similar therapeutic applications.  
Through systematic and selective point mutations, we have developed a 
highly potent and specific FXIa inhibitor. The most promising mutant 
FasxiatorN17R,L19E was evaluated for in vitro inhibitory kinetics and in vivo 
efficacy in thrombotic model. 
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4.2 Materials and methods 
4.2.1 Materials 
Thromboplastin-D and APTT-XL were purchased from Pacific Hemostasis, 
Thermo Scientific (Waltham, Massachusetts, USA). Thrombin from bovine 
plasma was purchased from Merck Millipore (Darmstadt, Germany). FVIIa, 
FIXa, FXa, FXIa, activated protein C, plasmin, thrombin and FXI deficient 
plasma were purchased from Hematologic Technologies (Essex Junction, 
Vermont, USA). FXIIa, kallikrein, trypsin and urokinase were purchased from 
Calbiochem, EMD Millipore (Billerica, Massachusetts, USA). 
Phosphatidylcholine and phosphatidylserine were purchased from 
Sigma-Aldrich (St. Louis, Missouri, USA). Chromogenic substrates, 
N-Benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroaniline 
hydrochloride and its methyl ester (S-2222), 
H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline dihydrochloride 
(S-2238), H-D-Valyl-L-leucyl-L-lysine-p- nitroaniline dihydrochloride (S-2251), 
H-D-Isoleucyl-L-prolyl-L- arginine-p-nitroaniline dihydrochloride (S-2288), 
H-D-Prolyl-L-phenylalanyl-L-arginine-p- nitroaniline dihydrochloride (S-2302), 
L-Pyroglutamyl-L-prolyl-L-arginine -p-nitroaniline hydrochloride (S-2366), 
L-Pyroglutamyl-glycyl-L-arginine-p-nitroaniline hydrochloride (S-2444) were 
purchased from DiaPharma (Westchester, Ohio, USA). D-leucyl-phenylglycyl- 
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arginine-p-nitroanilide diacetate (Spectrozyme FIXa) were purchased from 
Sekisui Diagnostics (Stanford, Connecticut, USA). 
Dithiothreitol, 40 % acrylamide and Coomassie Brilliant Blue R-250 were 
purchased from Bio-Rad Laboratories (Hercules, California, USA). Ammonia 
persulphate (APS) was purchased from AppliChem GmbH (Darmstadt, 
Germany). TEMED was purchased from MP Biomedicals (Solon, Ohio, USA). 
Tris-glycine SDS buffer was purchased from 1st Base (Singapore). Tris and 
Guanidine HCl were purchased from Alfa Aesar (Ward Hill, Massachusetts, 
USA). Pre-stained protein ladder was purchased from Fermentas (Burlington, 
Ontario, Canada). Reagents for N-terminal protein sequencing were 
purchased from Sematec Pte Ltd (Tokyo, Japan). All other chemicals used, 
unless otherwise indicated, were of analytical grade and were obtained from 
Sigma-Aldrich (St. Louis, Missouri, USA).  
4.2.2 Methods 
4.2.2.1 Size exclusion chromatography (SEC) 
Crude Bungarus fasciatus venom (100 mg) (a generous gift from Professor 
Cassian Bon, Pasteur Institute, Paris, France) was dissolved in 1 ml of distilled 
water and clarified by centrifugation at 13,200 rpm for 10 min. The clarified 
venom solution was applied to a HiLoad 16/60 Superdex 30 preparative grade 
size exclusion column (GE Healthcare Life Sciences, Piscataway, New Jersey, 
USA) equilibrated with 50 mM Tris-HCl buffer (pH 8.0) and eluted with the 
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same buffer using ÄKTA Prime Plus system (GE Healthcare Life Sciences, 
Piscataway, New Jersey, USA) at 0.5 ml/min flow rate. The elution of proteins 
from the column was monitored at 280 nm.  
4.2.2.2 Cation exchange chromatography (CEC) 
The pooled fractions from SEC were applied to a Bio-Rad S6 cation exchange 
chromatography column (Hercules, California, USA) and resolved by a 
gradient elution profile (flow rate of 2 ml/min) with buffer A being 50 mM 
Phosphate buffer pH 7.0 and buffer B being 50 mM Phosphate buffer pH 7.0 
containing 0.5 M NaCl using the Chromeleon Chromatography Data System 
on a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific, Waltham, 
Massachusetts USA). 
4.2.2.3 Reverse phase high performance liquid chromatography 
(RP-HPLC) 
Pooled fractions from SEC and cation exchange chromatography were 
applied to a Jupiter C18 (250 x 10 mm) reversed-phase column (Phenomenex, 
Torrance, California, USA) and resolved by a multi-step gradient elution profile 
(flow rate 5 ml/min) with buffer A being 0.1% TFA in water and buffer B being 
0.1% TFA in 80% acetonitrile water solution using the Chromeleon 
Chromatography Data System on a Dionex Ultimate 3000 HPLC system 
(Thermo Fisher Scientific, Waltham, Massachusetts USA). 
4.2.2.4 Electrospray ionization mass spectrometer (ESI-MS) 
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Samples (20 µl) were injected through the auto-sampler into a LCQ Fleet Ion 
Trap Mass Spectrometer (Thermo Scientific, Waltham, Massachusetts, USA) 
with a flow rate of 100 µl/min, the signals after injection were captured using 
full scan mode and masses of proteins and peptides were determined by 
Xcalibur software. 
4.2.2.5 Effect on activated partial thromboplastin time (aPTT)  
Human plasma was obtained from healthy donor’s blood by centrifugation of 
the blood (containing one part 3.2% sodium citrate and 9 parts of blood) at 
1500 rcf for 15 min. Equal volumes (50 µl) of human plasma, APTT-XL, 20 mM 
CaCl2 and various concentrations of protein diluted with HEPES buffer (25 mM, 
pH 7.4) were pre-warmed to 37°C individually. Protein was added to plasma 
and incubated for 10 min, followed by the addition of APTT-XL and further 
incubation of 3 min. Clotting was initiated by the addition of 20 mM CaCl2 to 
the mixture and the clot formation was measured using an Infinite M200 
microplate reader [170] (Tecan, Männedorf, Switzerland) at 650 nm for fibrin 
polymers formation [171].  
4.2.2.6 Prothrombin time (PT)  
Plasma, thromboplastin-D and various concentrations of protein diluted with 
HEPES buffer (25 mM, pH 7.4) were pre-warmed to 37°C individually. Protein 
(100 µl) was added to plasma (100 µl) and incubated for 10 min. Clotting was 
initiated by the addition of thromboplastin-D (100 µl) to the mixture and the clot 
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formation was measured using a BBL fibrometer (Becton Dickinson and Co., 
Maryland, USA) [172]. 
4.2.2.7 Pyridylethylation and digestion 
Pyridylethylation of cysteine residues of protein was carried out by dissolving 
protein (50-100 µg) into 1 ml of denaturing buffer (0.1 M Tris-HCl, pH 8.5, 6 M 
guanidine hydrochloride) followed by the addition of 5 µl of β-mercaptoethanol 
and 2 µl of 4-vinyl-pyridine.[204] Oxygen was displaced from the mixture by 
blowing nitrogen gas over the solution before sealing the tube. The mixture 
was further incubated at 37 ˚C for 1 h. The pyridylethylated protein sample was 
purified by RP-HPLC, lyophilized and digested with Lys-C and Arg-C for 2-16 
h, after which the resulting peptides were separated by RP-HPLC   
4.2.2.8 N-terminal sequencing 
N-terminal sequencing of the pyridylethylated proteins was performed by 
automated Edman degradation using a PPSQ31 protein sequencer 
(Shimadzu, Kyoto, Japan) equipped with an UV detector and a pump. The 
PTH amino acids were identified by matching their retention times with those 
of standards. The sequences obtained were compared to other protein 
sequences in the database using Basic Local Alignment Search Tool 
(BLAST). 
4.2.2.9 Recombinant expression, on-column folding and purification 
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The Fasxiator gene was synthesized by Geniwiz (South Plainfield, New Jersey, 
USA) according to the protein sequence and using E. coli preferred codons, 
and cloned into pET28a expression vector between EcoRI and HindIII 
(Thermo Scientific, Pittsburgh, PA, USA) restriction sites. pET28a plasmid 
containing the gene of interest was transformed into BL21 competent cells 
(homemade) and expression of the proteins was induced by 1 mM IPTG at 
18°C for 20 h [205]. The E. coli cells after induction were collected by 
centrifugation at 6,000 rpm for 30 min and re-suspended in phosphate 
buffered saline (PBS) containing 8 M Urea. The re-suspended solution was 
incubated for 2 h and sonicated for 5 min at 25°C to lyse the cells and then 
subjected to centrifugation at 15,000 rpm for 30 min. The supernatants were 
filtered through 0.45 µm filters, before mixing with Ni-NTA beads (Bio-Rad, 
Hercules, California, USA) and further incubated for 2 h at room temperature. 
The Ni-NTA beads were collected and washed extensively in sequence with 
PBS containing 8 M Urea, PBS containing 160 mM NaCl and PBS. After which, 
the Ni-NTA beads were added into PBS containing 0.5 mg/ml thrombin (from 
bovine plasma) and incubated in room temperature for 16 h to enzymatic 
release the folded protein. The released proteins in the PBS were 
concentrated by HPLC and lyophilized. After dissolving into H2O, the protein 
concentration was determined by measuring absorbance at 280 nm and using 





Figure 4.1 Synthetic gene sequences of Fasxiator. The synthetic gene was designed based 
on protein sequences and was optimized for E.coli expression.  
4.2.2.10 Circular dichroism spectroscopy 
Far-UV circular dichroism spectra (260-190 nm) of protein MilliQ water 
solution (0.08 – 0.1 mg/ml) was recorded using a Jasco J-810 
Spectropolarimeter (Jasco Corp., Tokyo, Japan) [206].  
4.2.2.11 Effect on intrinsic/extrinsic tenase complex 
The intrinsic and extrinsic tenase complex was reconstituted according the 
methods reported by Koyama et al. with minor modification [178].  
Activation of FVII: The FVIIIa used for reconstitution of intrinsic tenase 
complex was freshly activated from FVIII, purchased from Bayer 
Pharmaceutics (Leverkusen, Germany). FVIII was reconstituted to a final 
concentration of 100 units/ml. 100 units/ml FVIII (40 µl) was mixed with 6 µl of 
activation buffer, 2 µl of 25 nM α-thrombin and incubated at 37°C for 10 min. 
The reaction was stopped by adding 2 µl of 11,500 units/ml Hirudin and 
incubating at 37°C for 5 min. 
Reconstitution of intrinsic tenase: Intrinsic tenase complex was reconstituted 
by adding 6.25 µl each of activation buffer (50 mM HEPES pH 7.4, 140 mM 
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NaCl, 5 mM CaCl2, 0.1 % BSA), phosphatidylcholine: phosphatidylserine 
(PCPS) (7:3) (16 µM), FVIIIa (80 units/ml) and FIXa (160 pM) to a microtiter 
plate and incubating at 37°C for 10 min. Various concentrations of Inhibitors 
(12.5 µl) diluted with activation buffer were added and the mixture was 
incubated for another 15 min, followed by the addition of 12.5 µl of human FX 
(240 nM) and incubation for a further 2 min. The activation of FX to FXa by 
tenase complex was stopped by adding 25 µl of quenching buffer (50 mM 
HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 0.1 % BSA), after which 25 µl of 
2 mM S-2222 substrate was added. The cleavage of S-2222 by FXa was 
measured at 405 nm using the Infinite M200 microplate reader. PCPS, FIXa 
and FX were diluted with activation buffer from stock, while S2222 was diluted 
with distilled water. 
Reconstitution of extrinsic tenase: Extrinsic tenase complex was reconstituted 
by adding 6.25 µl each of activation buffer (50 mM HEPES pH 7.4, 140 mM 
NaCl, 5 mM CaCl2, 0.1 % BSA), PCPS (7:3) (16 µM), tissue factor (80 nM) and 
FVIIa (160 pM) to a microtiter plate and incubating at 37°C for 15 min. Various 
concentrations of inhibitors in the activation buffer (12.5 µl) were added and 
the mixture was incubated for another 15 min, followed by the addition of 12.5 
µl of human FX (240 nM) and incubation for a further 15 min. The activation of 
FX to FXa by tenase complex was stopped by adding 25 µl of quench buffer 
(50 mM HEPES pH 7.4, 140 mM NaCl, 50 mM EDTA, 0.1 % BSA), after which 
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25 µl of 2 mM S-2222 was added as a substrate for hydrolysis by FXa. The 
cleavage of S-2222 was measured at 405 nm using the Infinite M200 
microplate reader.  
4.2.2.12 Protease selectivity profile 
The selectivity profiles of the anticoagulant proteins were examined against 
twelve serine proteases: procoagulant serine proteases (FVIIa, FIXa, FXa, 
FXIa, FXIIa, kallikrein, and thrombin), anticoagulant serine protease (activated 
protein C), fibrinolytic serine proteases (urokinase and plasmin), and classical 
serine proteases (trypsin and chymotrypsin).  
50 µl of the respective serine protease diluted with activation buffer (50 mM 
HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 0.1 % BSA ) from stock was 
pre-incubated with 25 µl of different concentrations of proteins in a microtiter 
plate for 30 min at 37°C, followed by the addition of 25 µl the appropriate 
chromogenic substrate. In a total volume of 100 µl, for rFasxiator the final 
serine protease/ chromogenic substrate concentrations were as follows: FVIIa 
(200 nM)/S-2288 (1 mM), FIXa (150 nM)/Spectrozyme FIXa (1 mM), FXa (2 
nM)/S-2222 (0.5 mM), FXIa (0.5 nM)/S-2366 (0.5 mM), FXIIa (10 nM)/S-2302 
(0.5 mM), kallikrein (16 nM)/S-2302 (0.5 mM), thrombin (2 nM)/S-2238 (0.1 
mM), activated protein C (5 nM)/S-2366 (1 mM), urokinase (400 ng/ml)/S-2444 
(0.5 mM), plasmin (5 nM)/S-2251 (0.5 mM), chymotrypsin  (10 nM)/S-2586 
103 
 
(0.5 mM). The cleavage of substrate was measured at 405 nm using the 
Infinite M200 microplate reader. 
As the concentrations of rFasxiator variants (1 nM to 10 µM) used were much 
lower than rFasxiator (30 µM ~ 120 µM), the concentration of the serine 
proteases were concomitantly decreased (FVIIa 100 nM, FXa 1 nM, FXIIa 5 
nM, Kallikrein 2 nM, thrombin 1 nM, activated protein C 2 nM, plasmin 1 nM, 
chymotrypsin 5 nM) to increase the ratio of inhibitor to enzyme. The substrate 
concentrations of FXa (S2222 1 mM), FXIa (S2366 1 mM) and activated 
protein C (S2366 1.5 mM) were increased to allow for a longer monitor time.  
4.2.2.13 Surface plasmon resonance 
rFasxiator (50 µl of 500 nM, in 10 mM acetate buffer, pH 6.0) was immobilized 
on a COOH5 chip (SensiQ technologies, Oklahoma, Oklahoma, USA) using 
amine coupling with a SensiQ ® Pioneer system (SensiQ technology, 
Oklahoma, Oklahoma, USA). 145 µl of different concentrations of FXIa or 
chymotrypsin diluted in running buffer (10 mM HEPEs, 150 mM NaCl, 5 mM 
CaCl2 and 0.1 % Tween 20, pH 7.4) [207] were used as analytes at a flow rate 
of 20 µl/min and a dissociation time of 240 s was applied. The chip surface 
was regenerated with 25 µl of 10 mM glycine/HCl buffer pH 3.1 at a flow rate of 
50 µl/min and a dissociation time of 240 s after each analysis cycle.  
4.2.2.14 Western blotting 
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Concentration-dependent inhibition of FIX activation: 5 µl of 750 pM FXIa, 5 µl 
of 300 nM FIX and 5 µl of various concentration of recombinant inhibitor 
pre-warmed to 37 °C were mixed and further incubated at 37°C for 15 min 
before mixing with 5 µl of 4× SDS sample buffer and heated at 37°C for 10 min 
to stop the reaction. 
Time-dependent inhibition of FIX activation: 40 µl of 750 pM FXIa, 40 µl of 300 
nM FIX and 40 µl of buffer or 30 µM recombinant proteins pre-warmed to 37°C 
were mixed. From this mixture 15 µl aliquots were removed at indicated times, 
mixed with 5 µl of 4× SDS sample buffer and heated at 37°C for 10 min to stop 
the reaction. 
All the 20 µl was then loaded to a 10% SDS-PAGE, transferred to a 
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, California, USA) 
and probed for FIX and FIXa using mouse anti-FIX antibody (Hematologic 
Technologies, Essex Junction, Vermont, USA). 
4.2.2.15 Inhibition of FIX cleavage 
20 µl of indicated concentrations of recombinant protein or buffer was mixed 
with 15 µl of 667 pM FXIa and incubated at 37°C for 1 h. The cleavage of FIX 
was initiated by adding of 5 µl of 400 nM FIX into the above mixture. 2 min 
after adding FIX, 10 µl aliquots were removed from the mixture and quickly 
diluted by 125 times. 7.5 µl of the diluted solution was immediately mixed with 
7.5 µl of freshly activated FVIIIa (80 units/ml), 7.5 µl of activation buffer (50 
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mM HEPES pH 7.4, 140 mM NaCl, 5 mM CaCl2, 0.1 % BSA), 7.5 µl of 16 µM 
PCPS and incubated at 37°C for 10 min to form the intrinsic tenase complex. 
25 µl of the above intrinsic tenase complex was mixed with 25 µl of 120 nM FX 
and further incubated for 2 min in room temperature, after which,  25 µl of 
quench buffer was added, followed by 25 μl of 2 mM S2222. The cleavage of 
S2222 was measured at 405 nm using a microplate reader. PCPS, FIXa, FXIa, 
recombinant protein and FX were diluted with activation buffer from stock, 
while S2222 was diluted with distilled water [208]. 
4.2.2.16 Generation of progress curve of S2366 cleavage by FXIa 
Recombinant proteins, FXIa and substrate S2366 were pre-warmed to 37°C. 
25 µl of indicated concentrations of recombinant protein were mixed with 25 µl 
of 4 mM S2366. The reactions were started by adding of 50 µl of 1 nM FXIa 
and the hydrolysis of S2366 was measured at 405 nm using a microplate 
reader.  
4.2.2.17 Generation of point mutants  
Mutations were made through polymerase chain reactions using pET28a 
plasmid containing the original Fasxiator gene as a template and primers 
containing designed mismatch base pair(s). The components of the reactions 
are Pfu Turbo® DNA polymerase 0.4 µl  (1 U) (Stratagene, La Jolla, 
California, USA), dNTPs 2 µl (2 mM of each) (Thermo Scientific, Pittsburgh, 
PA, USA), primers forward and reverse 1 µl (0.75 µM each), pET28a plasmid 
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0.14 µl (20 ng), 10 × Pfu Turbo ® buffer 2 µl, ddH2O 13.46 µl. The annealing 
temperatures used were 54 °C and 60 °C, a total of 16 cycles of replication 
were carried out using a thermocycler (Bio-rad, Hercules, California, USA). 
The reaction mixtures were treated with DpnI 0.1 µl (1 U) (Thermo Scientific, 
Pittsburgh, PA, USA) and analyzed by 1% agarose gel for complete digestion 
before transformation into DH5α competent cells (homemade). Obtained 
clones were sequenced (service provided by 1st base, Singapore) and 
plasmids containing desired mutations were transformed into BL21 competent 
cells for protein expression. The induction and purification procedures were 
the same as described above. The molecular weights of purified mutated 
proteins were determined using ESI-MS as previously described to confirm the 
identity of the proteins. The proteins were quantified by measuring absorbance 



















Table 4.1 Primers for point mutagenesis. 

































4.2.2.18 Kinetic studies 




Ki determination for slow type inhibitor: Progress curves of slow type inhibitors 
were generated as described above. The progress curves were fitted into 
Equation 1 using KaleidaGraph 4.5 software [203]. 
P=Vs × t + (Vi-Vs)[1-exp(-Kobs × t)]/Kobs + P0                     Eqn  (1) 
P stands for amount of product; Vs: steady state velocity; Vi: initial state 
velocity; t: time; P0: correction factor for initial amount of product; Kobs: 
apparent first-order rate constant for the inter-conversion between Vs and Vi. 
Obtained Kobs were plotted against substrate concentration and inhibitor 
concentration respectively. 
In fixed inhibitor concentrations, for competitive inhibitors, Kobs decreases as 
substrate concentration is raise; for noncompetitive inhibitors, Kobs does not 
vary with substrate concentration, while for uncompetitive inhibitors, Kobs 
increase with increasing substrate concentration.  
With fixed substrate concentration, for type I inhibitor, plot of Kobs versus 
inhibitor concentration yields a straight line, while for type II inhibitor, plot of 
Kobs versus inhibitor concentration results in a hyperbola.  
Type 1 





For Type I inhibitor, the relationship between Kobs and inhibitor concentration [I] 
is given by Equation 2  
Kobs = K4 (1+[I]/Kiapp)                                          Eqn (2) 
For competitive inhibitor, the relationship between Kiapp and Ki were given by 
Equation 3 
Ki = Kiapp / (1 + [S]/Km)                                        Eqn (3) 
[S] stands for substrate concentration, Km stands for the Michaelis constant.  
Ki determination for fast type inhibitor: For fast type inhibitors, their Ki were 
calculated by Equation 4 [203]. 
Ki = IC50/ (1 + [S]/Km)                                         Eqn (4) 
IC50 were determined by fitting the respective dose-inhibition curve using 
GraphPad Prism software. 
4.2.2.19 FeCl3 induced carotid artery thrombosis model 
All animal experiments and procedures were carried out under protocol 041/12 
approved by Institutional Animal Care and Use Committee (IACUC), National 
University of Singapore. The FeCl3 induced carotid artery thrombosis model 
was performed as described previously [202, 210, 211]. C57BL/6 male mice 
(9-11 weeks old, 24.5-27.5g) (Invivos, Singapore) were anesthetized with an 
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i.p. injection of ketamine (75 mg/Kg) and medetomidine (1 mg/Kg). Two sets of 
independent experiments were performed to evaluate the efficacy of 
rFasxiator. In the first experiment, 0.1 ml protein (2 mg/ml) was injected into 
the mice via tail vein. The right carotid artery was exposed using blunt 
dissection and vascular injuries were caused by applying a filter paper of sizes 
of 2 mm × 2 mm saturated with 6% FeCl3 on top of the carotid artery for 3 min. 
In the second experiment higher concentration of protein (0.15 ml) was 
injected and intensity of injury was decreased by smaller filter papers (1 mm × 
1 mm) and lower FeCl3 (5%). After 3 min FeCl3 exposure, the filter paper was 
removed and the vessel was washed with sterile normal saline. To determine 
the time to occlusion, a miniature Doppler flow probe (Cat # MA0.5VB, 
Transonic Systems Inc., Ithaca, New York, USA) was placed around the 
carotid artery and blood flow was recorded using a Transonic flowmeter 
(Transonic Systems Inc., Ithaca, New York, USA). The maximal monitor time 
after injury is 30 min. Mice were killed by cervical dislocation immediately after 
conclusion of the experiment and prior to recovery from anesthesia. 
4.2.2.20 Statistical analysis 
Results are expressed as means ± SD unless otherwise described. Statistical 
differences among the animal groups were analyzed by unpaired t-test. 





4.3.1 Isolation of anticoagulants that selectively target intrinsic pathway 
In Chapter 2, Bungarus fasciatus venom was subjected to a two-step 
fractionation using size exclusion chromatography (SEC) and reversed phase 
high performance liquid chromatography (RP-HPLC) (Figure 2.7 / Figure 
4.2A-F). The molecular weights (MW) of each RP-HPLC fractions were then 
determined by electrospray ionization mass spectrometry (ESI-MS). Pooled 
fractions were tested for their effects on aPTT and PT (Figure 4.2G, data 
originated from Figure 2.8). 
Three RP-HPLC pools (B1, C1 and D1) prolonged aPTT without significant 
effects on PT (Figure 4.2G), indicating that they affected the intrinsic pathway, 
while leaving the extrinsic pathway unaffected. ESI-MS results indicated that 
these pools mainly contained two proteins with MW of 6977.5 ± 0.85 Da and 
7307.3 ± 0.67 Da (Table 4.2, data originated from Table 2.3). These two 
proteins were separated by introducing a cation exchange chromatography 
(CEC) step between SEC and RP-HPLC (Figure 14.2H-J). The homogeneity 
and mass of the purified proteins were determined by ESI-MS. The smaller 
protein (MW: 6977.5 ± 0.85 Da) was named BF01, and the larger molecule 
(MW: 7307.3 ± 0.67 Da) was named BF02. Both BF01 and BF02 prolonged 




Table 4.2 Molecular weights of proteins in RP-HPLC pooled fractions. 
Pool  A1  A2  A3  A4  B1  B2  C1  D1  D2  E1  E2  
Molecular 
Weight  




7268  6977 
/6433  




6505  6363 
/6325  
6373  
The molecular weights of BF01 and BF02 were highlighted. 
4.3.2 Protease specificity of novel anticoagulants 
To determine the protease specificity, BF01 and BF02 were screened against 
several procoagulant serine proteases in the coagulation pathway (Figure 4.3) 
and were found to selectively inhibit FXIa. The more abundant BF01 was 
further screened against 10 serine proteases (thrombin, FVIIa, FIXa, FXa, 
FXIa, FXIIa, Plasmin, Kallikrein, APC, Urokniase) in the coagulation cascade. 
Other than FXIa, BF01 (10 µM) did not inhibit the activities of other serine 




Figure 4.2: Identification of novel anticoagulants from Bungarus fasciatus venom. (A) 
SEC of B. fasciatus venom. Crude venom (100 mg) was dissolved in 50 mM Tris-HCl buffer (pH 
8.0) and separated on a HiLoad 16/60 Superdex 30 preparative grade column. Fractions (1 ml) 
were collected and pooled into pools A-E. Individual pools were subfractionated on a RP-HPLC 
column (B-F). Fractions with MW between 5 kDa and 8 kDa (Table S1) were pooled into A1, A2, 
A3, A4, B1, B2, C1, D1, D2, E1 and E2. (G) Anticoagulant activities of RP-HPLC fractions. 
Pooled fractions were evaluated using aPTT and PT in triplicate. Error bars represent standard 
deviations. Pools B1, C1 and D1 prolonged aPTT without significant effects on PT and were 
further characterized. MS studies revealed that pools B1, C1 and D1 mainly contain two 
proteins with molecular weights of 6977.5 ± 0.85 Da and 7307.3 ± 0.67 Da (Table S1). (H) 
Pooled SEC fractions containing anticoagulant proteins were loaded on a Bio-Rad S6 cation 
exchange chromatography column. Peak 1 contained BF01 (MW: 6977.5 ± 0.85 Da) and Peak 
2 contained BF02 (MW: 7307.3 ± 0.67 Da). (I and J) BF01 and BF02 were further fractionated 
using RP-HPLC. Fractions containing BF01 and BF02 were pooled and lyophilized for future 
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use. (K) BF01 and BF02 prolong aPTT at a final concentration of 3.75 μM. (L) Effects of BF01 
on various procoagulant proteases in the coagulation cascade were evaluated. Results indicate 
that both proteins are selective inhibitors of FXIa. (M) Alignment of the protein sequences with 
relevant Kunitz-type inhibitors. Dark grey: Cysteines; Light grey: Loop 1 and Loop 2 residues. 
The disulfide bridges were shown by solid lines.  
 
 
Figure 4.3: Effects of BF01 and BF02 on various procoagulant proteases in the blood 
coagulation cascade. Results indicate that both proteins are selective inhibitors of FXIa. 
4.3.3 Amino acid sequences of novel anticoagulants 
BF01 and BF02 were subjected to pyridylethylation, Lys-C/Arg-C digestion 
and protein sequencing. Elution profile of peptide fragments and sequencing 
data suggested that BF01 and BF02 are isoforms (Figure 4.4); BF02 has three 
additional amino acid residues at the C-terminal compared to BF01. BLAST 
searches indicated that BF01 and BF02 were Kunitz-type protease inhibitors.  
BF02 is only one residue different from a previously reported chymotrypsin 
inhibitor, Kunitz IX (BFIX), isolated from the venom of the same species [207]. 
However, its haemostatic effect has not been previously reported.  The 
sequences of BF01 and BF02 were aligned with BFIX, PN2KPI and other 
Kunitz-type chymotrypsin or trypsin inhibitors (Figure 4.2M). Interestingly, 
BF01/BF02 shows limited similarity with PN2KPI (45% identity; 58% similarity). 
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We focused on BF01 for further studies and it was named as Fasxiator (B. 




Figure 4.4: Sequence determination of BF01/02. (A) ESI-MS profile of BF01; (B) ESI-MS 
profile of BF02; (C-D) HPLC profile of BF01/02 after pyridylethylation; the major product had a 
molecular weight of 7614.2 Da (BF01)/ 7944.8 Da (BF02), while molecular weight of 7508.9 Da 
(BF01)/ 7840.2 Da (BF02) (minus one 4-pyridylethyl group) was also detected in the same peak. 
(E) HPLC profile of BF01/02 after Arg-C digestion; the molecular weights of major peaks are 
shown. (F) HPLC profile of BF01/02 after Lys-C digestion; the molecular weights of major peak 
are shown. (G) The amino acid sequence of BF01/02 was determined by N-terminal sequencing 
of pyridylethylated BF01/02 and peptides from Arg-C digestion of BF02. The molecular weights 
detected in Arg-C and Lys-C digestion were assigned to the expected peptides and these 
peptides were aligned with the full length sequence of BF02. The molecular weights of peptides 
are shown in the format of (calculated mass)/(determined mass). BF01 showed identical HPLC 
profile as BF02 except the presence of “RSS” at the C-terminal. The presences of two isoforms 
of Kunitz-type inhibitor that differ by “RSS” in the C-terminal in Bungarus fasciatus venom were 
recorded earlier [212]. 
4.3.4 Recombinant expression of Fasxiator  
Due to limited venom supply, Fasxiator was recombinantly expressed in E. coli 
and refolded. The bacterial lysate and refolded protein were visualized on a 15% 
SDS PAGE using Coomassie blue staining (Figure 4.5A). The refolded protein 
was further fractionated by RP-HPLC (Figure 4.5B). Recombinant Fasxiator 
(rFasxiator) has an additional five amino acid residues “GSEFM” in the 
N-terminal compared to BF01. The identity and homogeneity of rFasxiator was 
ascertained by ESI-MS (Figure 4.5C); MW of 7529.40 ± 0.85 Da matches the 
calculated mass from the sequence. rFasxiator showed similar secondary 
structure (Figure 4.5D), inhibitory effect on FXIa and chymotrypsin (Figure 
4.5E) and anticoagulant activity (Figure 4.5F) compared to native Fasxiator. 
Thus, rFasxiator is structurally and functionally similar to native Fasxiator and 




Figure 4.5: Recombinant expression and purification of rFasxiator. (A) SDS PAGE of total 
bacterial lysate and thrombin cleavage product from Ni-NTA beads; (B) Purification of thrombin 
cleavage products using RP-HPLC; (C) ESI-MS profile of purified recombinant protein 
(rFasxiator). rFasxiator has an additional five amino acid residues in the N-terminal compared 
with Fasxiator.  (D) Circular dichroism spectra of Fasxiator and rFasxiator; (E) Inhibition of 
chymotrypsin and FXIa activities by Fasxiator and rFasxiator; (F) Prolongation of aPTT by 
Fasxiator and rFasxiator. Results indicate that Fasxiator and rFasxiator share similar structure 
and activity (D-F). 
4.3.5 rFasxiator selectively inhibits FXIa 
The anticoagulant activity and protease specificity of rFasxiator were 
determined. rFasxiator doubled aPTT at ~3 µM but had no significant effect on 
PT up to 100 µM (Figure 4.6A). rFasxiator was tested for its effect on extrinsic 
and intrinsic tenase complexes (Figure 4.7), as well as various serine 
proteases involved in the coagulation cascade (Figure 4.6B). rFasciator 
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selectively inhibits FXIa (IC50 ~1.5 µM); it failed to significantly inhibit other 
serine proteases even at 120 µM. The inhibition kinetics of rFasxiator on FXIa 
using chromogenic substrate S2366 (Figure 4.6C-D) indicated that rFasxiator 
is a slow-type inhibitor, with IC50 values changing from 3 µM (no pre-incubation) 
to 1.5 µM (1 hr pre-incubation). In contrast, rFasxiator was a fast type inhibitor 
of chymotrypsin with an IC50 of 1 µM (data not shown).  
 
Figure 4.6: Anticoagulant activity and protease specificity of rFasxiator. (A) Effect of 
rFasxiator on aPTT and PT. rFasxiator prolonged aPTT in a dose-dependent manner, while it 
had no significant effect on PT; (B) rFasxiator selectively inhibits FXIa among the serine 
proteases in the blood coagulation cascade. (C) Progress curves of S2366 cleavage by FXIa in 
the presence of different concentrations of rFasxiator. (D) Effects of incubation time on the 
inhibition of FXIa by rFasxiator. Dose-inhibition curve shifts to the left with 1 h incubation. 





Figure 4.7: Effect of rFasxiator on the intrinsic and the extrinsic tenase complexes. 
rFasxiator had no significant inhibitory effect on the activity of both complexes. 
4.3.6 rFasxiator prolongs aPTT through inhibition of FXIa 
As rFasxiator inhibits the cleavage of small peptide substrates by FXIa, we 
examined the interaction of rFasxiator with FXIa.  
Firstly, we determined the affinity of rFasxiator to FXIa using surface plasmon 
resonance (SPR). rFasxiator was immobilized on the surface of a COOH5 
chip and different concentrations of FXIa were used as analyte (Figure 4.8A). 
The sensorgrams indicated strong interaction of rFasxiator with FXIa; we 
calculated a KD of 20.15 nM assuming a 1:1 stoichiometry and single step 
binding. Similarly, rFasxiator interacted with chymotrypsin with a KD of 29.3 nM 
(data not shown). This KD value is similar to that of chymotrypsin inhibitor BFIX 
(~50 nM) reported in earlier [207].  
Secondly, we examined the effect of rFasxiator on the cleavage of FIX, the 
physiological substrate of FXIa. The cleavage of FIX by FXIa was monitored 
using western blotting in both the presence and absence of 10 µM rFasxiator. 
The presence of rFasxiator slowed down the cleavage of FIX (Figure 4.8B, 
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upper panel). At 15 min, rFasxiator exerted a dose-dependent inhibition of FIX 
cleavage by FXIa (Figure 4.8B, lower panel). The amount of cleavage product, 
FIXa, was also quantified by the chromogenic assays (Figure 4.8C). rFasxiator 
was found to inhibit the activation of FIX with a similar potency as the inhibition 
of FXIa cleavage of small peptide substrates (IC50 ~3 µM).  
Finally, we tested the effect of rFasxiator on the prolongation of aPTT in 
normal and FXI-deficient human plasma. rFasxiator failed to prolong aPTT in 
FXI-deficient plasma, while it was able to prolong aPTT in FXI rescued plasma 
with a similar potency as in normal human plasma (Figure 4.8D). This result 
strongly suggests that FXI is necessary for rFasxiator’s function as an 
anticoagulant, whereby prolongation of aPTT could have been achieved via 
the inhibition of FXIa. To the best of our knowledge, this is the first exogenous 
protein that selectively targets FXIa.  
 
Figure 4.8: rFasxiator interacts with and inhibits FXIa.  (A) High affinity binding of 
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rFasxiator to FXIa. In SPR studies, rFasxiator was immobilized and various concentrations of 
FXIa were used as the analyte. FXIa binds to rFasxiator with a KD of 20.15 nM. rFasxiator also 
binds chymotrypsin with a KD of 29.3 nM (data not shown); (B) Inhibition of cleavage of FIX by 
rFasxiator. FIX and FIXa were detected by western blotting. rFasxiator shows time-dependent 
(upper panel) and dose-dependent (lower panel) inhibition of activation of FIX; (C) Inhibition of 
activation of FIX by rFasxiator. The FIXa generated was quantified by its hydrolytic activity on 
chromogenic substrate (activity in the absence of rFasxiator was defined as 100%); (D) FXIa is 
the target for rFasxiator for its anticoagulant effects. aPTT is prolonged by rFasxiator in normal 
plasma, but not in FXI-deficient plasma. The anticoagulant effects were observed when 10 nM 
FXI was added to FXI-deficient plasma. Data points represent average of duplicates. Thus, FXI 
is the main target of rFasxiator.  
4.3.7 Improvement of rFasxiator potency by site-directed mutagenesis  
As the in vitro studies showed that rFasxiator prolonged aPTT through 
inhibition of FXIa, the anticoagulant effect of rFasxiator was tested in mouse 
plasma. Unfortunately, unlike in human plasma, rFasxiator failed to prolong 





Figure 4.9: Effects of rFasxiator on aPTT of human (A) and murine (B) plasma. Clotting of 
plasma was monitored by absorbance at 650 nm. aPTT of human plasma was prolonged by 
rFasxiator, but rFasxiator had no significant effect in murine plasma. rFasxiator does not inhibit 
murine FXIa or inhibits it in a much less potency than inhibiting human FXIa. 
To improve the potency and selectivity of rFasxiator, specific residues in loops 
1 and 2 of rFasxiator were selected based on the co-crystal structure of 
PN2KPI and FXIa catalytic domain (PDB Id: 1ZJD) [213] (Figure 4.10A, B). 
The following single point mutations were carried out: (1) P1 substitutions 
N17A, N17K and N17R; (2) P2’ substitutions L19A and L19M; (3) P3’ 
substitution R15A; and (4) P3, P4’ exchange R15P,P21R (all in loop 1) and (5) 
N36F substitution (in loop 2). All the mutants were expressed and purified 
using the same procedures as the rFasxiator protein. The homogeneity and 
identity of each mutant were ascertained by ESI-MS (Table 4.3 and Figure 
4.11).  
All mutants were tested for FXIa inhibition (Figure 4.10C). Mutation of P1, as 
expected, had a significant effect on the inhibitory activity; rFasxiatorN17A lost 
~75% of the inhibitory activity, while mutation to positively charged Lys and 
Arg significantly enhanced it. All the other substitutions at P2’, P3’, P4’ and P3 
resulted in decreased or had no significant effect on the inhibitory activity. We 
determined the specificity of rFasxiatorN17K and rFasxiatorN17R for the serine 
proteases in the coagulation pathway. Although these mutations increased the 
potency, the selectivity was lost: rFasxiatorN17K has similar selectivity towards 
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FXIa and plasmin (Figure 4.10D), while rFasxiatorN17R is only marginally 
selective towards FXIa compared to plasmin and kallikrein (Figure 4.10E).  
 
Figure 4.10: Structure-function relationships of rFasxiator. (A) Sequence alignment of two 
FXIa-specific Kunitz-type inhibitors. Yellow color: identical residues; green color: conserved 
residues. To increase potency and selectivity of rFasxiator, we selected residues (identified by 
arrow heads) that are involved in interaction with FXIa; (B) Interaction between PN2KPI and 
FXIa light chain (protease domain), FXIac, as determined by 3D structure of the complex.[213] 
Only relevant segments are shown. Red: FXIa residues involved in interaction with PN2KPI; 
Dark blue: Loop I (GPCRAMISR) residues of PN2KPI; Green: Loop 2 (FYGGC) residues of 
PN2KPI; Light blue: Hydrogen bonds; The guanidinium group of Arg15 (P1) in PN2KPI interacts 
with the carboxylate group of Asp189 of FXIac to form a salt bridge in the S1 pocket; Pro13 (P3) 
help Cys14 (P2) and Gly12 (P4) found hydrogen bonds with Lys192 of FXIac by turning the 
backbone; Met17 (P2’) and Ser19 (P4’) interact with Arg37D of FXIa; Phe34 of PN2KPI is in van 
der Waals contact with Tyr143 of FXIac. (C) FXIa inhibition by site-directed mutants of 
rFasxiator (40 min pre-incubation with FXIa). Two mutants rFasxiatorN17R and rFasxiatorN17K 
show significant increase in their potency; Selectivity profiles of rFasxiatorN17K (D) and 
rFasxiatorN17R (E) (30 min pre-incubation of enzyme and inhibitor). Further mutations are 
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needed for improving selectivity. 
Table 4.3 Molecular weights of rFasxiator mutants first set. 
Mutants N17A N17R N17K L19A L19M R15A R15P,P21R N36F 
Calculated MW 7485.53 7570.64 7542.63 7486.48 7546.59 7443.45 7528.56 7561.63 
Determined MW 7486 7571.8 7543.9 7487 7547.2 7444 7529 7562.2 
 
Figure 4.11 ESI-MS of first set point mutations. The molecular weights of the first set 




To enhance the selectivity of rFasxiator, rFasxiatorN17R was chosen for further 
modifications. The P2’ L residue was mutated to A/E/F/N/R/S (Figure 4.12 and 
Table 4.4). All the double mutants were then evaluated for their ability to inhibit 
FXIa and plasmin (Figure 4.13). rFasxiatorN17R,L19E showed the best selectivity 
among all mutants toward FXIa. Comparison of selectivities revealed that 
rFasxiatorN17R,L19E had better selectivity over FVIIa, FXa, FXIIa, kallikrein, APC, 
plasmin, and chymotrypsin than rFasxiatorN17R (Figure 4.14A). The 
dose-response studies indicated that the IC50 for FXIa inhibition by 
rFasxiatorN17R, rFasxiatorN17K and rFasxiatorN17R,L19E with 40 min incubation 
were 0.94 nM, 2.96 nM and 1.26 nM, respectively (Figure 4.14B).  The 
inhibitory potencies of these mutants increased with prolongation of incubation 
time with FXIa (Figure 4.14C) and hence are also slow-type inhibitors.  Thus, 
with two mutations in rFasxiatorN17R,L19E, we significantly improved the 
inhibitory potency (1000 fold) and selectivity towards FXIa. 
Table 4.4 Molecular weights of rFasxiator mutants second set. 
Mutants N17R,L19A N17R,L19E N17R,L19F N17R,L19N N17R,L19R N17R,L19S 
Calculated MW 7528.56 7586.6 7604.66 7571.58 7613.67 7544.56 




Figure 4.12 ESI-MS of second set point mutations. The molecular weights of the second set 




Figure 4.13: Selectivity of double variants (mutations second set). In order to increase the 
selectivity of rFasxiatorN17R, we have mutated the P2’ residue “L” to A/E/F/N/R/S. Since 
rFasxiatorN17R suffered from poor selectivity toward Plasmin, for a screening, we tested the dose 
dependent inhibition of the new variants against FXIa and Plasmin (A-F) without pre-incubation 
of inhibitor with proteases. rFasxiatorN17R,L19E showed best selectivity toward FXIa over plasmin. 
4.3.8 Inhibition kinetics of rFasxiatorN17R,L19E 
To further understand the interaction with FXIa, we determined the kinetic 
parameters of rFasxiatorN17R,L19E. Progress curves of cleavage of S2366 by 
FXIa with (i) fixed substrate concentration and different concentrations of 
rFasxiaotorN17R,L19E (Figure 4.14D), and (ii) fixed rFasxiatorN17R,L19E 
concentration and different concentrations of S2366 were plotted (data not 
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shown). The curves were fitted into Eqn 1 (Materials and Methods) to 
determine Kobs. Kobs decreases with the increasing substrate concentration 
(Figure 4.14E). Hence, rFasxiatorN17R,L19E is a competitive inhibitor. As the plot 
of Kobs versus rFasxiatorN17R,L19E concentrations (Figure 4.14F) shows a 
straight line, rFasxiatorN17R,L19E is a type I slow-type inhibitor with a Ki of 0.86 
nM using Eqn 2 and 3 (Materials and Methods). For comparison, we also 
determined the dose-dependent inhibition of other serine proteases (Figure 
1.14G). Ki values of rFasxiatorN17R,L19E in inhibition of trypsin, plasmin, FXa, 
FVIIa and kallikrein were obtained and compared with those of PN2KPI (Table 
4.5). rFasxiatorN17R,L19E inhibited FXIa with similar potency as PN2KPI (0.86 
nM versus 0.81 nM), while their selectivity are different. rFasxiatorN17R,L19E 
dropped 2-5 folds in selectivity against plasmin, FXa and FVIIa, while gained 
28.9 fold and 323 folds selectivity against kallikrein and trypsin comparing to 
PN2KPI. Thus we have developed a new selective inhibitor of FXIa, which has 




Figure 4.14: Functional characterization of rFasxiatorN17R,L19E. (A) Comparison of selectivity 
between rFasxiatorN17R,L19E and rFasxiatorN17R. rFasxiatorN17R,L19E has better selectivity over 
FVIIa, FXa, FXIIa, kallikrein, APC, plasmin, and chymotrypsin; (B) Dose-dependent inhibition of 
FXIa by rFasxiatorN17R,L19E, rFasxiatorN17R and rFasxiatorN17K (40 min pre-incubation); (C) 
Time-dependent inhibition of FXIa by rFasxiatorN17R,L19E, rFasxiatorN17R and rFasxiatorN17K. (D) 
Effect of rFasxiatorN17R,L19E on cleavage of S2366 by FXIa. The curves were fitted into Eqn 1 to 
determine Kobs; (E) Kobs plotted against substrate concentration. The decrease in inhibition with 
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increasing concentrations of substrate suggests that rFasxiatorN17R,L19E is a competitive inhibitor; 
(F) Kobs were plotted against rFasxiatorN17R,L19E concentration. A straight line indicates that 
rFasxiatorN17R,L19E is a type I slow-type inhibitor. (G) Selectivity of rFasxiatorN17R,L19E against 
different serine proteases (40 min pre-incubation).   rFasxiatorN17R,L19E has high potency and 
good selectivity to FXIa. 
 
Table 4.5 Comparison of Ki of rFasxiatorN17R,L19E with PN2KPI 
 rFasxiatorN17R,L19E/  
Fold to FXIa  
PN2KPI/  
Fold to FXIa 
FXIa  0.86 nM/ 1  0.81 nM/ 1  
Trypsin  9.7 nM/ 11.3  0.03 nM/ -27  
Kallikrein  5297.7 nM/ 6160.1  183 nM/ 225.9  
Plasmin  145.5 nM/ 169.2  459 nM/ 566.7  
FVIIa  693 nM/ 805.8  3500 nM/ 4320  
FXa  718 nM/ 834  1150 nM/ 1419.8  
 
4.3.9 rFasxiatorN17R,L19E prolongs FeCl3-induced carotid artery thrombosis  
The anticoagulant effects of rFasxiatorN17R,L19E were quantified by aPTT and 
PT in human and murine plasma. rFasxiatorN17R,L19E prolonged aPTT in a 
dose-dependent manner (Figure 4.15A) and doubled aPTT at around 300 nM, 
but had no significant effect on PT up to 40 µM in human plasma (Figure 4.16). 
Similarly, it also prolonged aPTT in mice plasma in a dose-dependent manner, 
however, the potency was about 10 fold weaker (doubled aPTT at ~4 µM). 




We used FeCl3-induced carotid artery thrombosis model to evaluate the 
antithrombotic effects of rFasxiatorN17R,L19E. In the first set of experiments, 0.2 
mg rFasxiatorN17R,L19E almost doubled the occlusion time (5.57 min versus 9.55 
min) in the test animals compared to control animals (Figure 4.15B). While all 
the control animals conformed to a one step formation of thrombus (flow 
gradually reduced to zero and maintained until the end point), four of the 
treated animals showed diffused events (flow reduced first, bounced back to 
normal and reduced again). We, therefore, repeated the animal experiments 
with the increased inhibitor (0.3 mg) and reduced the injury strength. Under 
these conditions, 6 control animals attained occlusion times in around 10 min, 
but no occlusion was found until 30 min in the 7th mouse. In treated animals 
there was no occlusion until the end of experimental period (30 min) (Figure 
4.15C). Thus, rFasxiatorN17R,L19E exhibited antithrombotic effects in mouse 
carotid artery thrombosis. The in vivo data complemented with our in vitro data 




Figure 4.15: Anti-thrombotic effect of rFasxiatorN17R,L19E in FeCl3-induced carotid artery 
thrombosis model in mice. (A) Potency of rFasxiator in prolonging aPTT in both human and 
murine plasma. Human plasma data represents average of triplicates, while mice plasma data 
represents average of duplicates; (B) Thrombosis was induced by 6% FeCl3, 2 mmⅹ2 mm filter 
paper; 200 µg rFasxiatorN17R,L19E per mice. Significant differences between two groups were 
calculated using paired t-test, P<0.05; (C) Thrombosis was induced by 5% FeCl3, 1 mmⅹ1 mm 
filter paper; 300 µg rFasxiatorN17R,L19E per mice. Significant differences between two groups 




Figure 4.16: Effects of rFasxiatorN17R,L19E on PT. rFasxiatorN17R,L19E was not able to prolong 
PT in human plasma up to a concentration of 40 µM. Figure A-C represent for triplicates. 
4.4 Conclusion and discussion  
FXI is an important player of the intrinsic pathway; it is involved in the 
feedback loop that maintains the generation of thrombin to promote 
coagulation [214]. Activation of FXI by FXIIa propagates fibrin formation 
through activation of FIX. Recently, FXI/FXIa is recognized as a potential 
target for designing anti-thrombotic drugs with minimal bleeding effects [167, 
215]. In fact, several groups have successfully reduced thrombosis generation 
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without increasing bleeding in animals through targeting FXI/FXIa. For 
example, mice treated with FXI antisense oligonucleotides were protected 
against FeCl3/stenosis-induced inferior vena cava thrombosis and 
FeCl3-induced mesenteric vein thrombosis, with no effect on partial 
hepatectomy surgical bleeding model [200]. Baboons receiving anti-FXI 
antibody were protected against collagen-initiated thrombus development 
without affecting bleeding time [197]. BMS-262084, a small irreversible 
inhibitor of FXIa produces antithrombotic effects with minimal increase in 
bleeding time in both rabbits and rats [216, 217].  
Fasxiator is a Kunitz-type serine protease inhibitor. It has only one residue 
different from a chymotrypsin inhibitor BFIX isolated from same venom [207]. 
However, the haemostatic effects of BFIX were not explored. Fasxiator (FXIa 
and chymotrypsin inhibitor) showed low identity (<50%) with PN2KPI (trypsin 
and FXIa inhibitor), BPTI (trypsin, plasmin, kallikrein and FXIa inhibitor), HlChl 
(chymotrypsin inhibitor) [218], AvKTI (trypsin and plasmin inhibitor) [219] and 
BBPTI-1 (chymotrypsin inhibitor) [220]. Because of its distinct sequence, we 
characterized the anticoagulant property, serine protease specificity and the 
inhibitory effects of rFasxiator on FXIa in detail. rFasxiator inhibits intrinsic 
pathway, while leaves extrinsic pathway unaffected. rFasxiator selectively 
inhibits FXIa among the serine proteases and tenase complexes involved in 
the coagulation cascade. Using four completely different methods (SPR, 
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western blotting, chromogenic and standard coagulation assays), we have 
shown that rFasxiator interacts with FXIa with high affinity and inhibits 
cleavage and activation of FIX, and thus exerts its anti-coagulation function 
through targeting FXIa. Thus, we have identified and successfully expressed 
rFasxiator, a selective FXIa inhibitor from B. fasciatus venom.  
Further characterization of rFasxiator in mouse models was hindered by its 
inability to prolong aPTT in murine plasma. Further, the inhibitory effects of 
rFasxiator on FXIa are relatively weak compared to PN2KPI and several other 
small inhibitors of FXIa (µM versus nM) [198, 199]. Thus, we attempted to 
increase the potency of rFasxiator through specific point mutations. The major 
challenge is to achieve both strong potency and high selectivity, as most of the 
coagulation factors are trypsin-like proteases with their selectivity dependent 
on minor differences in the active-site pocket. To understand molecular details 
of interaction between FXIa and Kunitz inhibitor, we used the co-crystal 
structure of PN2KPI and FXIa catalytic domain (FXIac) (PDB: 1ZJD) as a 
reference. The key interactions between PN2KPI and FXIa are as follows: (a) 
the guanidinium group of Arg15 (P1) in PN2KPI interacts directly with the 
carboxylate group of Asp189 of FXIac to form a salt bridge in the S1 pocket; (b) 
Pro13 (P3) helps Cys14 (P2) and Gly12 (P4) to form hydrogen bonds with 
Lys192 of FXIac by turning the backbone; (c) Met17 (P2’) and Ser19 (P4’) 
interact with Arg37D of FXIa; and (d) Phe34 of PN2KPI is in van der Waals 
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contact with Tyr143 of FXIac [213]. Thus, we chose the corresponding 
residues (P1, P3, P2’, P4’ and the first residue in loop II) in rFasxiator for 
mutagenesis study. As predicted, the P1 residue is the most essential residue 
for inhibitory activity. Changing Asn17 (P1) in rFasxiator to FXIa preferred 
residue, arginine and lysine, significantly improved the potency of inhibition. 
However, mutations designed to mimic the loop 1 structure of PN2KPI failed to 
improve inhibitory potency.   
rFasxiatorN17K and rFasxiatorN17R showed 100-1000 times increment in potency. 
However, further efforts were needed to optimize the specificity and selectivity 
of rFasxiatorN17K and rFasxiatorN17R. Since mutations in P2’ significantly 
affected the selectivity of PN2KPI [221], we mutated Leu19  to residues of 
different properties. The properties/residues are: Small/Ala; Nucleophilic/Ser; 
Hydrophobic/Pro; Aromatic/Phe; Acidic/Glu; Amide/Asn; and Basic/Arg. 
Except for rFasxiatorN17R,L19P, all the other mutants were successfully 
expressed and evaluated for their protease selectivity. Glutamate in P2’ 
position is the least preferred residue by kallikrein, APC, plasmin, FXIIa and 
chymotrypsin; rFasxiatorN17R,L19E showed dramatic loss of inhibitory effect on 
these enzymes. In contrast, FXIa tolerated an acidic residue in P2’ position. 
This Glutamate may interact with Arg37D of FXI and form a salt bridge. Thus, 
by modifying P1 and P2’ sites of rFasxiator, we have successfully improved 
the potency and specificity of rFasxiator. These results suggest that it is 
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possible to change potency/selectivity of type inhibitors to a specific serine 
protease with only limited modifications.  
The comparison of rFasxiatorN17R,L19E with PN2KPI indicated that 
rFasxiatorN17R,L19E inhibited FXIa with similar potency as PN2KPI (0.86 nM as 
compared to 0.81 nM), but their specificities are different. 
Recently, a naturally deleted form of tissue factor pathway inhibitor, 
Desmolaris, was isolated from bat saliva [317]. Desmolaris inhibited 
FeCl3-induced carotid artery thrombus without impairing hemostasis. Thus, the 
author argues that FXIa is the primary in vivo target for Desmolaris at 
antithrombotic concentrations. However, desmolaris interacts and inhibits 
FXIa and FXa at similar strength in in vitro assays and blocked FXa and 
kallikrein activities in in vivo assays at higher concentrations. 
rFasxiatorN17R,L19E treated animals were protected against FeCl3-induced 
carotid artery thrombosis and the protective effects are related to injury 
strength. Similar observations were also made with FXI-deficient mice [211]; 
FXI-deficient mice were fully protected against thrombosis induced by 5% 
FeCl3, partially protected against 7.5% FeCl3, and showed almost no 
protection against 10% FeCl3. Thus, disruption of FXI provides milder 
protection against artery thrombosis, unlike thrombin inhibition. This may be 
because thrombin is downstream of FXIa in the thrombus formation and thus a 
more direct target for inhibition of thrombus growth [214, 215, 222]. The 
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diffused pattern observed suggested that rFasxiatorN17R,L19E, played a role in 
the growth/stability of thrombus, which is consistent with the phenomena 
observed elsewhere [197, 202]. Platelet deposition and fibrin accumulation 
was reduced in vascular graft occlusion in FXI antibody treated baboon [197] 
and thrombi inside the carotid artery was flushed away by blood flow in some 
of the PN2KPI treated mice [202]. Thus, rFasxiatorN17R,L19E prevent thrombosis 
formation in vivo. To evaluate toxicity, we administered rFasxiator or 
rFasxiatorN17R,L19E at a single dosage of 50 mg/kg through intraperitoneal 
injections or 10 mg/kg through intravenous injections in C57BL/6 mice. These 
mice showed no pathologic symptoms and they survived more than three days 
without any complications. Thus, rFasxiator and rFasxiatorN17R,L19E have 
low/no acute toxicity in healthy animals. Inhibitory kinetic study indicates that 
rFasxiatorN17R, rFasxiatorN17K and rFasxiatorN17R,L19E are slow-type inhibitors. 
However, we were not able to determine the residue(s) responsible for 
slow/fast inhibition so far.   
In summary, we have isolated a novel exogenous FXIa inhibitor, Fasxiator， 
from B. fasciatus venom. Recombinant double mutant has high potency and 
selectivity towards FXIa and it inhibits occlusion in mouse carotid artery 





























Conclusion and Future Work 
5.1 Conclusion 
At the beginning of this study, we focused our efforts in identifying novel 
proteins from the venom of banded krait, Bungarus fasciatus. Through 
sequential fractionation coupled with functional assays (chapter two of the 
thesis), we have successfully isolated two types of proteins that possess 
anticoagulant activities: BF-AC1/2 (extrinsic tenase complex inhibitors) and 
Fasxiator (FXIa inhibitors). 
In the third chapter of this thesis, we have described the properties of the 
extrinsic tenase complex inhibitors, BF-AC1 and BF-AC2, in detail. Structurally, 
they are isoforms of β-bungarotoxins; functionally, they selectively inhibit the 
extrinsic tenase complex through a PLA2 enzymatic activity-dependent 
manner. Further studies using β-bungarotoxins from other sources suggested 
that the inhibitory activities on extrinsic tenase complex may ubiquitously exist 
in this protein family and factors other than PLA2’s enzymatic activity 
contributes to their inhibitory potency on extrinsic tenase complex. Thus, we 
have expanded the catalogue of known anticoagulants. 
In chapter four, we characterized a selective FXIa inhibitor, Fasxiator. Due to 
the limit supply of Bungarus fasciatus venom, we recombinantly expressed 
Fasxiator (rFasxiator) using E. coli system. rFasxiator is structurally and 
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functionally similar to native Fasxiator. It interacts with and inhibits FXIa to 
exert its anticoagulant function. To further improve the potency and selectivity 
of rFasxiator, a series of variants were generated and evaluated. Variant 
rFasxiatorN17R,L19E, which had the best balance between potency and 
selectivity successfully showed antithrombotic effects in FeCl3 induced mice 
carotid artery thrombosis model. Thus, Fasxiator is a potential candidate for 
developing novel anti-thrombotic agents. A patent has been filed on the usage 
of Fasxiator and its variants as anti-thrombotics. 
5.2 Future Work 
5.2.1 Future work on BF-AC1/2 
Our results indicated that BF-AC1/2 exert their anticoagulant activity through a 
PLA2 enzymatic activity dependent manner. However, the functions of the 
Kunitz-type inhibitor subunit were unclear. Thus, future work can be focused 
on the study of the contributions of Kunitz subunit in the anticoagulant activity. 
One strategy would be to recombinantly express PLA2 subunit and Kunitz 
subunit separately and further test their anticoagulant effects individually. As 
Kunitz domain may help in the binding of BF-AC1/2 with the extrinsic tenase 
complex, SPR binding assays can be adopted to study the interactions 
between the expressed Kunitz domain and the various components of the 
extrinsic tenase complex. 
5.2.2 Future work on Fasxiator  
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In chapter four we have demonstrated that Fasxiator is a potential candidate 
for developing of novel anticoagulants. Further characterizations/modifications 
of Fasxiator and its variants can be done in the following aspects: 1) 
Evaluation of efficacy and safety using animal models; 2) Co-crystal structure 
with FXIa to determine interaction mode; 3) Hybridization of active domain 
with scaffold to minimize the sizes of the inhibitor.  
5.2.2.1 Evaluation of efficacy and safety using animal models 
The purpose of this aspect is to further elaborate the in vivo effects of 
Fasxiator and its variants. 
As described in chapter four rFasxiatorN17R,L19E protected mice against FeCl3 
induced carotid artery thrombosis model, however the efficacy of 
rFasxiatorN17R,L19E as an anti-thrombotic agents needs to be further 
characterized using different thrombosis models such as stenosis-induced 
deep vein thrombosis models and collagen-initiated thrombus models 
(represent of different procoagulant stimuli as compared to FeCl3 treatment), 
as well as in other species of animals, such as in primates (represent of 
species specificity).  
To evaluate the safety of rFasxiatorN17R,L19E, it needs to be tested for bleeding 
effects when administering into animals, as the major limitations associated 
with anticoagulant drugs are excessive bleeding. This can be done with 
established bleeding models, such as tail vein bleeding and partial 
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hepatectomy surgical bleeding models. The tail vein bleeding model is 
currently under optimization process with collaborators in the laboratory.  
5.2.2.2 Co-crystal structure with FXIa to determine interaction mode 
The purpose of this aspect is to provide further insights on how to improve the 
properties of Fasxiator and its variants as antithrombotic agents and 
anticoagulants. 
The catalytic domain of FXIa has been successfully expressed in yeast and it 
has been widely used for co-crystallization structural studies with various FXIa 
inhibitors.  
(r)Fasxiator and its variants are slow type inhibitors, which means the onset of 
inhibition is slow and thus may compromise their efficacy as anticoagulants. 
Through comparing the co-crystallization structure of FXIa-Fasxiator 
complexes with complexes of FXIa and fast active-site inhibitors, we can 
potentially get information on how to design fast type inhibitors of FXIa while 
using the backbone of rFasxiator.   
5.2.2.3 Hybridization of active domain of Fasxiator with small scaffold to 
minimize the sizes of the inhibitor. 
The purpose of this aspect is to improve the pharmaceutical properties of 
rFasxiator and its variants. 
The co-crystal structure of PN2KPI with FXIa active domain revealed that the 
interaction of PN2KPI with FXIa confined in the two loops of PN2KPI. Our 
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mutagenesis study suggested that the few residues inside Loop I played a 
fundamental role in determining the potency and selectivity of rFasxiator. Thus, 
a small scaffold mimicking the structure of Loop I of rFasxiator and with the 
Loop I residues of rFasxiator incorporated is potentially able to exert a similar 
inhibitory function as rFasxiator.  
One candidate of such scaffolds is conotoxin. Two families of conotoxins are 
well documented. Alpha-conotoxins isolated from Conus venoms contain 
11-19 residues and preferentially fold into the globular conformation that 
possesses a specific disulfide pairing pattern (C1-3, C2-4). chi-conotoxins are 
a group of conotoxins (also called lambda conotoxins) with the conserved 
cysteine framework of alpha-conotoxins but with alternative disulfide pairing 
(C1-4, C2-3) and thus result in a ribbon conformation.  
For a preliminary study, we have designed two peptides with the conserved 
cysteine residues of conotoxins and with the sequences of PN2KPI and 
rFasxiatorN17R,L19E incorporated respectively. The two peptide sequences are 
rFasxiatorN17R,L19E-“ACCTGRCRAEIPCF” and PN2KPI-“ACCTGPCRAMISCW” 
respectively. The peptides were then refolded using air-oxidation and purified 
by RP-HPLC. Interestingly, peptide designed based on rFasxiatorN17R,L19E 
showed inhibitory effects while peptide designed based on PN2KPI failed to 
display activity. However, the potency and selectivity of the active peptide 
remains to be determined. 
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Purification procedures need to be improved to separate the isoforms 
generated during air oxidation before quantifying the potency of the active 
products. Once pure isoforms are obtained further efforts are needed to 
determine the pairing of cysteines and the structures of the active peptides. 




















Fasxiator, a novel FXIa inhibitor from snake venom, and its site-specific 
mutagenesis to improve potency and selectivity.  
Journal of Thrombosis and Haemostasis.  
W Chen; LP. D. Carvalho; M. Y. Chan; RM Kini and TS Kang 
 
Identification and characterization of novel inhibitors on extrinsic tenase 
complex from Bungarus fasciatus (banded krait) venom. 
Thrombosis and Haemostasis 
W Chen; LC Goh; TS Kang and RM Kini 
 
PCT patent: PCT/SG2014/000315, Compositions and Methods for Inhibiting 
Thrombogenesis.  



















1. Harris, J., Snake toxins, A.L. Harvey, Editor. 1991, Pergamon Press: New 
York :. p. 91-129. 
2. Koh, D.C., A. Armugam, and K. Jeyaseelan, Snake venom components and 
their applications in biomedicine. Cell Mol Life Sci, 2006. 63(24): p. 3030-41. 
3. Chang, C.C. and C.Y. Lee, ISOLATION OF NEUROTOXINS FROM THE VENOM 
OF BUNGARUS MULTICINCTUS AND THEIR MODES OF NEUROMUSCULAR 
BLOCKING ACTION. Arch Int Pharmacodyn Ther, 1963. 144: p. 241-57. 
4. King, G.F., et al., A rational nomenclature for naming peptide toxins from 
spiders and other venomous animals. Toxicon, 2008. 52(2): p. 264-76. 
5. Barber, C.M., G.K. Isbister, and W.C. Hodgson, Alpha neurotoxins. Toxicon, 
2013. 66: p. 47-58. 
6. Nirthanan, S. and M.C. Gwee, Three-finger alpha-neurotoxins and the 
nicotinic acetylcholine receptor, forty years on. J Pharmacol Sci, 2004. 94(1): 
p. 1-17. 
7. Nirthanan, S., et al., Non-conventional toxins from Elapid venoms. Toxicon, 
2003. 41(4): p. 397-407. 
8. Servent, D., et al., Only snake curaremimetic toxins with a fifth disulfide bond 
have high affinity for the neuronal alpha7 nicotinic receptor. J Biol Chem, 
1997. 272(39): p. 24279-86. 
9. Antil-Delbeke, S., et al., Molecular determinants by which a long chain toxin 
from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine 
receptor. J Biol Chem, 2000. 275(38): p. 29594-601. 
10. Rosenthal, J.A., et al., The functional role of positively charged amino acid 
side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a 
His-tagged recombinant alpha-bungarotoxin. Biochemistry, 1999. 38(24): p. 
7847-55. 
11. Lewis, R.L. and L. Gutmann, Snake venoms and the neuromuscular junction. 
Semin Neurol, 2004. 24(2): p. 175-9. 
12. Rowan, E.G., What does beta-bungarotoxin do at the neuromuscular 
junction? Toxicon, 2001. 39(1): p. 107-18. 
13. Faure, G. and C. Bon, Crotoxin, a phospholipase A2 neurotoxin from the 
South American rattlesnake Crotalus durissus terrificus: purification of 
several isoforms and comparison of their molecular structure and of their 
biological activities. Biochemistry, 1988. 27(2): p. 730-8. 
14. Hanley, M.R., Crotoxin effects on Torpedo californica cholinergic excitable 
vesicles and the role of its phospholipase A activity. Biochem Biophys Res 
Commun, 1978. 82(1): p. 392-401. 
15. Breithaupt, H., K. Rubsamen, and E. Habermann, Biochemistry and 
pharmacology of the crotoxin complex. Biochemical analysis of crotapotin 




16. Harvey, A.L. and B. Robertson, Dendrotoxins: structure-activity relationships 
and effects on potassium ion channels. Curr Med Chem, 2004. 11(23): p. 
3065-72. 
17. Harvey, A.L., Twenty years of dendrotoxins. Toxicon, 2001. 39(1): p. 15-26. 
18. Gasparini, S., et al., Delineation of the functional site of alpha-dendrotoxin. 
The functional topographies of dendrotoxins are different but share a 
conserved core with those of other Kv1 potassium channel-blocking toxins. J 
Biol Chem, 1998. 273(39): p. 25393-403. 
19. Imredy, J.P. and R. MacKinnon, Energetic and structural interactions 
between delta-dendrotoxin and a voltage-gated potassium channel. J Mol 
Biol, 2000. 296(5): p. 1283-94. 
20. Danse, J.M., et al., On the site by which alpha-dendrotoxin binds to 
voltage-dependent potassium channels: site-directed mutagenesis reveals 
that the lysine triplet 28-30 is not essential for binding. FEBS Lett, 1994. 
356(2-3): p. 153-8. 
21. Harvey, A.L., et al., Changes to biological activity following acetylation of 
dendrotoxin I from Dendroaspis polylepis (black mamba). Toxicon, 1997. 
35(8): p. 1263-73. 
22. Smith, L.A., et al., Site-directed mutagenesis of dendrotoxin K reveals amino 
acids critical for its interaction with neuronal K+ channels. Biochemistry, 
1997. 36(25): p. 7690-6. 
23. Wang, F.C., et al., Identification of residues in dendrotoxin K responsible for 
its discrimination between neuronal K+ channels containing Kv1.1 and 1.2 
alpha subunits. Eur J Biochem, 1999. 263(1): p. 222-9. 
24. Camargo, A.C., et al., Bradykinin-potentiating peptides: beyond captopril. 
Toxicon, 2012. 59(4): p. 516-23. 
25. Koh, C.Y. and R.M. Kini, From snake venom toxins to 
therapeutics--cardiovascular examples. Toxicon, 2012. 59(4): p. 497-506. 
26. Moreau, M.E., et al., Expression of metallopeptidases and kinin receptors in 
swine oropharyngeal tissues: effects of angiotensin I-converting enzyme 
inhibition and inflammation. J Pharmacol Exp Ther, 2005. 315(3): p. 1065-74. 
27. Acharya, K.R., et al., Ace revisited: a new target for structure-based drug 
design. Nat Rev Drug Discov, 2003. 2(11): p. 891-902. 
28. Cushman, D.W., et al., Design of potent competitive inhibitors of 
angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl 
amino acids. Biochemistry, 1977. 16(25): p. 5484-91. 
29. Schweitz, H., et al., A new member of the natriuretic peptide family is 
present in the venom of the green mamba (Dendroaspis angusticeps). J Biol 
Chem, 1992. 267(20): p. 13928-32. 
30. Joseph, R., et al., Hypotensive agents from snake venoms. Curr Drug Targets 
Cardiovasc Haematol Disord, 2004. 4(4): p. 437-59. 
31. Lisy, O., et al., Design, synthesis, and actions of a novel chimeric natriuretic 
peptide: CD-NP. J Am Coll Cardiol, 2008. 52(1): p. 60-8. 
149 
 
32. Lee, C.Y., et al., Pharmacodynamics of a novel designer natriuretic peptide, 
CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol, 
2009. 49(6): p. 668-73. 
33. Joubert, F.J. and N. Taljaard, The primary structure of a short neurotoxin 
homologue (S4C8) from Dendroaspis jamesoni kaimosae (Jameson's mamba) 
venom. Int J Biochem, 1980. 12(4): p. 567-74. 
34. de Weille, J.R., et al., Calciseptine, a peptide isolated from black mamba 
venom, is a specific blocker of the L-type calcium channel. Proc Natl Acad Sci 
U S A, 1991. 88(6): p. 2437-40. 
35. Fry, B.G., et al., Molecular evolution and phylogeny of elapid snake venom 
three-finger toxins. J Mol Evol, 2003. 57(1): p. 110-29. 
36. Jeyaseelan, K., et al., Six isoforms of cardiotoxin in malayan spitting cobra 
(Naja naja sputatrix) venom: cloning and characterization of cDNAs. Biochim 
Biophys Acta, 1998. 1380(2): p. 209-22. 
37. Chang, L.S., H.B. Huang, and S.R. Lin, The multiplicity of cardiotoxins from 
Naja naja atra (Taiwan cobra) venom. Toxicon, 2000. 38(8): p. 1065-76. 
38. Forouhar, F., et al., Structural basis of membrane-induced cardiotoxin A3 
oligomerization. J Biol Chem, 2003. 278(24): p. 21980-8. 
39. Dufton, M.J. and R.C. Hider, The structure and pharmacology of elapid 
cytotoxins., in Snake toxins, A.L. Harvey, Editor. 1991, Pergamon Press: New 
York :. p. 259-302. 
40. Wang, C.H., et al., Glycosphingolipid-facilitated membrane insertion and 
internalization of cobra cardiotoxin. The sulfatide.cardiotoxin complex 
structure in a membrane-like environment suggests a lipid-dependent 
cell-penetrating mechanism for membrane binding polypeptides. J Biol Chem, 
2006. 281(1): p. 656-67. 
41. Laure, C.J., [The primary structure of crotamine (author's transl)]. Hoppe 
Seylers Z Physiol Chem, 1975. 356(2): p. 213-5. 
42. Chang, C.C., S.J. Hong, and M.J. Su, A study on the membrane depolarization 
of skeletal muscles caused by a scorpion toxin, sea anemone toxin II and 
crotamine and the interaction between toxins. Br J Pharmacol, 1983. 79(3): p. 
673-80. 
43. Bieber, A.L., R.H. McParland, and R.R. Becker, Amino acid sequences of 
myotoxins from Crotalus viridis concolor venom. Toxicon, 1987. 25(6): p. 
677-80. 
44. Fox, J.W., M. Elzinga, and A.T. Tu, Amino acid sequence and disulfide bond 
assignment of myotoxin a isolated from the venom of Prairie rattlesnake 
(Crotalus viridis viridis). Biochemistry, 1979. 18(4): p. 678-84. 
45. Kini, R.M., Toxins in thrombosis and haemostasis: potential beyond 
imagination. J Thromb Haemost, 2011. 9 Suppl 1: p. 195-208. 
46. Koh, C.Y. and R.M. Kini, Molecular diversity of anticoagulants from 
haematophagous animals. Thromb Haemost, 2009. 102(3): p. 437-53. 
150 
 
47. Gardiner, E.E. and R.K. Andrews, The cut of the clot(h): snake venom 
fibrinogenases as therapeutic agents. J Thromb Haemost, 2008. 6(8): p. 
1360-2. 
48. Yamada, D., F. Sekiya, and T. Morita, Prothrombin and factor X activator 
activities in the venoms of Viperidae snakes. Toxicon, 1997. 35(11): p. 
1581-9. 
49. Wang, S., et al., Purification and partial characterization of a novel 
fibrinogenase from the venom of Deinagkistrodon acutus: Inhibition of 
platelet aggregation. Protein Expr Purif, 2014. 99: p. 99-105. 
50. Stocker, K., et al., Protein C activators in snake venoms. Behring Inst Mitt, 
1986(79): p. 37-47. 
51. Kini, R.M., Excitement ahead: structure, function and mechanism of snake 
venom phospholipase A2 enzymes. Toxicon, 2003. 42(8): p. 827-40. 
52. Israeli-Rosenberg, S., et al., Integrins and integrin-associated proteins in the 
cardiac myocyte. Circ Res, 2014. 114(3): p. 572-86. 
53. Podolnikova, N.P., et al., The interaction of integrin alphaIIbbeta3 with fibrin 
occurs through multiple binding sites in the alphaIIb beta-propeller domain. J 
Biol Chem, 2014. 289(4): p. 2371-83. 
54. Calvete, J.J., Brief history and molecular determinants of snake venom 
disintegrin evolution., in Toxins and hemostasis from bench to bedside., R. 
Manjunatha Kini, et al., Editors. 2011, Springer: Dordrecht ; New York :. p. 
285-300  
55. Huang, T.F., et al., Trigramin. A low molecular weight peptide inhibiting 
fibrinogen interaction with platelet receptors expressed on glycoprotein 
IIb-IIIa complex. J Biol Chem, 1987. 262(33): p. 16157-63. 
56. Xiong, J.P., et al., Crystal structure of the extracellular segment of integrin 
alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 2002. 
296(5565): p. 151-5. 
57. Calvete, J.J., The continuing saga of snake venom disintegrins. Toxicon, 2013. 
62: p. 40-9. 
58. Proimos, G., Platelet aggregation inhibition with glycoprotein IIb--IIIa 
inhibitors. J Thromb Thrombolysis, 2001. 11(2): p. 99-110. 
59. Clemetson, K.J., T. Morita, and R. Manjunatha Kini, Scientific and 
standardization committee communications: classification and 
nomenclature of snake venom C-type lectins and related proteins. J Thromb 
Haemost, 2009. 7(2): p. 360. 
60. Arlinghaus, F.T. and J.A. Eble, C-type lectin-like proteins from snake venoms. 
Toxicon, 2012. 60(4): p. 512-9. 
61. Morita, T., Structures and functions of snake venom CLPs (C-type lectin-like 
proteins) with anticoagulant-, procoagulant-, and platelet-modulating 
activities. Toxicon, 2005. 45(8): p. 1099-114. 
62. Atoda, H., M. Hyuga, and T. Morita, The primary structure of coagulation 
factor IX/factor X-binding protein isolated from the venom of Trimeresurus 
151 
 
flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core 
protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin 
E. J Biol Chem, 1991. 266(23): p. 14903-11. 
63. Ogilvie, M.L., J.W. Byl, and T.K. Gartner, Platelet-aggregation is stimulated 
by lactose-inhibitable snake venom lectins. Thromb Haemost, 1989. 62(2): p. 
704-7. 
64. Polgar, J., et al., Platelet activation and signal transduction by convulxin, a 
C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom 
via the p62/GPVI collagen receptor. J Biol Chem, 1997. 272(21): p. 13576-83. 
65. Chung, C.H., H.C. Peng, and T.F. Huang, Aggretin, a C-type lectin protein, 
induces platelet aggregation via integrin alpha(2)beta(1) and GPIb in a 
phosphatidylinositol 3-kinase independent pathway. Biochem Biophys Res 
Commun, 2001. 285(3): p. 689-95. 
66. Matsui, T. and J. Hamako, Structure and function of snake venom toxins 
interacting with human von Willebrand factor. Toxicon, 2005. 45(8): p. 
1075-87. 
67. Read, M.S., R.W. Shermer, and K.M. Brinkhous, Venom coagglutinin: an 
activator of platelet aggregation dependent on von Willebrand factor. Proc 
Natl Acad Sci U S A, 1978. 75(9): p. 4514-8. 
68. Wang, R., R.M. Kini, and M.C. Chung, Rhodocetin, a novel platelet 
aggregation inhibitor from the venom of Calloselasma rhodostoma (Malayan 
pit viper): synergistic and noncovalent interaction between its subunits. 
Biochemistry, 1999. 38(23): p. 7584-93. 
69. Horii, K., et al., Crystal structure of EMS16 in complex with the integrin 
alpha2-I domain. J Mol Biol, 2004. 341(2): p. 519-27. 
70. Shiu, J.H., et al., Solution structure of gamma-bungarotoxin: the functional 
significance of amino acid residues flanking the RGD motif in integrin binding. 
Proteins, 2004. 57(4): p. 839-49. 
71. Banerjee, Y., et al., Hemextin AB complex, a unique anticoagulant protein 
complex from Hemachatus haemachatus (African Ringhals cobra) venom 
that inhibits clot initiation and factor VIIa activity. J Biol Chem, 2005. 280(52): 
p. 42601-11. 
72. Župunski, V., D. Kordiš, and F. Gubenšek, Adaptive evolution in the snake 
venom Kunitz/BPTI protein family. FEBS Letters, 2003. 547(1-3): p. 131-136. 
73. Cardle, L. and M.J. Dufton, Foci of amino acid residue conservation in the 3D 
structures of the Kunitz BPTI proteinase inhibitors: how do variants from 
snake venom differ? Protein Eng, 1997. 10(2): p. 131-6. 
74. Masci, P.P., et al., Textilinins from Pseudonaja textilis textilis. 
Characterization of two plasmin inhibitors that reduce bleeding in an animal 
model. Blood Coagul Fibrinolysis, 2000. 11(4): p. 385-93. 
75. Trikha, M. and M.T. Nakada, Platelets and cancer: implications for 
antiangiogenic therapy. Semin Thromb Hemost, 2002. 28(1): p. 39-44. 
152 
 
76. Colman, R.W., et al., Overview of Hemostasis, in Hemostasis and thrombosis : 
basic principles and clinical practice, R.W. Colman, et al., Editors. 2006, 
Lippincott Williams & Wilkins: Philadelphia, PA :. p. 3-16. 
77. Schapira, M., C.F. Scott, and R.W. Colman, Protection of human plasma 
kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The 
role of high molecular weight kininogen. Biochemistry, 1981. 20(10): p. 
2738-43. 
78. Longas, M.O. and T.H. Finlay, The covalent nature of the human 
antithrombin III--thrombin bond. Biochem J, 1980. 189(3): p. 481-9. 
79. Weitz, J.I., et al., Clot-bound thrombin is protected from inhibition by 
heparin-antithrombin III but is susceptible to inactivation by antithrombin 
III-independent inhibitors. J Clin Invest, 1990. 86(2): p. 385-91. 
80. Weitz, J.I., B. Leslie, and M. Hudoba, Thrombin binds to soluble fibrin 
degradation products where it is protected from inhibition by 
heparin-antithrombin but susceptible to inactivation by 
antithrombin-independent inhibitors. Circulation, 1998. 97(6): p. 544-52. 
81. Liaw, P.C., et al., Comparison of heparin- and dermatan sulfate-mediated 
catalysis of thrombin inactivation by heparin cofactor II. J Biol Chem, 1999. 
274(39): p. 27597-604. 
82. Esmon, C.T., Thrombomodulin as a model of molecular mechanisms that 
modulate protease specificity and function at the vessel surface. Faseb j, 
1995. 9(10): p. 946-55. 
83. Rezaie, A.R., et al., Protein Z-dependent protease inhibitor binds to the 
C-terminal domain of protein Z. J Biol Chem, 2008. 283(29): p. 19922-6. 
84. Morrissey, J.H. and N.J. Mutch, Tissue Factor Structure and Function, in 
Hemostasis and thrombosis : basic principles and clinical practice, R.W. 
Colman, et al., Editors. 2006, Lippincott Williams & Wilkins: Philadelphia, 
PA :. p. 91-106. 
85. Morrissey, J.H., et al., Quantitation of activated factor VII levels in plasma 
using a tissue factor mutant selectively deficient in promoting factor VII 
activation. Blood, 1993. 81(3): p. 734-44. 
86. Nakagaki, T., et al., Initiation of the extrinsic pathway of blood coagulation: 
evidence for the tissue factor dependent autoactivation of human 
coagulation factor VII. Biochemistry, 1991. 30(45): p. 10819-24. 
87. Di Scipio, R.G., K. Kurachi, and E.W. Davie, Activation of human factor IX 
(Christmas factor). J Clin Invest, 1978. 61(6): p. 1528-38. 
88. Hoffman, M., et al., Factors IXa and Xa play distinct roles in tissue 
factor-dependent initiation of coagulation. Blood, 1995. 86(5): p. 1794-801. 
89. Bevers, E.M., P. Comfurius, and R.F. Zwaal, Changes in membrane 
phospholipid distribution during platelet activation. Biochim Biophys Acta, 
1983. 736(1): p. 57-66. 
153 
 
90. Atkins, J.S. and P.R. Ganz, The association of human coagulation factors VIII, 
IXa and X with phospholipid vesicles involves both electrostatic and 
hydrophobic interactions. Mol Cell Biochem, 1992. 112(1): p. 61-71. 
91. Shima, M., et al., A factor VIII neutralizing monoclonal antibody and a 
human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit 
factor VIII binding to von Willebrand factor and to phosphatidylserine. 
Thromb Haemost, 1993. 69(3): p. 240-6. 
92. Naito, K. and K. Fujikawa, Activation of human blood coagulation factor XI 
independent of factor XII. Factor XI is activated by thrombin and factor XIa in 
the presence of negatively charged surfaces. J Biol Chem, 1991. 266(12): p. 
7353-8. 
93. Fujikawa, K., et al., The mechanism of activation of bovine factor IX 
(Christmas factor) by bovine factor XIa (activated plasma thromboplastin 
antecedent). Biochemistry, 1974. 13(22): p. 4508-16. 
94. Bouma, B.N. and J.H. Griffin, Human blood coagulation factor XI. Purification, 
properties, and mechanism of activation by activated factor XII. J Biol Chem, 
1977. 252(18): p. 6432-7. 
95. Thompson, R.E., R. Mandle, Jr., and A.P. Kaplan, Association of factor XI and 
high molecular weight kininogen in human plasma. J Clin Invest, 1977. 60(6): 
p. 1376-80. 
96. McMullen, B.A., K. Fujikawa, and E.W. Davie, Location of the disulfide bonds 
in human coagulation factor XI: the presence of tandem apple domains. 
Biochemistry, 1991. 30(8): p. 2056-60. 
97. Fujikawa, K., et al., Amino acid sequence of human factor XI, a blood 
coagulation factor with four tandem repeats that are highly homologous 
with plasma prekallikrein. Biochemistry, 1986. 25(9): p. 2417-24. 
98. Gailani, D. and G.J. Broze, Jr., Factor XI activation in a revised model of blood 
coagulation. Science, 1991. 253(5022): p. 909-12. 
99. Baglia, F.A. and P.N. Walsh, Prothrombin is a cofactor for the binding of 
factor XI to the platelet surface and for platelet-mediated factor XI activation 
by thrombin. Biochemistry, 1998. 37(8): p. 2271-81. 
100. Baglia, F.A. and P.N. Walsh, Thrombin-mediated feedback activation of 
factor XI on the activated platelet surface is preferred over contact activation 
by factor XIIa or factor XIa. J Biol Chem, 2000. 275(27): p. 20514-9. 
101. Baglia, F.A., et al., Factor XI binding to the platelet glycoprotein Ib-IX-V 
complex promotes factor XI activation by thrombin. J Biol Chem, 2002. 
277(3): p. 1662-8. 
102. Lipscomb, M.S. and P.N. Walsh, Human platelets and factor XI. Localization 
in platelet membranes of factor XI-like activity and its functional distinction 
from plasma factor XI. J Clin Invest, 1979. 63(5): p. 1006-14. 
103. Schiffman, S. and C.H. Yeh, Purification and characterization of platelet 
factor XI. Thromb Res, 1990. 60(1): p. 87-97. 
154 
 
104. Hu, C.J., et al., Tissue-specific expression of functional platelet factor XI is 
independent of plasma factor XI expression. Blood, 1998. 91(10): p. 3800-7. 
105. Hsu, T.C., et al., Molecular cloning of platelet factor XI, an alternative splicing 
product of the plasma factor XI gene. J Biol Chem, 1998. 273(22): p. 
13787-93. 
106. Soons, H., et al., Inhibition of factor XIa by antithrombin III. Biochemistry, 
1987. 26(15): p. 4624-9. 
107. Meijers, J.C., R.A. Vlooswijk, and B.N. Bouma, Inhibition of human blood 
coagulation factor XIa by C-1 inhibitor. Biochemistry, 1988. 27(3): p. 959-63. 
108. Saito, H., et al., Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc Natl 
Acad Sci U S A, 1979. 76(4): p. 2013-7. 
109. Walsh, P.N., et al., Regulation of factor XIa activity by platelets and alpha 
1-protease inhibitor. J Clin Invest, 1987. 80(6): p. 1578-86. 
110. Smith, R.P., D.A. Higuchi, and G.J. Broze, Jr., Platelet coagulation factor 
XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science, 1990. 
248(4959): p. 1126-8. 
111. Zhang, Y., et al., The mechanism by which heparin promotes the inhibition of 
coagulation factor XIa by protease nexin-2. J Biol Chem, 1997. 272(42): p. 
26139-44. 
112. Scandura, J.M., et al., Progress curve analysis of the kinetics with which 
blood coagulation factor XIa is inhibited by protease nexin-2. Biochemistry, 
1997. 36(2): p. 412-20. 
113. Walsh, P.N. and D. Gailani, Factor XI, in Hemostasis and thrombosis : basic 
principles and clinical practice, R.W. Colman, et al., Editors. 2006, Lippincott 
Williams & Wilkins: Philadelphia, PA :. 
114. Berliner, S., et al., Dental surgery in patients with severe factor XI deficiency 
without plasma replacement. Blood Coagul Fibrinolysis, 1992. 3(4): p. 465-8. 
115. von dem Borne, P.A., J.C. Meijers, and B.N. Bouma, Feedback activation of 
factor XI by thrombin in plasma results in additional formation of thrombin 
that protects fibrin clots from fibrinolysis. Blood, 1995. 86(8): p. 3035-42. 
116. Tan, A.K. and D.L. Eaton, Activation and characterization of 
procarboxypeptidase B from human plasma. Biochemistry, 1995. 34(17): p. 
5811-6. 
117. Bajzar, L., R. Manuel, and M.E. Nesheim, Purification and characterization of 
TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem, 1995. 270(24): 
p. 14477-84. 
118. Rosen, E.D., D. Gailani, and F.J. Castellino, FXI is essential for thrombus 
formation following FeCl3-induced injury of the carotid artery in the mouse. 
Thromb Haemost, 2002. 87(4): p. 774-6. 
119. Gruber, A. and S.R. Hanson, Factor XI-dependence of surface- and tissue 




120. Suttie, J.W., Warfarin and vitamin K. Clin Cardiol, 1990. 13(4 Suppl 6): p. 
Vi16-8. 
121. Sands, C.D., E.S. Chan, and T.E. Welty, Revisiting the significance of warfarin 
protein-binding displacement interactions. Ann Pharmacother, 2002. 36(10): 
p. 1642-4. 
122. Hacobian, M. and S.Z. Goldhaber, Pharmacogenomics and Warfarin 
Anticoagulation, in New therapeutic agents in thrombosis and thrombolysis, 
J.E. Freedman and J. Loscalzo, Editors. 2009, Informa Healthcare: New York :. 
p. 37-47. 
123. Hirsh, J. and R. Raschke, Heparin and low-molecular-weight heparin: the 
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
Chest, 2004. 126(3 Suppl): p. 188s-203s. 
124. Schulman, S., Anticoagulants for the Treatment of Venous 
Thromboembolism, in New therapeutic agents in thrombosis and 
thrombolysis, J.E. Freedman and J. Loscalzo., Editors. 2009, Informa 
Healthcare: New York :. p. 155-169. 
125. Canales, J.F. and J.J. Ferguson, Low-molecular-weight heparins : mechanisms, 
trials, and role in contemporary interventional medicine. Am J Cardiovasc 
Drugs, 2008. 8(1): p. 15-25. 
126. Messmore, H.L., Jr., Heparin-induced thrombocytopenia: historical review. 
Clin Appl Thromb Hemost, 1999. 5 Suppl 1: p. S2-6. 
127. Bauer, K.A., Fondaparinux sodium: a selective inhibitor of factor Xa. Am J 
Health Syst Pharm, 2001. 58 Suppl 2: p. S14-7. 
128. Walenga, J.M., et al., Fondaparinux: a synthetic heparin pentasaccharide as 
a new antithrombotic agent. Expert Opin Investig Drugs, 2002. 11(3): p. 
397-407. 
129. Herbert, J.M., et al., Biochemical and pharmacological properties of SANORG 
34006, a potent and long-acting synthetic pentasaccharide. Blood, 1998. 
91(11): p. 4197-205. 
130. Fox, K.A., et al., Influence of renal function on the efficacy and safety of 
fondaparinux relative to enoxaparin in non ST-segment elevation acute 
coronary syndromes. Ann Intern Med, 2007. 147(5): p. 304-10. 
131. Wong, P.C., et al., Apixaban, an oral, direct and highly selective factor Xa 
inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb 
Haemost, 2008. 6(5): p. 820-9. 
132. Hirsh, J., M. O'Donnell, and J.W. Eikelboom, Beyond unfractionated heparin 
and warfarin: current and future advances. Circulation, 2007. 116(5): p. 
552-60. 
133. Kakar, P., T. Watson, and G.Y. Lip, Drug evaluation: rivaroxaban, an oral, 
direct inhibitor of activated factor X. Curr Opin Investig Drugs, 2007. 8(3): p. 
256-65. 
134. Markwardt, F., Past, present and future of hirudin. Haemostasis, 1991. 21 
Suppl 1: p. 11-26. 
156 
 
135. Berry, C.N., et al., Effects of the synthetic thrombin inhibitor argatroban on 
fibrin- or clot-incorporated thrombin: comparison with heparin and 
recombinant Hirudin. Thromb Haemost, 1994. 72(3): p. 381-6. 
136. Parry, M.A., J.M. Maraganore, and S.R. Stone, Kinetic mechanism for the 
interaction of Hirulog with thrombin. Biochemistry, 1994. 33(49): p. 
14807-14. 
137. Bates, S.M. and J.I. Weitz, Direct thrombin inhibitors for treatment of arterial 
thrombosis: potential differences between bivalirudin and hirudin. Am J 
Cardiol, 1998. 82(8b): p. 12p-18p. 
138. Harenberg, J., et al., New anticoagulants - promising and failed 
developments. Br J Pharmacol, 2012. 165(2): p. 363-72. 
139. Kennedy, B., et al., Emerging anticoagulants. Curr Med Chem, 2012. 19(20): 
p. 3388-416. 
140. Furie, B. and B.C. Furie, Mechanisms of Thrombus Formation. New England 
Journal of Medicine, 2008. 359(9): p. 938-949. 
141. Bates, S.M. and J.I. Weitz, New anticoagulants: beyond heparin, 
low-molecular-weight heparin and warfarin. British Journal of Pharmacology, 
2005. 144(8): p. 1017-1028. 
142. Hart, R.G., L.A. Pearce, and M.I. Aguilar, Meta-analysis: antithrombotic 
therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. 
Ann Intern Med, 2007. 146(12): p. 857-67. 
143. Singer, D.E., et al., The net clinical benefit of warfarin anticoagulation in 
atrial fibrillation. Ann Intern Med, 2009. 151(5): p. 297-305. 
144. Wein, L., et al., Pharmacological venous thromboembolism prophylaxis in 
hospitalized medical patients: a meta-analysis of randomized controlled 
trials. Arch Intern Med, 2007. 167(14): p. 1476-86. 
145. Hirsh, J., et al., Guide to anticoagulant therapy: Heparin : a statement for 
healthcare professionals from the American Heart Association. Circulation, 
2001. 103(24): p. 2994-3018. 
146. Link, K.P., The discovery of dicumarol and its sequels. Circulation, 1959. 19(1): 
p. 97-107. 
147. Gould, M.K., et al., Low-molecular-weight heparins compared with 
unfractionated heparin for treatment of acute deep venous thrombosis. A 
meta-analysis of randomized, controlled trials. Ann Intern Med, 1999. 
130(10): p. 800-9. 
148. Quinlan, D.J., A. McQuillan, and J.W. Eikelboom, Low-molecular-weight 
heparin compared with intravenous unfractionated heparin for treatment of 
pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann 
Intern Med, 2004. 140(3): p. 175-83. 
149. Eikelboom, J.W., et al., Unfractionated heparin and low-molecular-weight 
heparin in acute coronary syndrome without ST elevation: a meta-analysis. 
Lancet, 2000. 355(9219): p. 1936-42. 
157 
 
150. Schulman, S., Advantages and limitations of the new anticoagulants. J Intern 
Med, 2014. 275(1): p. 1-11. 
151. Shameem, R. and J. Ansell, Disadvantages of VKA and requirements for novel 
anticoagulants. Best Pract Res Clin Haematol, 2013. 26(2): p. 103-14. 
152. Kazmi, R.S. and B.A. Lwaleed, New anticoagulants: how to deal with 
treatment failure and bleeding complications. Br J Clin Pharmacol, 2011. 
72(4): p. 593-603. 
153. Salim, I., et al., Anticoagulation in atrial fibrillation and co-existent chronic 
kidney disease: efficacy versus safety. Expert Opinion on Drug Safety, 2013. 
12(1): p. 53-63. 
154. Goel, R. and K. Srivathsan, Newer oral anticoagulant agents: a new era in 
medicine. Curr Cardiol Rev, 2012. 8(2): p. 158-65. 
155. Schulman, S., et al., Dabigatran versus warfarin in the treatment of acute 
venous thromboembolism. N Engl J Med, 2009. 361(24): p. 2342-52. 
156. Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med, 2009. 361(12): p. 1139-51. 
157. Bauersachs, R., et al., Oral rivaroxaban for symptomatic venous 
thromboembolism. N Engl J Med, 2010. 363(26): p. 2499-510. 
158. Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial 
fibrillation. N Engl J Med, 2011. 365(10): p. 883-91. 
159. Uchino, K. and A.V. Hernandez, Dabigatran association with higher risk of 
acute coronary events: meta-analysis of noninferiority randomized 
controlled trials. Arch Intern Med, 2012. 172(5): p. 397-402. 
160. Mega, J.L., et al., Rivaroxaban in patients with a recent acute coronary 
syndrome. N Engl J Med, 2012. 366(1): p. 9-19. 
161. Danalev, D., Inhibitors of serine proteinases from blood coagulation cascade 
- view on current developments. Mini Rev Med Chem, 2012. 12(8): p. 721-30. 
162. Landefeld, C.S. and R.J. Beyth, Anticoagulant-related bleeding: clinical 
epidemiology, prediction, and prevention. Am J Med, 1993. 95(3): p. 315-28. 
163. Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med, 2009. 361(12): p. 1139-51. 
164. van Montfoort, M.L. and J.C. Meijers, Anticoagulation beyond direct 
thrombin and factor Xa inhibitors: indications for targeting the intrinsic 
pathway? Thromb Haemost, 2013. 110(2): p. 223-32. 
165. Wang, X., et al., Effects of factor XI deficiency on ferric chloride-induced vena 
cava thrombosis in mice. J Thromb Haemost, 2006. 4(9): p. 1982-8. 
166. Cheng, Q., et al., A role for factor XIIa-mediated factor XI activation in 
thrombus formation in vivo. Blood, 2010. 116(19): p. 3981-9. 
167. Muller, F., D. Gailani, and T. Renne, Factor XI and XII as antithrombotic 
targets. Curr Opin Hematol, 2011. 18(5): p. 349-55. 
168. Salomon, O., et al., Reduced incidence of ischemic stroke in patients with 
severe factor XI deficiency. Blood, 2008. 111(8): p. 4113-7. 
158 
 
169. Salomon, O., et al., Patients with severe factor XI deficiency have a reduced 
incidence of deep-vein thrombosis. Thromb Haemost, 2011. 105(2): p. 
269-73. 
170. Gupta, A., et al., Distinct functions of activated protein C differentially 
attenuate acute kidney injury. J Am Soc Nephrol, 2009. 20(2): p. 267-77. 
171. Andrades, M.E., et al., Glycolaldehyde induces fibrinogen post-translational 
modification, delay in clotting and resistance to enzymatic digestion. Chem 
Biol Interact, 2009. 180(3): p. 478-84. 
172. Banerjee, Y., et al., Hemextin AB complex--a snake venom anticoagulant 
protein complex that inhibits factor VIIa activity. Pathophysiol Haemost 
Thromb, 2005. 34(4-5): p. 184-7. 
173. Cummings, B.S., J. McHowat, and R.G. Schnellmann, Phospholipase A(2)s in 
cell injury and death. J Pharmacol Exp Ther, 2000. 294(3): p. 793-9. 
174. Atanasov, V.N., et al., Hemolytic and anticoagulant study of the neurotoxin 
vipoxin and its components--basic phospholipase A2 and an acidic inhibitor. 
Biochemistry (Mosc), 2009. 74(3): p. 276-80. 
175. Ward, M., Pyridylethylation of Cysteine Residues, in The Protein Protocols 
Handbook, J. Walker, Editor. 2002, Humana Press. p. 461-463. 
176. Pratt, C.W. and D.M. Monroe, Microplate coagulation assays. Biotechniques, 
1992. 13(3): p. 430-3. 
177. Greenberg, C.S., et al., Cleavage of blood coagulation factor XIII and 
fibrinogen by thrombin during in vitro clotting. J Clin Invest, 1985. 75(5): p. 
1463-70. 
178. Koyama, T., et al., Analysis for sites of anticoagulant action of plancinin, a 
new anticoagulant peptide isolated from the starfish Acanthaster planci, in 
the blood coagulation cascade. Gen Pharmacol, 1998. 31(2): p. 277-82. 
179. Diaz-Oreiro, C. and J.M. Gutierrez, Chemical modification of histidine and 
lysine residues of myotoxic phospholipases A2 isolated from Bothrops asper 
and Bothrops godmani snake venoms: effects on enzymatic and 
pharmacological properties. Toxicon, 1997. 35(2): p. 241-52. 
180. Pawlak, J., et al., Denmotoxin, a three-finger toxin from the colubrid snake 
Boiga dendrophila (Mangrove Catsnake) with bird-specific activity. J Biol 
Chem, 2006. 281(39): p. 29030-41. 
181. Kini, R.M. and Y. Banerjee, Dissection approach: a simple strategy for the 
identification of the step of action of anticoagulant agents in the blood 
coagulation cascade. J Thromb Haemost, 2005. 3(1): p. 170-1. 
182. Kruck, T.P. and D.M. Logan, Neurotoxins from Bungarus fasciatus venom: a 
simple fractionation and separation of alpha- and beta-type neurotoxins and 
their partial characterization. Biochemistry, 1982. 21(21): p. 5302-9. 
183. Hanley, M.R., et al., Neurotoxins of Bungarus multicinctus vernom. 




184. Kondo, K., H. Toda, and K. Narita, Characterization of phospholipase A 
activity of beta1-bungarotoxin from Bungarus multicinctus venom. I. Its 
enzymatic properties and modification with p-bromophenacyl bromide. J 
Biochem, 1978. 84(5): p. 1291-300. 
185. Kondo, K., K. Narita, and C.Y. Lee, Chemical properties and amino acid 
composition of beta1-bungarotoxin from the venom of Bungarus 
multicinctus (Formosan banded krait). J Biochem, 1978. 83(1): p. 91-9. 
186. Kondo, K., K. Narita, and C.Y. Lee, Amino acid sequences of the two 
polypeptide chains in beta1-bungarotoxin from the venom of Bungarus 
multicinctus. J Biochem, 1978. 83(1): p. 101-15. 
187. Kini, R.M. and H.J. Evans, The role of enzymatic activity in inhibition of the 
extrinsic tenase complex by phospholipase A2 isoenzymes from Naja 
nigricollis venom. Toxicon, 1995. 33(12): p. 1585-90. 
188. Condrea, E., C.C. Yang, and P. Rosenberg, Lack of correlation between 
anticoagulant activity and phospholipid hydrolysis by snake venom 
phospholipases A2. Thromb Haemost, 1981. 45(1): p. 82-5. 
189. Condrea, E., C.C. Yang, and P. Rosenberg, Additional evidence for a lack of 
correlation between anticoagulant activity and phospholipid hydrolysis by 
snake venom phospholipases A2. Thromb Haemost, 1982. 47(3): p. 298. 
190. Ouyang, C., et al., Mechanism of the anticoagulant action of phospholipase A 
purified from Trimeresurus mucrosquamatus (Formosan habu) snake venom. 
Toxicon, 1981. 19(1): p. 113-20. 
191. Kerns, R.T., et al., Targeting of venom phospholipases: the strongly 
anticoagulant phospholipase A(2) from Naja nigricollis venom binds to 
coagulation factor Xa to inhibit the prothrombinase complex. Arch Biochem 
Biophys, 1999. 369(1): p. 107-13. 
192. Kini, R.M., Structure-function relationships and mechanism of anticoagulant 
phospholipase A2 enzymes from snake venoms. Toxicon, 2005. 45(8): p. 
1147-61. 
193. Inada, M., et al., Determinants of the inhibitory action of purified 14-kDa 
phospholipases A2 on cell-free prothrombinase complex. J Biol Chem, 1994. 
269(42): p. 26338-43. 
194. Kondo, K., et al., Amino acid sequence of beta 2-bungarotoxin from 
Bungarus multicinctus venom. The amino acid substitutions in the B chains. J 
Biochem, 1982. 91(5): p. 1519-30. 
195. Crosby, J.R., et al., Antithrombotic effect of antisense factor XI 
oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol, 2013. 
33(7): p. 1670-8. 
196. Younis, H.S., et al., Antisense inhibition of coagulation factor XI prolongs 
APTT without increased bleeding risk in cynomolgus monkeys. Blood, 2012. 
119(10): p. 2401-8. 
160 
 
197. Tucker, E.I., et al., Prevention of vascular graft occlusion and 
thrombus-associated thrombin generation by inhibition of factor XI. Blood, 
2009. 113(4): p. 936-44. 
198. Deng, H., et al., Synthesis, SAR exploration, and X-ray crystal structures of 
factor XIa inhibitors containing an alpha-ketothiazole arginine. Bioorg Med 
Chem Lett, 2006. 16(11): p. 3049-54. 
199. Lin, J., et al., Design, synthesis, and biological evaluation of peptidomimetic 
inhibitors of factor XIa as novel anticoagulants. J Med Chem, 2006. 49(26): p. 
7781-91. 
200. Zhang, H., et al., Inhibition of the intrinsic coagulation pathway factor XI by 
antisense oligonucleotides: a novel antithrombotic strategy with lowered 
bleeding risk. Blood, 2010. 116(22): p. 4684-92. 
201. Van Nostrand, W.E., et al., Immunopurification and protease inhibitory 
properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem, 
1990. 265(17): p. 9591-4. 
202. Wu, W., et al., The kunitz protease inhibitor domain of protease nexin-2 
inhibits factor XIa and murine carotid artery and middle cerebral artery 
thrombosis. Blood, 2012. 120(3): p. 671-7. 
203. Navaneetham, D., D. Sinha, and P.N. Walsh, Mechanisms and specificity of 
factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic 
trypsin inhibitor. J Biochem, 2010. 148(4): p. 467-79. 
204. Ward, M., Pyridylethylation of Cysteine Residues. The protein protocols 
handbook, 2002: p. 461-463. 
205. Millers, E.K., et al., Crystal structure of textilinin-1, a Kunitz-type serine 
protease inhibitor from the venom of the Australian common brown snake 
(Pseudonaja textilis). FEBS J, 2009. 276(11): p. 3163-75. 
206. Roy, A., et al., Structural and functional characterization of a novel 
homodimeric three-finger neurotoxin from the venom of Ophiophagus 
hannah (king cobra). J Biol Chem, 2010. 285(11): p. 8302-15. 
207. Chen, C., et al., Solution structure of a Kunitz-type chymotrypsin inhibitor 
isolated from the elapid snake Bungarus fasciatus. J Biol Chem, 2001. 
276(48): p. 45079-87. 
208. Marcinkiewicz, M.M., D. Sinha, and P.N. Walsh, Productive recognition of 
factor IX by factor XIa exosites requires disulfide linkage between heavy and 
light chains of factor XIa. J Biol Chem, 2012. 287(9): p. 6187-95. 
209. Copeland, R.A., Tight Binding Inhibitors & Time-dependent Inhibition, in 
Enzymes : a practical introduction to structure, mechanism and data analysis 
2000, Wiley-VCH: New York :. p. 305-349. 
210. Eckly, A., et al., Mechanisms underlying FeCl3-induced arterial thrombosis. J 
Thromb Haemost, 2011. 9(4): p. 779-89. 
211. Wang, X., et al., Effects of factor IX or factor XI deficiency on ferric 
chloride-induced carotid artery occlusion in mice. J Thromb Haemost, 2005. 
3(4): p. 695-702. 
161 
 
212. Liu, C.S., T.C. Wu, and T.B. Lo, Complete amino acid sequences of two 
protease inhibitors in the venom of Bungarus fasciatus. Int J Pept Protein Res, 
1983. 21(2): p. 209-15. 
213. Navaneetham, D., et al., Structural and mutational analyses of the molecular 
interactions between the catalytic domain of factor XIa and the Kunitz 
protease inhibitor domain of protease nexin 2. J Biol Chem, 2005. 280(43): p. 
36165-75. 
214. Emsley, J., P.A. McEwan, and D. Gailani, Structure and function of factor XI. 
Blood, 2010. 115(13): p. 2569-77. 
215. Schumacher, W.A., et al., Inhibition of factor XIa as a new approach to 
anticoagulation. Arterioscler Thromb Vasc Biol, 2010. 30(3): p. 388-92. 
216. Wong, P.C., et al., A small-molecule factor XIa inhibitor produces 
antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J 
Thromb Thrombolysis, 2011. 32(2): p. 129-37. 
217. Schumacher, W.A., et al., Antithrombotic and hemostatic effects of a small 
molecule factor XIa inhibitor in rats. Eur J Pharmacol, 2007. 570(1-3): p. 
167-74. 
218. Alim, M.A., et al., A hemocyte-derived Kunitz-BPTI-type chymotrypsin 
inhibitor, HlChI, from the ixodid tick Haemaphysalis longicornis, plays 
regulatory functions in tick blood-feeding processes. Insect Biochem Mol Biol, 
2012. 42(12): p. 925-34. 
219. Wan, H., et al., A spider-derived Kunitz-type serine protease inhibitor that 
acts as a plasmin inhibitor and an elastase inhibitor. PLoS One, 2013. 8(1): p. 
e53343. 
220. Guo, C.T., et al., Purification, characterization and molecular cloning of 
chymotrypsin inhibitor peptides from the venom of Burmese Daboia russelii 
siamensis. Peptides, 2013. 43: p. 126-32. 
221. Navaneetham, D., et al., P1 and P2' site mutations convert protease nexin-2 
from a factor XIa inhibitor to a plasmin inhibitor. J Biochem, 2013. 153(2): p. 
221-31. 
222. Kravtsov, D.V., et al., Factor XI contributes to thrombin generation in the 
absence of factor XII. Blood, 2009. 114(2): p. 452-8. 
 
